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ABSTRACT
Mechanisms of Induced Cell Death in Bluetongue Virus
Challenged Human Cell Lines
by
Justin Darrel Hoopes, Doctor of Philosophy
Utah State University, 2009
Major Professor: Dr. Joseph K.-K. Li
Department: Biology
Bluetongue virus (BTV) is a pathogenic member of the Reoviridae family.
BTV does not cause disease in humans, but is capable of selectively infecting
and killing certain transformed human cell lines. Understanding BTV’s
oncotrophism may lead to new therapeutics for treating cancer. This study
focused on the underlying mechanisms of BTV-induced cell death in carcinoma
cell lines. It was our hypothesis that BTV infects human carcinoma transformed
cells, produces mRNA and protein, induces a strong inflammatory response,
induces mitogen activated protein kinase (MAPK)-based pro-apoptotic signaling,
inhibits PKB-based signaling, and eventually kills the cell by inducing apoptosis.
Three carcinoma cell lines (A498, HEP-G2, and A549) were independently
infected with BTV. In each cell line we determined: (1) cell viability over the
course of infection; (2) BTV induced cytokine expression profile and magnitude of
expression; (3) BTV viral RNA expression profile and magnitude of expression;
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(4) BTV viral protein expression profile and magnitude of expression; (5) changes
in BTV induced cell death and cytokine expression in cells with protein kinase B
(PKB), p38-MAPK, extracellular receptor kinase (ERK-1/2), stress-activated
protein kinase (SAPK-JNK), Src kinase, platelet-derived growth factor receptor
(PDGFR) kinase, epidermal growth factor receptor (EDGFR) kinase, or Janus
kinase (JAK) activity inhibited; (6) intracellular changes in PKB, p38-MAPK, ERK1/2, and SAPK-JNK phosphorylation as a result of BTV infection; and (7) BTVinduced changes in tyrosine phosphorylation.
We determined that BTV infects and kills all three cell lines in a cell line
dependent manner. Relative cell death between cell lines was proportional to
cytokine expression, but inversely proportional to viral protein expression. Only
tyrosine kinase inhibitors influenced BTV-induced cell death and cytokine
expression. Both A498 and A549 cells constitutively expressed phosphorylated
PKB and p38 MAPK, of which both were de-phosphorylated during BTV
infection. Tyrosine phosphorylation remained active, with elevated tyrosine
phosphorylation exclusively in infected cells.
We conclude that BTV-induced cell death and cytokine expression are a
function of the cell’s response to infection and are directly related through
intracellular signaling. These pathways are only partially poly I:C inducible, but
include PKB and tyrosine kinase signaling.
(171 pages)
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CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW
INTRODUCTION

BTV in the News
On 18 August, 2006, an outbreak of bluetongue virus (BTV) was reported
in southern Netherlands; the first reported incidence of BTV anywhere in northern
Europe (IAHD, 2006). Following confirmation in the Netherlands and the UK, an
immediate ban on live exports of sheep, cattle and goats and "living products"
including sperm, cells and embryos was established. In addition, transportation
was restricted for all ruminants within 100 kilometers of the incident case (BBC
News, 2006). Europe’s International Animal Health Division, a division of the
Department of Environment Food and Rural Affairs, categorizes BTV among its
list of high impact diseases of major concern. Since the initial report on 18
August, outbreaks of BTV have been reported in France, Luxemborg, and
Germany. The causative agent was determined to be serotype 8, the first
incidence of this serotype anywhere in Europe (BBC News, 2006).
This report from the Netherlands is an example of the epizootic nature of
the BTV and the economic impact this virus can have. Historically, the United
States has experienced multiple outbreaks of BTV (Ackerman and Giroux, 2006).
The economic impact of these outbreaks on international trade poses a greater
threat to the livestock industry than the disease itself (McDill, 2002). Because of
this, BTV was listed among the registered agents of the Agricultural Bioterrorism
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Protection Act (2002). Economically, BTV is estimated to cost the United States
$125 million annually in lost trade (Bram et al., 2002). Because of the recent
epidemic, and resultant economic impact, BTV is generating greater interest by
governments, the veterinary industry, and by researchers.

Viral Phylogeny and Epidemiology
BTV is classified in the Reoviridae family among the Orbivirus genus and
is the most studied virus within this genus. The Reoviridae family encompasses
nine distinct genera of segmented double-stranded RNA (dsRNA) viruses (Joklik,
1983). Members of the Reoviridae family are extremely diverse in tropism as
well as pathology (Urbano and Urbano, 1994). Generally, members of the
Reoviridae share a non-enveloped icosahedral capsid approximately 70 nm in
diameter, a dsRNA genome composed of 10 to 12 segments, incomplete virion
uncoating, non-polyadenylated 5’ capped mRNA, and viral packaging of all
proteins necessary for replication (Nibert et al.,1996). The Orbivirus genus
includes 14 serogroups based on complement fixation (Borden et al., 1971),
including viruses such as African hose sickness virus (AHSV), epizootic
hemorrhagic disease virus (EHDV), and BTV (Verwoerd et al., 1979). There is
no common antigen to all serogroups though BTV identification is often hindered
by cross-reactions with many of these antigenically related viruses (McDill,
2002). BTV is the prototype species and the most studied member of this genus
(Verwoerd et al., 1979).
Five serotypes of BTV circulate within the United States, while there are
24 known serotypes worldwide. The 24 serotypes are classified into three major
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groupings: North American, Australian, and African (Gould, 1988b). The
endemic U.S. serotypes include 2, 10, 11, 13, and 17, though serotype 1 was
isolated from a white-tail deer in Louisiana in Nov 2004 (Johnson et al., 2006).
Gene homology studies suggest serotype 10 is the principle ancestor to the U.S.
serotypes, while serotype 2 is the most distantly related (Hwang et al., 1993).
Historically, natural genetic reassortment has been observed only within specific
groups (Gould, 1988a).
BTV causes bluetongue disease in both domestic and wild ruminants.
BTV primarily affects sheep and is most severe in European breeds (Gorman,
1990). White-tailed deer and antelope are also very susceptible. Cattle, goats,
North American elk, elephants, buffalo, and dromedary camels may also be
infected by BTV but usually display subclinical symptoms, potentially serving
more as a reservoir for the virus (American Veterinary Medical Association,
2006). BTV is not contagious. It is only transmissible through an arthropod
vector, most commonly biting midges in the genus Culicoides (Erasmus, 1975).
As a result, disease outbreak and transmission are associated with Culicoides
habitat and not animal habitat or behavior. While habitat and behavior have little
impact, bluetongue disease severity is heavily dependent on the species, breed,
age, health status, multiplicity of infection (MOI) and infecting viral serotype (Roy,
1992).

Disease Pathology
The hallmarks of bluetongue disease include the production of primary
lesions (inflammation and ulceration of mucosal surfaces) around the mouth 7-10
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Fig. 1-1. A BTV-infected
sheep from northern
Europe. Bluetongue
disease in sheep is
characterized by fever,
depression, emaciation,
cyanosis of the tongue, and
swelling of the muzzle,
eyelids, and ears. Photo
courtesy of the Food and
Agriculture Organization of
the United Nations.

days post infection (P.I.) and cyanosis of the tongue (Spruell, 1905). Discoloring
of the tongue is due to oxygen deprivation caused both by inflammatory capillary
constriction as well as disseminated intravascular coagulation caused by viralinduced endothelial damage (Howerth and Tyler, 1988). In sheep it causes
soremuzzle, characterized by fever (up to 107.6 F) as well as depression,
emaciation, and swelling of the muzzle, eyelids, and ears (Hardy and Price,
1952). A sheep displaying the symptoms of bluetongue disease is shown in Fig.
1-1. Severe inflammation can also compromise mobility and respiration. Fetal
abortion usually occurs if ewes are infected during the first trimester of
pregnancy. Observed mortality rates have been as high as 75% in some
outbreaks (Manso-Ribeiro et al., 1957). If death does occur it is usually within 8
to 10 days as a result of pharyngeal lesions and/or heart failure (Mahrt and
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Osburn, 1986). Surviving animals can often experience hair loss, sterility,
cracked hooves and muzzle, as well as delayed growth (Jeggo et al., 1983).

BTV Virion Structure
BTV is a nonenveloped icosahedral virus with two capsid layers, arranged
in a T3 structural morphology around the inner core (Els and Verwoerd, 1969).
The total virus particle is around 68-70 nm wide (Martin and Zweerink, 1972).
The genome of BTV consists of 10 dsRNA segments (Verwoerd, 1970; Verwoerd
et al., 1970), ranging from 822 to 3954 base pairs in size, for a total genome of
1.9 X 104 base pairs (Verwoerd et al., 1970). The genome segment and size of
each protein can be seen in Table 1-1. The names of each gene are derived
from their electrophoretic motility, classified into large (L), medium (M), and small
(S). Each gene encodes a specific protein, except for the smallest gene segment
(S4), which encodes two proteins via an overlapping second reading frame
(Mertens and Sangar, 1985). Of the 11 proteins, 7 are found within the structure
of the virus, while 4 facilitate the replication cycle, but are not included within the
viral particle itself. The exact functions of these non-structural proteins are
unknown. A schematic of the virus can be seen in Fig. 1-2. The inner core is
composed of viral proteins (VP)1, VP4, and VP6 closely associated with viral
dsRNA. Surrounding this is the inner capsid composed of VP3 and VP7. The
outer capsid is composed of VP2 and VP5 non-covalently associated with the
inner capsid (Verwoerd et al., 1972; Huismans et al., 1987b).
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TABLE 1-1
Bluetongue Virus Gene Segments, Encoded Proteins,
Location Within Virion, and Putative Function.
Genome
Segment
L1
L2
L3
M1
M2
M3
S1
S2
S3
S4

Base
Pairs
3954
2926
2772
2011
1639
1770
1156
1123
1046
822

Encoded
protein
VP1
VP2
VP3
VP4
VP5
NS1
VP7
NS2
VP6
NS3/3A

Virion location

Function

Inner core
Outer shell
Core
Inner core
Outer shell
Non-structural
Core
Non-structural
Inner core
Non-structural

RNA polymerase/transcriptase
Structural – Adhesion
Structural
5’- mRNA capping enzyme
Structural – hemeagglutination
Virion transport
Structural
mRNA binding
RNA helicase
Viral progeny release

FIG. 1-2. BTV virion
structure. The virion is
composed of 10 dsRNA
segments packaged
along with VP1, VP4, and
VP6 within a VP3/VP7
capsid. The inner
VP3/VP7 capsid is
subsequently covered in
a VP2/VP5 outer capsid.
The virus is not
enveloped. Each viral
protein is indicated on the
diagram by their
respective number.
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BTV Genome and Proteins
The largest viral protein is VP1 (Huang et al., 1995). Derived from the L1
gene, VP1 is a subcore component which functions as an RNA-dependent RNA
polymerase, serving dual roles as transcriptase and replicase (Roy, 1992; Boyce
et al., 2004). In vitro replicase activity shows little specificity for BTV genes,
suggesting specificity is derived from its association with VP4 and VP6 (Boyce et
al., 2004). After endocytosis and upon removal of the outer capsid layer, VP1
begins production of mRNA from within the core particle (Watanabe et al., 1968;
Grimes et al., 1998). Following mRNA production, VP1 replicates new genomic
dsRNA from previously synthesized mRNA by strand displacement (Roy, 1992).
VP2 and VP5, derived from the L2 and M2 genes respectively, constitute
the outer capsid layer. VP2 represents the major variable epitope which defines
serotype (Kahlon et al., 1983) and is the recognition marker responsible for
endocytosis (Huismans and Erasmus, 1981). Purified VP2 displays
hemagglutinin activity through binding to glycophorin A, a sialoglycoprotein
component of erythrocytes (Hassan and Roy, 1999) suggesting VP2 may be
responsible for transmission by Culicoides. At present, the cellular recognition
region on VP2 has not been identified, though Hassan and Roy (1999) suggest
the receptor is likely a glycoprotein. Gene sequences show that there are 16
conserved cysteine residues present (Huismans and Van Dijk, 1990), though
VP2 does not appear to be covalently linked to VP5 (Verwoerd et al., 1972).
VP5 is more structurally conserved than VP2 (Mecham et al., 1986) likely
due to VP5’s association with the core proteins (Verwoerd et al., 1972). VP5 is
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sometimes referred to as GP5 because it is glycosylated with short unbranched
carbohydrates (Yang and Li, 1993). VP5 can bind to different agglutinating
lectins, probably contributing to the hemeagglutination properties of BTV. Its
main function appears to be membrane permeabilization of the endosomal
compartment facilitating release of uncoated virus into the cytoplasm (Hassan et
al., 2001). VP5 shares structural features with class I fusion proteins of
enveloped viruses (Forzan et al., 2004), which may give BTV its ability to
associate with and permeabilize membranes. Extracellular treatment of
mammalian cells with recombinant VP2 and VP5 together can result in apoptosis
(Mortola et al., 2004), though the mechanism or function of this is currently
unknown.
VP3 and VP7, derived from L3 and S1 genes respectively, together make
up the inner capsid layer. The VP3 and VP7 sequences are highly conserved
among all serotypes (Huismans and Erasmus, 1981). Both are very hydrophobic
(Yu et al., 1988; Huismans and Van Dijk, 1990) and can assemble in an alternate
host without other viral proteins present (French and Roy 1990; Kar et al., 2005).
VP7 exists as a trimer which is inserted into an organized VP3 dimer matrix
(Burroughs et al., 1995), as shown in Fig. 1-2. VP7 is the most abundant of BTV
proteins found within the viral particle (Huismans et al., 1987b). The N-terminal
region of VP7 has been shown to protrude to the surface of the outer capsid
(Hyatt and Eaton, 1988), conveying the serogroup-specificity of BTV (Wang et
al., 1996). Because of this, VP7 has generated great interest as a target for a
universal BTV vaccine. It is the only protein for which the crystal structure is
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known (Grimes et al., 1995). BTV can infect insect cells once the inner capsid is
assembled (through VP7’s RGD tripeptide motif) but cannot infect mammalian
cells until the outer capsid is assembled (Tan et al., 2001).
VP4 (M1 gene product) is a highly conserved inner core protein present at
5-10 copies per virion (Huismans and Van Dijk, 1990). VP4 together with VP1
attach to the underside of VP3 within the viral core in (Nason et al., 2004). VP4
has been shown to nonspecifically bind single stranded RNA (ssRNA) (Huang et
al., 1993) via an essential leucine-zipper motif near the c-terminus of the protein
(Ramadevi et al., 1998b). VP4 is also an NTP hydrolase (Ramadevi and Roy,
1998), RNA 5’-triphosphatase (Martinez-Costas et al., 1998), inorganic
pyrophosphatase (Martinez-Costas et al., 1998), a type 1 and type 2 methylase
(Ramadevi et al. 1998a), as well as a guanylyltransferase (Huang et al., 1993).
In short, VP4 performs all of the reactions necessary for complete 5’ guanine
capping of viral encoded messenger RNA (mRNA), prior to translation.
Gene S3 encodes VP6, the last of the three minor inner core proteins.
Each virion carries approximately 36 copies of this protein (Huismans and
VanDijk, 1990). VP6 has nucleoside triphosphatase, RNA binding, and helicase
activity (Stauber et al., 1997). VP6 is highly conserved among serotypes and is
the most polar of all the BTV proteins (Fukusho et al., 1989). ATP binding has
been linked to the conserved AXXGXGK(110)V motif (Kar and Roy, 2003). VP6
contains multiple nucleic acid binding domains (Hayama and Li, 1994) and
probably functions within the core virion as a dsRNA stabilizer (Roy, 1989; Roy et
al., 1990) and during transcription as an RNA-helicase (Roy, 1996).
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Gene M3 encodes non-structural protein, NS1. It contains 552 amino
acids and is predicted to be 64 kDa in size (Urakawa and Roy, 1988). The M3
gene was originally designated the M2 gene. M2 is now designated to encode
VP5. NS1 is the most abundantly produced viral protein (Huismans and Van
Dijk, 1990). It is highly conserved among BTV serotypes, though it shows only
around 50% sequence conservation with other Orbiviruses (Huismans and
Cloete, 1987). Its function within the cell is unknown; however, within the viral
inclusion body (VIB) it has been suggested to act as a molecular chaperone to
prevent core particle assembly before VP1, 4, 6 and the genome are
incorpoarated (Hewat et al., 1992). Upon entry into the cytoplasm, the NS1
protein will spontaneously polymerize into tubules (Huismans, 1979; Huismans
and Els, 1979) between 50 and 68 nm in diameter with a 9 nm banding
(Huismans and Els, 1979; Hewat et al., 1992). The tubules associate with the
intermediate filaments of the cytoskeleton (Eaton et al., 1988). The presence of
NS1 tubules is one of the most notable pathological conditions of BTV infection
observed under a microscope (Lecatsas, 1968). The function of these tubules
has not been established though they are probably involved in viral transport to
and from VIBs (Eaton et al., 1988).
Encoded by the S2 gene, NS2 is produced abundantly within the cell.
NS2 alone forms inclusion bodies in transfected insect cells (Thomas et al.,
1990). Within inclusion bodies, NS2 binds ssRNA non-specifically, but does not
bind to dsRNA (Huismans et al., 1987a; Uitenweerde et al., 1995). Three RNA
binding domains have been identified in this protein (Fillmore et al., 2002). NS2’s
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proposed role is to associate with newly formed mRNA to protect it from
destruction prior to its encapsidation. NS2 may also be responsible for ensuring
that only the 10 distinct mRNAs are condensed prior to dsRNA synthesis during
genome replication and viral morphogenesis (Eaton et al., 1988; Lymperopoulos
et al., 2006).
NS2 is the only known phosphorylated BTV protein (Huismans et al.,
1987a). Phosphorylation occurs on two serine residues at positions 249 and 259
(Modrof et al., 2005). NS2 phosphorylation can occur in vitro (Huismans et al.,
1987a) but unlike rotavirus NSP2, a functional homolog, NS2 does not
autophosphorylate (Taraporewala et al., 2001). Instead, cellular kinases are
necessary for phosphorylation. In addition, recombinant NS2 displays nucleotidyl
phosphatase activity (Horscroft and Roy, 2000) as opposed to NSP2’s NTPase
only activity (Taraporewala et al., 2001). Phosphorylation of NS2 somewhat
reduces affinity for ssRNA, but appears essential for the formation of VIBs
(Modrof et al., 2005).
S4, the smallest gene encodes the NS3 and NS3a proteins. The gene
contains two in phase open reading frames (ORFs); the primary ORF starting at
base position 20 and the second ORF starting at base position 59 (Van Dijk and
Huismans, 1988). The exact functions of either protein is unknown, but they
have been shown to be associated with cellular membranes and hydropathy
plots show two distinct hydrophobic membrane spanning domains at amino acids
118 to 141 and 162 to 182 (Huismans and Van Dijk, 1990). NS3/3a can be
found naturally in both n-linked glycosylated and non-glycosylated forms (Wu et
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al., 1992). Glycosylation occurs at an asparagine in position 150 on the protein
(Bansal et al., 1998). Hyatt et al. (1993) suggested NS3 facilitates the release of
virus by causing local lesions in the cell membrane. NS3 and NS3a also contain
the characteristic P(T/S)AP and PPXY membrane binding motifs found at residus
7-10 on the p6 region of the human HIV-1 GAG protein (Garrus et al., 2001) and
in membrane-associated proteins of filo-, rhabdo-, and oncoretroviruses (Craven
et al., 1999; Harty et al., 2000). The presence of these motifs also suggest a role
for NS3/3a in progeny release through recruiting cellular proteins. Wirblich et al.
(2006) have recently shown NS3 to recruit Tsg101, a component of the
ubiquitinization ESCRT-1 complex, though this motif, and that depletion of
Tsg101 through RNA interference inhibits the release of BTV from infected cells.
NS3, through yeast two-hybrid studies, has also been shown to associate with
cellular protein p11 (calpactin light chain) though an N-terminal domain (Beaton
et al., 2002). This protein is part of the annexin II complex involved in exocytosis.
NS3 also binds VP2 though a c-terminal domain (Beaton et al., 2002),
suggesting NS3 may bridge association between assembled viral particles and
exocytosis machinery. NS3 has also recently been shown to have viroporin like
properties (Han and Harty, 2004). Viroporins are a group of hydrophobic
transmembrane proteins that can form hydrophilic pores in a lipid bilayer. The
formation of these pores would allow release of progeny virus by direct
penetration of the cell membrane. Even though the functions of NS3 have not
been definitively stated, it is certain that NS3 plays an important role in the
release of viral progeny.
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Measuring BTV RNA and Protein Expression
The 10 genes described previously all play an essential role in replication
and changes in their expression can affect replication rates and fitness. Various
methods have been developed to measure BTV RNA and protein expression.
One way BTV RNA can be detected and quantitated is through quantitative real
time PCR (qRT-PCR) (Buccambusco, 2005). This process involves purifying
total RNA from a sample, followed by reverse transcription of RNA to
complimentary DNA (cDNA) and subsequent PCR. The PCR reaction takes
place in the presence of Cyber Green, a flourescent intercalating dye. Primers
specific to each viral gene lead to specific amplification of the target gene.
Amplification of the target gene results in more Cyber Green intercalation leading
to a higher fluorescent signal. This signal can be used to quantify the amount of
each viral gene present in the sample.
Available methods for quantifying BTV protein are not as automated as
RT-PCR. BTV viral protein is measured by Western blot. Western blotting is the
process of probing for a specific protein using enzyme labeled antibodies-specific
to the protein of interest. Sample is resolved by polyacrylamide gel
electrophoresis then transferred to a polyvinylidene fluoride (PVDF) membrane.
The membrane is then blocked to prevent non-specific binding and incubated
with BTV specific antibody. Antibody binding is detected by the addition of the
linked enzyme’s substrate.
When antibodies to specific BTV proteins are not commercially available,
antisera is used instead. BTV antiserum reacts to the major antigenic epitopes
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within the viral capsids, predominantly VP2 followed by VP7, VP5, and VP3,
respectively.
Viral Replication Cycle
BTV is a fully infectious virus, meaning it carries all of the proteins
necessary to begin replication. This is necessary as the genome is dsRNA which
must be processed by specialized proteins. BTV primarily infects endothelial
cells of the vascular wall, in vivo. Utilizing VP2 attachment protein, the virus is
taken into clathrin coated endosomes by endocytosis (Sturzenbecker et al.,
1987). In tissue culture, adsorption usually occurs within 20 minutes P.I. (Howell
et al., 1967). Within the endosome, as the pH is lowered, VP2 is lost and VP5
binds to the endosomal membrane where it promotes viral penetration into the
cytoplasm (Dales, 1973; Tyler et al., 1985). Once the outer capsid has been
removed, the RNA-dependent RNA polymerase (VP1) becomes activated (Van
Dijk and Huismans, 1980). The core particle then binds cellular intermediate
filaments (Eaton and Hyatt, 1989) and begins to produce and release mRNA into
the cytoplasm (Bowne and Jochim, 1967). New mRNA is 5’ guanidine capped
(Furwichi and Shatkin, 1977) by VP4 (Huang et al., 1993), but not
polyadenylated. This mRNA is used for translation and later condensed by NS2
(Zweerink et al., 1971) into viral inclusion bodies where it associates with VP3
dimers (Kar et al., 2004). Once associated with VP3, mRNA is then converted
into viral genomic dsRNA (Acs et al., 1971).
When all the necessary components are gathered, morphogenesis of the
inner core takes place within the VIB (Morgan and Zweerink, 1975; Zarbl et al.,
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1980). After exiting the VIB, VP2, and VP5 are added to form the outer capsid.
From there, virulent particles may either stay in the cell (Howell and Verwoerd,
1971) or be released through the aid of NS3/3a. Release can occur through
direct penetration of the cell membrane (Hyatt et al., 1993) or though budding
(Bowne and Ritchie,1970; Foster and Jones, 1979). Both events have been
seen, though viral release in mammalian cells through budding is noted in less
than 5% of cases. If virus is released by budding, the membrane is lost shortly
thereafter.
Non-Ruminant Host Relationship
BTV is known to infect a broad diversity of host species and the severity of
disease is just as diverse across these species, though bluetongue disease does
not occur in humans and mice. There is a rare BTV strain which has been
reported to replicate in mice (Brewer and Osburn, 1998) though this has yet to be
independently confirmed. Species specificity is less clear in vitro where BTV can
replicate in a wide variety of cell lines (McPhee et al., 1982). It is normally
cultured in hamster kidney (BHK-21) cells or in African green monkey kidney
(Vero) cells.
Challenge of some human cell lines with BTV has recently been shown to
induce apoptotic cell death (Xiao et al., 2004). This observation may be related
to the transformed nature of the cells and other experiments have shown that
BTV infection of human primary cells does not cause cell death (Hu et al., 2008).
These findings suggest BTV may be an oncolytic virus, meaning the virus
replicates more efficiently in cancer cells than in normal cells (Guo et al., 2005).
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Cancer cells often make a good host for viruses for reasons that include mutated
tumor suppressor genes and inactivated antiviral interferon pathways (Myers et
al., 2005; Galanis et al., 2005). The mechanisms which allow BTV’s selective
oncolysis are unknown.

Innate Immunity
One mechanism by which BTV can induce cell death is through activation
of innate immunity. Innate immunity includes viral defenses which are intrinsic to
each cell independent of the host immune system. Innate defenses to dsRNA
include toll-like receptors (TLRs), type I interferons (IFNα and IFNβ), and RNAinterference.
TLRs are molecular pattern recognition receptors (Aderem and Ulevitch,
2000). There are currently 13 recognized TLRs, each having affinity for a
specific pattern commonly expressed by pathogens (Takeda et al., 2003). For
example, lipopolysaccharide (LPS) is recognized by TLR4 leading to activation of
cells and expression of numerous inflammatory cytokines (Ståhl et al., 2006).
TLRs display differential tissue and cell expression highly dependent on the
function of the receptor (Hopkins and Sriskandan, 2005). Though each TLR has
its own specific function, virtually all utilize the same MyD88 cell signaling
pathway leading to inflammation. The exception is TLR3, which utilizes a
MyD88-independent signaling pathway (Meylan et al., 2004). TLR signaling is
graphically represented in Fig. 1-3.
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FIG. 1-3. Toll-like receptor
(TLR) signaling. TLR’s are
innate pattern recognition
receptors which activate host
defense mechanisms through
MyD88-dependent and independent pathways. Double
stranded RNA is recognized by
the TLR3 receptor in the
endosome which can induce
antiviral proteins and
inflammatory mediators.

TLR3 specifically recognizes dsRNA (Hopkins and Sriskandan, 2005).
This innate receptor is of particular interest with respect to BTV because the
genome of BTV is dsRNA. Double-stranded RNA does not naturally exist in
mammalian cells. If present, it is treated as a product of infection with an RNA
virus. In the case of ssRNA viruses, dsRNA is generated as part of the genomic
replication process as the RNA-dependent RNA polymerase makes replicate
copies of the viral genome. The genome will be packaged as ssRNA, but dsRNA
is an intermediate as well as a byproduct of incomplete packaging.
Unlike ssRNA viruses, BTV’s dsRNA genome can induce innate immunity
through TLR3 or through cytoplasmic receptors such as retinoic acid-induced
protein I (RIG-I) and melanoma differentiation-associated gene-5 (MDA-5)
(Andrejeva et al., 2004; Yoneyama et al., 2004; Kato et al., 2005; Gitlin et al.,
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2006) to cause cell death and cytokine expression (Hoebe et al., 2004), even
without viral replication.
In addition to avoiding TLR’s and cytoplasmic receptors, dsRNA must also
avoid degradation of viral mRNA caused by activation of the cellular RNAinduced silencing complex (RISC) and simultaneous activation of the type I
interferon response (Saha et al., 2006). RISC formation is part of the RNA
interference (RNAi) process first characterized in the nematode worm
Caenorhabditis elegans (Fire et al., 1998). Double-stranded RNA was later
shown to induce the formation of the RISC complex which would target and
destroy mRNA complementary to the dsRNA sequence (Sledz and Williams,
2005).
Double stranded RNA can also induce type I interferons which are
autocrine and paracrine cytokines that induce transcription of numerous antiviral
genes (Theofilopoulos et al., 2005).

Both RNAi and type I interferon production

are defense mechanisms intended to prevent the virus from completing
replication. Even though BTV attempts to protect its dsRNA genome by
sequestering it in the viral core particle during transcription, it is particularly
vulnerable to this mechanism because dsRNA is prevalent within the cell at every
stage of infection (Grimes et al., 1998).
Types of Viral-Induced Cell Death
BTV induces both apoptotic and necrotic cell death. Apoptosis is tightly
controlled, programmed cell death. Necrosis encompasses any other type of cell
death (Kerr et al., 1972). Apoptosis is specifically, an energy-dependent,
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asynchronous, genetically controlled process by which unnecessary or damaged
single cells self-destruct upon apoptotic activation (Martin, 1993; Earnshaw,
1995). One major characteristic of apoptosis is that an apoptotic cell has little
impact on surrounding cells (Bar, 1996), while necrosis is characterized by
widespread damage and inflammation (Kam and Ferch, 2000). This is because
reactive oxygen species and toxic proteins are released from necrotic cells,
causing localized tissue damage. In the animal host, BTV infection often causes
secondary necrosis as a result of severe inflammation and vasoconstriction
(DeMaula et al., 2002a; DeMaula et al., 2002b), but in mammalian cell culture,
infection usually results in apoptosis (Nagaleekar et al., 2007).
Apoptosis is used by the host to regulate, renew, and protect itself. It is
particularly important in viral host defense. This is because a virus relies on the
cellular machinery to complete replication and a cell which undergoes apoptosis
can no longer be used by the virus to replicate. If the apoptotic system is
compromised, the host is more susceptible to viral infection as well as many
other diseases, including cancer (Osaki et al., 2004). Some viruses directly
inhibit apoptosis in their target cells to prolong host cell life thereby prolonging
replication. Examples include Papilloma virus and Adenovirus which both
encode p53 inhibitors (Zekri et al., 2006; Ying et al., 2007). P53 is an essential
component in regulating the cell cycle as well as recombination after genomic
damage. When p53 is inhibited, the cell continually replicates and is unable to
undergo apoptosis (Zekri et al., 2006).
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On a systemic level there are three phases to apoptosis (Arends and
Wyllie, 1991). First, the cell detaches from adjacent cells and the genomic DNA
is digested by specific endonucleases and packaged into organelles (Wyllie,
1997). Second, the organelles are released as membrane-bound vesicles to be
recycled by neighboring cells. Last, the remaining apoptotic body is
phagocytosed by myeloid cells (Wyllie, 1997).
Apoptotic stimuli are broadly categorized into four major groups; including
DNA damage; activation of death receptors (Fas receptor, TNF receptor);
stimulation of apoptotic pathways (kinase inhibitors); and damage by UV, heat, or
peroxides (Kam and Ferch, 2000). Inflammation is generally not a product of
apoptosis though some transcription factors associated with viral-induced
apoptosis are also associated with cytokine expression (Heylbroeck et al.,
2000).
BTV-Induced Cytokine Expression
Within the body, an infected cell will recruit the help of the systemic
immune system and send a warning to neighboring cells to minimize viral spread.
This is done through the secretion of cytokines. The mechanisms of cytokine
induction are diverse and often dependent on the infecting agent. The effects of
cytokine induction are just as diverse as the mechanisms of induction.
Cytokines are hormone-like proteins produced by nearly all cells. They
are the predominant mode of communication within the immune system.
Through cytokines, the immune system regulates stem cell differentiation (Bishop
et al., 2002), inflammation (Arai et al., 1990), angiogenesis (Carmeliet, 2000), as
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well as many other events. Correspondingly, aberrant cytokine expression is
also often involved in progression and pathogenesis of disease (Whicher and
Evans, 1990).
Studying cytokines provides insight into how a cell is responding to
infection and how the immune system as a whole is managing the infection.
Cytokines often perform multiple functions and regularly share receptors (Akira et
al., 1990). A single cytokine can elicit one effect on one cell type, a different
effect on another cell type and a completely different response when
administered concomitantly with other cytokines (Akira et al., 1990). This
diversity of activity allows the immune system to control a great variety of events
with a relatively small repertoire of signaling agents. This diversity also makes
interpreting the effects of cytokine expression very difficult.
In the past, there have been few cytokine studies on BTV infection. This
is due predominantly to the limited availability of testing materials for ruminant
species. The use of RT-PCR has allowed researchers to do limited cytokine
studies on an mRNA expression level (DeMaula et al., 2002a; DeMaula et al.,
2002b). Though not as accurate as protein based tests in determining cytokine
concentrations, mRNA studies have provided some information about the native
host cytokine response to BTV infection.
Within native hosts, BTV infection results in severe pathological effects,
including prominent swelling systemically, hemorrhaging, and inflammationinduced necrosis (Spruell, 1905; Chiang et al., 2006; DeMaula et al., 2002a).
DeMaula et al. (2002a) found that BTV infection of ovine lung microvascular
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endothelial cells (ECs) showed increased transcription of genes encoding IL-1β
and IL-8, but little IL-6. Transcription of these same genes was markedly higher
in bovine lung microvascular ECs. These differences between sheep and cattle
are significant when considering that ovine ECs had lower incidence of infection
and produced significantly less virus than did bovine ECs (DeMaula et al., 2001),
but have much higher rate of mortality.
These experiments show that cytokine expression from infected cells in
natural ovine and bovine hosts is greatly elevated and consistent with
inflammation, though the diversity of cytokines tested was small. Recently
Chiang et al. (2006) performed cytokine mRNA testing in human endothelial cells
infected with BTV-10 and found mRNA expression increased for IL-1β, IL-6, IL-8,
and TNFα. They also found that the stimulation of cells with
polyinosinic:polycytidilic acid (poly I:C) resulted in expression of the same
cytokines, suggesting that the cause of expression in these cells is due to innate
immunity to dsRNA.
There are four classes of cytokines which can be observed in BTVinfected human carcinoma transformed cells. These include inflammatory
cytokines, chemokines, TH1 type differentiators, and angiogenesis factors.
Inflammatory cytokines are those which promote inflammation at the site of
infection. Chemokines are a class of cytokines which are chemotactic for
specific lymphocytes (Baggiolini et al., 1997). TH1 differentiators are cytokines
which promote TH1 type T-cell activation as opposed to TH2 type activation.
(Clerici and Shearer, 1993).
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The last set of cytokines are promoters of angiogenesis. Angiogenesis is
the process of creating these new blood vessels; and thus, it is an important
component of human growth. As the body grows, the demand for oxygen
increases. To accommodate for greater demand, new blood vessels must be
constructed. This is a complex process incorporating breakdown of old tissue,
cleanup of digested tissue, and formation of new vascular endothelial cells in its
place (Carmeliet, 2000). Angiogenesis plays a critical role in tumor progression
as well because the tumor’s oxygen demands increase dramatically the larger
the tumor and the more aggressively the tumor is growing (Carmeliet and Jain,
2000; Patan, 2004). BTV infection may inhibit angiogenic factor expression
which would affect the tumor’s ability to grow.
Measuring Cytokine Expression
Cytokine expression is determined by either quantifying cytokine mRNA
using RT-PCR or cytokine protein by reporter-linked immunoassay. The most
accepted immunoassay is a sandwich (capture) ELISA (Knight et al., 2004). This
process uses two antibodies. One antibody is bound to a solid phase (i.e. microwell plate) and then incubated with sample. As the sample is incubated,
cytokines in solution are captured by the anchored antibody. Following this, each
well is incubated with a second enzyme-linked antibody. The second antibody
binds to a different region on the cytokine. This binding is detected by monitoring
the activity of the attached enzyme. Enzyme activity is proportional to the
amount of cytokine present in the sample. One of the best ways to improve
interpretation is to assay for multiple cytokines (Knight et al., 2004; Leng et al.,
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2008). The profile of cytokine type and concentration helps to generate a clearer
picture of the cellular response as well as the underlying cell signaling taking
place. Conventional ELISAs, while allowing the researcher to test many samples
at one time, can test only one type of cytokine in a single test. This makes
cytokine profiling costly with respect to time, reagents, and sample volume. The
expense of these factors makes multiplexed assays the preferred choice for
profiling. Multiplex formats have included fluorescent bead-based assays as well
as printed arrays (Morgan et al., 2004). Both methodologies allow the researcher
to simultaneously measure multiple cytokines in a relatively small volume.
Intracellular Signaling During BTV Infection
Fundamental to any biological system is accurate communication. A
biological system as a whole can communicate through various signals including:
neuronal signals, chemical hormones, cytokines, and contact. Accurate
intracellular communication is just as important. Within a cell, signals from the
environment must be relayed through the membrane and then throughout the
cell. This is necessary for the cell to properly respond to its environment. In
addition, intracellular signals must be passed to the nucleus for proper regulation
of gene expression. Finally, changes in gene activity or demand must be relayed
to the rest of the system and properly accounted for in order to keep the system
in homeostasis. When communication pathways are disrupted, pathology
inevitably follows.
The cell is analogous to the modern automobile; equipped with sensors
throughout the entire system, ready to notify the driver of any potentially
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deleterious condition. Likewise, the cell employs a brigade of regulatory
molecules responsible for monitoring and reporting the extracellular and
intracellular environment. Also like the automobile, a simple change in one
process, if not properly identified and accounted for can lead to greater problems.
The regulatory molecules discussed above are collectively classified as
signaling molecules, with some responsible for detecting changes and others
responsible for relaying messages to the proper system. Signaling molecules
are a large and diverse group of proteins, but even with a large assortment of
signaling proteins, the cell often utilizes the same protein in multiple signaling
pathways and regularly cascades signals via multiple messengers (Kornblau et
al., 2006; Chang and Karin, 2001; Pearson et al., 2001). The use of the
cascading process allows the signal to be rapidly amplified and disseminated
through multiple systems, such that small triggers can induce dramatic changes.
Cascading also means slight alterations in the makeup of the signaling
framework can have dramatic end results. It also makes it more difficult for
researchers to distinguish and discern signaling pathways.
The most common way signals are relayed along the cascade is through
reversible phosphorylation (Johnson and Lewis, 2001). The regulation of action
by reversible phosphorylation was first discovered in 1952 by Edwin G. Krebs
(Krebs, 1981) with the recognition that glycogen phosphorylase was reversibly
regulated by phosphorylation. Though phosphorylation was first discovered in
eukaryotes, bacteria were later shown to utilize similar phosphorylation signaling
(Deutscher and Saier, 2005). Since its first discovery, scientists have discovered
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500+ kinases, but have mainly succeeded in revealing the complexity of signal
transduction and regulation (Manning et al., 2002).
Phosphorylation signals are relayed by transferring a phosphoryl group
from ATP to the hydroxyl group of the amino acid. Because of the need for a
hydroxyl group, there are only three candidate amino acids for phosphorylation:
serine, threonine, and tyrosine (Johnson et al., 2001). Once covalently attached,
the protein is referred to as a phospho-protein. Phosphate groups are
transferred to proteins by kinases and removed by phosphatases (Mumby and
Walter, 1993). Protein kinases make up the largest family of genes in eukaryotes
(Rubin et al., 2000; Lander et al., 2001). The family is classified into three types:
those which can phosphorylate serine and threonine, those which can
phosphorylate tyrosine, and those which can phosphorylate any of the three
(Kitamura et al., 1998; Hubbard and Till, 2000; Cobb and Goldsmith, 1995).
Phosphorylation occurs after the protein has been folded, restricting
phosphorylation sites to the surface of a protein.
The impact of phosphorylation is different for every protein, with effects
dependent on the site(s) of phosphorylation. It is not uncommon for a protein to
have multiple phosphorylation sites, with the pattern of phosphorylation defining
the activity of the protein (Mayo et al., 2005; Xie et al., 2001).
Because of the import of intracellular signaling to homeostasis, aberrant
intracellular signaling often leads to disease. Cancer is commonly attributed to
mutations in apoptotic and cell cycle related signaling. For example, the protein
kinase Ras is a known oncogene (Bos, 1989). Normally, it is a GTPase involved
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in regulating various signaling pathways. One of the pathways it regulates is the
MAPK pathway. When mutated to an overactive state, Ras can induce
constitutive activation of the cell cycle causing cancer (Lodish et al., 2000).
In cases where cancer is the result of changes in intracellular signaling,
treatment can be very complex because inhibition of the mutated kinase can
have consequences on other known and unknown pathways. Even so, there are
cancer drugs on the market which are specific kinase inhibitors (Reuter et al.,
2000).
Protein kinase A, B, and C (PKA, PKB, and PKC, respectively) are three
of the earliest kinases discovered with involvement in many signaling pathways
(Newton, 2003). Each has a common conserved kinase core and a regulatory
domain. The regulatory domain is where the kinase is regulated by
phosphorylation and dephosphorylation but also helps target the kinase to the
appropriate cellular location (Newton, 2003). PKB is of interest in this study as it
is directly involved in cell survival.
PKB, plays a critical role in controlling the balance between survival and
apoptosis (Yoeli-Lerner and Toker, 2006). There are 3 known isoforms which
are generally considered to have the same function (Toker and Yoeli-Lerner,
2006). PKB promotes cell survival by inhibiting apoptosis through its ability to
inactivate by phosphorylation several targets involved in apoptosis. Prolonged
survivability is the direct result of constitutive over phosphorylation of PKB in
numerous cancers (Yoeli-Lerner and Toker, 2006). Elevation in PKBphosphorylation makes the cell more resistant to apoptosis while declines in
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PKB-phosphorylation make the cell more susceptible to apoptosis (Jeong et al.,
2007). One hypothesis is that PKB is constitutively phosphorylated in carcinoma
cells promoting survivability and that infection with BTV triggers an independent
apoptotic mechanism which causes a reduction in PKB phosphorylation, thereby
allowing the immortalized cell to enter apoptosis.
Besides suppressing PKB phosphorylation, BTV is also hypothesized to
be activating pro-apoptotic processes. One of the major pro-apoptotic signaling
pathways associated with infection is the p38 mitogen-activated protein kinase
(p38 MAPK) pathway (Porras et al., 2004). P38 MAPK is also a known
oncogene as aberrant MAPK phosphorylation can lead to prolonged survivability
(Huynh et al., 2003).
MAPKs include more than p38 MAPK. Other MAPKs influence cell
growth, differentiation, apoptosis, as well as cellular responses to stress
(Ashwell, 2006). Mutations in each member of the MAPK family can cause
cancer. In addition, because of their involvement in the inflammation and cell
cycle regulation, each member could also be involved in BTV-induced cell death
and cytokine expression (Hersey et al., 2006).
In general, MAPKs are a set of serine/threonine kinases which are
evolutionarily conserved (Widmann et al., 1999). The MAPK subfamily is
activated by dual phosphorylation at a domain composed of a tyrosine two amino
acids downstream of threonine in the TXXY motif (Ashwell, 2006). MAPKs are
inactive in their unphosphorylated state and become active when phosphorylated
by MAPK kinases (MKKs). MKKs are in turn phosphorylated by MAPK kinase
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kinases (MKKKs) (Dodeller and Schulze-Koops, 2006). As a minimum, MAPKs
require three sequential phosphorylations in order to be activated (Ray and
Sturgill, 1988). Once active, each member has a specific effector that it in turn
activates by phosphorylation (Raman et al., 2007).
The MAPKs include three subfamilies: Extracellular signal-regulated
kinases ERK1 and ERK2, Src associated protein kinases (SAPK) also known as
c-Jun NH2-terminal kinases (SAPK-JNK1, -2, and -3), and the four p38 MAPK
enzymes p38α, β, γ, δ (Johnson and Lapadat, 2002). A fourth MAPK, ERK5, has
also been identified though little is presently known about it (Zhou et al., 1995).
The MAPK subfamilies each have specific functions. ERK1 and ERK2 are
involved in the regulation of mitosis and meiosis (Lloyd, 2006; Meloche and
Pouysségur, 2007). They can be activated by stimuli including growth factors,
cytokines, virus infection, transforming agents and carcinogens (Wang, 2007;
Valerie et al., 2007). The ERK-1/2 path can also be activated by the protooncogene RAS (Dance et al., 2008). Mutated RAS persistently activates ERK1/2 which has been known to contribute to the increased proliferation rate of
tumor cells (Ruscica et al., 2007).
The SAPK-JNK subfamily members are stress-activated proteins often
activated when protein synthesis has been inhibited (Kyriakis et al., 1995; Singh
and Czaja, 2007). SAPK-JNKs phosphorylate the c-Jun transcription factor,
which is part of the AP-1 transcription complex involved in transcription
regulation, including cytokine gene expression (Salh, 2007). SAPK-JNK’s are
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also important in controlling apoptosis (Tournier et al., 2000; Takeda et al.,
2007).
The third subfamily includes the p38 MAPKs. There are four known p38
MAPK isoforms with similar function. P38 MAPK was first discovered from its
involvement in TNFα-induced inflammation (Grivennikov et al., 2006; Aggarwal et
al., 2006). P38 MAPK is also involved in the expression of various other
cytokines (Schindler et al., 2007; Patil and Kirkwood, 2007). In addition to the
usual pathway of activation, p38 MAPK can also be activated by the nonenzymatic protein TAB1 (Ge et al., 2002), suggesting that there are multiple
mechanisms of p38 MAPK regulation.
P38 MAPK is also known to be associated with innate defense against
dsRNA (Williams, 1999; Williams, 2001; Servant et al., 2002) and is a strong
promoter of inflammation upon microbial challenge (O’Neill, 2006). Viral-induced
p38 MAPK activation generally leads to cell death as well as elevated cytokine
production. Chiang et al. (2006) observed p38 MAPK phosphorylation in BTV
challenged primary lung microvascular endothelial cells. They also found this
activation could be reproduced using synthetic dsRNA. In their studies, dsRNAinduced the expression of the cytokines IL-1β, IL-6, and TNFα, consistent with
p38 MAPK phosphorylation via innate immunity.
OBJECTIVES AND HYPOTHESIS
BTV preferentially replicates in transformed human cells relative to
primary cells. Understanding this selective trophism may lead to future
treatments for cancer. Our objectives were to determine how BTV replication in
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carcinoma transformed human cells differs from replication in traditional host
cells and how the human cells respond to BTV infection, including induction of
apoptosis, changes in cytokine expression, and changes in intracellular signaling.
Our hypothesis was that cell death and cytokine expression were directly related
to viral replication and were the result of innate immune responses to BTV
genomic dsRNA.
REFERENCES
Ackerman, G. A., and Giroux, J. (2006). A history of biological disasters of
animal origin in North America. Rev. Sci. Tech. 25, 83-92.
Acs, G., Klett, H., Schonberg, M., Christman, J., Levin, D. H., and Silverstein, S.
C. (1971). Mechanism of reovirus double-stranded ribonucleic acid
synthesis in vivo and in vitro. J. Virol. 8, 684-689.
Aderem, A., and Ulevitch, R.J. (2000). Toll-like receptors in the induction of the
innate immune response. Nature 406, 782-782.
Aggarwal, B. B., Shishodia, S., Takada, Y., Jackson-Bernitsas, D., Ahn, K.S.,
Sethi, G., and Ichikawa, H. (2006). TNF blockade: An inflammatory
issue. Ernst Schering Res. Found. Workshop 56, 161-186.
Agricultural Bioterrorism Protection Act of 2002. (2002). Federal Register:
August 12, 2002. 67, 52383-52389.
Akira S., Hirano, T., Taga, T., and Kishimoto, T. (1990). Biology of
multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF).
FASEB J. 4, 2860-2867.
American Veterinary Medical Association. (2006). Bluetongue backgrounder.
http://www.avma.org/reference/backgrounders/bluetongue_bgnd.asp.
Andrejeva, J., Childs, K. S., Young, D. F., Carlos, T. S., Stock, N., Goodbourn,
S., and Randall, R.E. (2004). The V proteins of paramyxoviruses bind the
IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFNbeta promoter. Proc. Natl. Acad. Sci. USA 101, 17264–17269.

32
Arai, K. I., Lee, F., Miyajima, A., Miyatake, S., Arai, N., and Yokota, T. (1990).
Cytokines: co-ordinators of immune and inflammatory responses. Ann.
Rev. Biochem. 59, 783-836.
Arends, M. J., and Wyllie, A. H. (1991). Apoptosis: An overview. British Medical
Bulletin 32, 223-254.
Ashwell, J. D. (2006). The many paths to p38 mitogen-activated protein kinase
activation in the immune system. Nat. Rev. Immunol. 6, 532-540.
Bansal, O. B., Stokes, A., Bansal, A., Bishop, D., and Roy, P. (1998).
Membrane organization of bluetongue virus nonstructural glycoprotein
NS3. J. Virol. 72, 3362-3369.
Baggiolini, M., Dewald, B., and Moser, B. (1997). Human chemokines: An
update. Ann. Rev. Immunol. 15, 675-705.
Bar, P. R. (1996). Apoptosis – the cell’s silent exit. Life Science 59, 369-78.
BBC News. (2006). Bluetongue virus hits Dutch farm. BBC News:
http://news.bbc.co.uk/1/sci/tech/5263456.stm.
Beaton, A. R., Rodriguez, J., Reddy, Y. K., and Roy, P. (2002). The membrane
trafficking protein calpactin forms a complex with bluetongue virus protein
NS3 and mediates virus release. Proc. Natl. Acad. Sci. USA 99, 1315413159.
Bishop, A. E., Buttery, L. D., and Polak, J. M. (2002). Embryonic stem cells. J.
Pathol. 97, 424-429.
Borden, E. C., Shope, R. E., and Murphy, F. A. (1971). Physicochemical and
morphological relationships of some arthropod-borne viruses to
bluetongue virus--a new taxonomic group. Physiocochemical and
serological studies. J. Gen. Virol. 13, 261-271.
Bos, J. (1989). Ras oncogenes in human cancer, a review. Cancer Res. 49,
4682-4689.
Bowne, J. G., and Jochim, M. M. (1967). Cytopathologic changes and
development of inclusion bodies in cultured cells infected with bluetongue
virus. Am. J. Vet. Res. 28, 1091-1105.
Bowne, J. G., and Ritchie, A. E. (1970). Some morphological features of
bluetongue virus. Virology 40, 903-911.

33
Boyce, M., Wehrfritz, J., Noad, R., and Roy, P. (2004). Purified recombinant
bluetongue virus VP1 exhibits RNA replicase activity. J. Virol. 78, 39944002.
Bram, R. A., George, J. E., Reichard, R. E., and Tabachnick, J. W. (2002).
Threat of foreign arthropod-born pathogens to livestock in the United
States. J. Med. Entomol. 39, 405-416.
Brewer, A. W., and Osburn, B. I. (1998). Sequential distribution of neurovirulent
and avirulent strains of bluetongue virus in neonatal mice by RT-PCR.
Arch. Virol. 143, 145-155.
Buccambusco, M. (2005). Kinetic analysis of bluetongue viral mRNA by
quantitative real-time polymerase chain reaction. In “A Kinetic Analysis of
Bluetongue Virus Messenger RNA and Protein” (M. Buccambusco, ed.),
pp. 16-54. Utah State University Press, Logan, UT.
Burroughs, J. N., Grimes, J. M., Mertens, P. P., and Stuart, D. I. (1995).
Crystallization and preliminary X-ray analysis of the core particle of
bluetongue virus. Virology 210, 217-220.
Carmeliet, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nat.
Med. 6, 389-95.
Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in cancer and other
diseases. Nature 407, 249-257.
Chang, L., and Karin, M. (2001). Mammalian MAP kinase signalling cascades.
Nature 410, 37–40.
Chiang, E. T., Persaud-Sawin, D. –T, Kulkarni, S., Garcia, J. G., and Imani, F.
(2006). Bluetongue virus and double-stranded RNA increase human
vascular permeability: Role of p38 MAPK. J. Clin. Immunol. 26, 406-416.
Clerici, M., and Shearer, G. M. (1993). A Th1 to Th2 switch is a critical step in
the etiology of HIV infections. Immunol. Today 14, 107-111.
Cobb, M. H., and Goldsmith, E. J. (1995). How MAP kinases are regulated. J.
Biol. Chem. 270, 14843-14846.
Craven, R. C., Harty, R. N., Paragas, J., Palese, P., and Wills, J. W. (1999). Late
domain function identified in the vesicular stomatitis virus M protein by use
of rhabdovirus-retrovirus chimeras. J. Virol. 73, 3359-3365.
Dales, S. (1973). Early events in cell-animal virus interactions. Bacteriol. Rev.
37, 103-135.

34
Dance, M., Montagner, A., Salles, J. P., Yart, A., and Raynal, P. (2008). The
molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase
(ERK1/2) pathway. Cell Signal. 20, 453-49.
DeMaula, C.D., Jutila, M. A., Wilson, D. W. and MacLachlan, N. J. (2001).
Infection kinetics, prostacyclin release and cytokine-mediated modulation
of the mechanism of cell death during bluetongue virus infection of
cultured ovine and bovine pulmonary artery and lung microvascular
endothelial cells. J. Gen. Virol. 82, 787-794.
DeMaula, C. D., Leutenegger, C. M., Bonneau, K. R., and MacLachlan, N. J.
(2002a). The role of endothelial cell-derived inflammatory and vasoactive
mediators in the pathogenesis of bluetongue. Virology 296, 330-337.
DeMaula, C. D., Leutenegger, C. M., Jutila, M. A., and MacLachlan, N. J.
(2002b). Bluetongue virus-induced activation of primary bovine lung
microvascular endothelial cells. Vet. Immunol. Immunopathol. 86, 147157.
Deutscher, J., and Saier, M. H., Jr. (2005). Ser/Thr/Tyr protein phosphorylation
in bacteria - for long time neglected, now well established. J. Mol.
Microbiol. Biotechnol. 9, 125-131.
Dodeller, F., and Schulze-Koops, H. (2006). The p38 mitogen-activated protein
kinase signaling cascade in CD4 T cells. Arthritis Res. Ther. 8, 205.
Earnshaw, W. C. (1995). Nuclear changes in apoptosis. Curr. Opin. Cell Biol. 7,
337-343.
Eaton, B. T., and Hyatt, A. D. (1989). Association of bluetongue virus with the
cytoskeleton. Subcell. Biochem. 15, 233-273.
Eaton, B. T., Hyatt, A. D., and White, J. R. (1988). Localization of the
nonstructural protein NS1 in bluetongue virus-infected cells and its
presence in virus particles. Virology 163, 527-537.
Els, H. J., and Verwoerd, D. W. (1969). Morphology of bluetongue virus.
Virology 38, 213-219.
Erasmus, B. J. (1975). Bluetongue in sheep and goats. Aust. Vet. J. 51, 165170.
Fillmore, G. C., Lin, H., and Li, J. K. –K. (2002). Localization of the singlestranded RNA-binding domains of bluetongue virus nonstructural protein
NS2. J. Virol. 76, 499-506.

35
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C.
(1998). Potent and specific genetic interference by double-stranded RNA
in Caenorhabditis elegans. Nature 391, 806-811.
Forzan, M., Wirblich, C., and Roy, P. (2004). A capsid protein of nonenveloped
bluetongue virus exhibits membrane fusion activity. Proc. Natl. Acad. Sci.
USA 101, 2100-2105.
Foster, N. M., and Jones, R. H. (1979). Multiplication rate of bluetongue virus in
the vector Culicoides variipennis (Diptera: Ceratopogonidae) infected
orally. J. Med. Entomol. 15, 302-303.
French, T. J., and Roy, P. (1990). Synthesis of bluetongue virus (BTV) corelike
particles by a recombinant baculovirus expressing the two major structural
core proteins of BTV. J. Virol. 64, 1530-1536.
Fukusho, A., Yu, Y., Yamaquchi, S., and Roy, P. (1989). Completion of the
sequence of bluetongue virus serotype 10 by the characterization of a
structural protein, VP6, and a non-structural protein, NS2. J. Gen. Virol.
70, 1677-1689.
Furwichi, Y., and Shatkin, A. J. (1977). 5'- Termini of reovirus mRNA: ability of
viral cores to form caps post-transcriptionally. Virology 77, 566-578.
Galanis, E., Okuno, S. H., Nascimento, A. G., Lewis, B. D., Lee, R. A., Oliveira,
A. M., Sloan, J. A., Atherton, P., Edmonson, J. H., Erlichman, C., Randlev,
B., Wang, Q., Freeman, S., and Rubin, J. (2005). Phase I-II trial of
ONYX-015 in combination with MAP chemotherapy in patients with
advanced sarcomas. Gene Ther. 12, 437-445.
Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K.
H., Wang, H. E., Wettstein, D. A., Stray, K. M., Cote, M., Rich, R. L.,
Myszka, D. G., and Sundquist, W. I. (2001). Tsg101 and the vacuolar
protein sorting pathway are essential for HIV-1 budding. Cell 107, 55-65.
Ge, B., Gram, H., Di Padova, F., Huang, B., New, L., Ulevitch, R. J., Luo, Y., and
Han, J. (2002). MAPKK-independent activation of p38alpha mediated by
TAB1-dependent autophosphorylation of p38alpha. Science 295, 12911294.
Gitlin, L., Barchet, W., Gilfillan, S., Cella, M., Beutler, B., Flavell, R. A., Diamond,
M. S., and Colonna, M. (2006). Essential role of MDA-5 in type I IFN
responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. USA 103, 8459-8464.

36
Gorman, B. M. (1990). The bluetongue viruses. Curr. Top. Microbiol. Immunol.
162, 1-19.
Gould, A. R. (1988a). Conserved and non-conserved regions of the outer coat
protein, VP2, of the Australian bluetongue serotype 1 virus, revealed by
sequence comparison to the VP2 of North American BTV serotype 10.
Virus Res. 9, 145-158.
Gould, A. R. (1988b). The use of recombinant DNA probes to group and type
orbiviruses. A comparison of Australian and South African isolates. Arch.
Virol. 99, 205-220.
Grimes, J., Basak, A. K., Roy, P., and Stuart, D. (1995). The crystal structure of
bluetongue virus VP7. Nature 373, 167-170.
Grimes, J. M., Burroughs, J. N., Gouet, P., Diprose, J. M., Malby, R., Zientara,
S., Merttens, P. P. C., and Stuart, D. I. (1998). The atomic structure of
the bluetongue viurs core. Nature 395, 470-478.
Grivennikov, S. I., Kuprash, D. V., Liu, Z. G., and Nedospasov, S. A. (2006).
Intracellular signals and events activated by cytokines of the tumor
necrosis factor superfamily: From simple paradigms to complex
mechanisms. Int. Rev. Cytol. 252, 129-161.
Guo, Z. S., Naik, A., O’Malley, M. E., Popovic, P., Demarco, R., Hu, Y., Yin, X.,
Yang, S., Zeh, H. J., Moss, B., Lotze, M. T., and Bartlett, D. L. (2005).
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host
range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res. 65, 99919998.
Han, Z., and Harty, R. N. (2004). The NS3 protein of bluetongue virus exhibits
viroporin-like properties. J. Biol. Chem. 279, 43092-43097.
Hardy, W., and Price, D. A. (1952). Soremuzzle of sheep. J. Am. Vet. Med.
Assoc. 120, 23-25.
Harty, R. N., Brown, M. E., Wang, G., Huibregtse, J., and Hayes, F. P. (2000). A
PPXY motif within the VP40 protein of Ebola virus interacts physically and
functionally with a ubiquitin ligase: Implications for filovirus budding. Proc.
Natl. Acad. Sci. USA 97, 13871-6.
Hassan, S. H., Wirblich, C., Forzan, M., and Roy, P. (2001). Expression and
functional characterization of bluetongue virus VP5 protein: Role in cellular
permeabilization. J. Virol. 75, 8356-8367.

37
Hassan, S. S., and Roy, P. (1999). Expression and functional characterization
of bluetongue virus VP2 protein role in cell entry. J. Virol. 73, 9832-42.
Hayama, E., and Li, J. K. –K. (1994). Mapping and characterization of antigenic
epitopes and the nucleic acid-binding domains of the VP6 protein of
bluetongue viruses. J. Virol. 68, 3604-3611.
Hersey, P., Zhuang, L., and Zhang, X. D. (2006). Current strategies in
overcoming resistance of cancer cells to apoptosis melanoma as a model.
Int. Rev. Cytol. 251, 131-158.
Hewat, E. A., Booth, T. F., Wade, R. H., and Roy, P. (1992). 3-D reconstruction
of bluetongue virus tubules using cryoelectron microscopy. J. Struct. Biol.
108, 35-48.
Heylbroeck, C., Balachandran, S., Servant, M. J., DeLuca, C., Barber, G. N., Lin,
R., and Hiscott, J. (2000). The IRF-3 transcription factor mediates sendai
virus-induced apoptosis. J. Virol. 74, 3781-3792.
Hoebe, K., Janssen, E., and Beutler, B. (2004). The interface between innate
and adaptive immunity. Nat. Immunol. 5, 971-974.
Hopkins, P. A., and Sriskandan, S. (2005). Mammalian Toll-like receptors: to
immunity and beyond. Clin. Exp. Immunol. 140, 395–407.
Horscroft, N. J., and Roy, P. (2000). NTP binding and phosphohydrolase activity
associated with purified bluetongue virus non-structural protein NS2. J.
Gen. Virol. 81, 1961-1965.
Howell, P. G., and Verwoerd, D. W. (1971). Bluetongue virus. Virol. Monogr. 9,
35-74.
Howell, P. G., Verwoerd, D. W., and Oellermann, R. A. (1967). Plaque
formation by bluetongue virus. Onderstepoort J. Vet. Res. 34, 317-332.
Howerth, E. W., and Tyler, D. E. (1988). Experimentally induced bluetongue
virus infection in white-tailed deer ultrastructural findings. Am. J. Vet. Res.
49, 1914-1922.
Hu, J., Dong, D. Y., Li, J. K. -K., Chen, D. E., Liang, K., and Liu, J. (2008).
Selective in vitro cytotoxic effect of human cancer cells by bluetongue
virus-10. Acta Oncologica 47, 124-134.
Huang, I. J., Hayama, E., Jeong, Y. J., and Li, J. K. –K. (1993). Conservation of
the segment 4 gene sequence and of a leucine zipper motif in VP4 among
five US bluetongue viruses. Virology 195, 772-779.

38
Huang, I. J., Hwang, G. Y., Yang, Y. Y., Hayama, E., and Li, J. K. –K. (1995).
Sequence analyses and antigenic epitope mapping of the putative RNAdirected RNA polymerase of five U.S. bluetongue viruses. Virology 214,
280-288.
Hubbard, S. R., and Till, J. H. (2000). Protein tyrosine kinase structure and
function. Annu. Rev. Biochem. 69, 373-398.
Huismans, H. (1979). Protein synthesis in bluetongue virus-infected cells.
Virology 92, 385-396.
Huismans, H., and Cloete, M. (1987). A comparison of different cloned
bluetongue virus genome segments as probes for the detection of virusspecified RNA. Virology 158, 373-380.
Huismans, H., and Els, H. J. (1979). Characterization of the tubules associated
with the replication of three different orbiviruses. Virology 92, 397-406.
Huismans, H., and Erasmus, B. J. (1981). Identification of the serotype-specific
and group-specific antigens of bluetongue virus. Onderstepoort J. Vet.
Res. 48, 51-58.
Huismans, H., and van Dijk, A. A. (1990). Bluetongue virus structural
components. Curr. Top. Microbiol. Immunol. 162, 21-41.
Huismans, H., van Dijk, A. A., and Bauskin, A. R. (1987a). In vitro
phosphorylation and purification of a nonstructural protein of bluetongue
virus with affinity for single-stranded RNA. J. Virol. 61, 3589-3595.
Huismans, H., van Dijk, A. A., and Els, H. J. (1987b). Uncoating of parental
bluetongue virus to core and subcore particles in infected L cells. Virology
157, 180-188.
Huynh, H., Nguyen, T. –T. –T., Chow, K. H. P., Tan, P. H., Soo, K. C., and Tran,
E. (2003). Over-expression of the mitogen-activated protein kinase
(MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor
progression and apoptosis. BMC Gastroenterol. 3, 1-21.
Hwang, G. Y., Chiou, J. F., Yang, Y. Y., and Li, J. K. –K. (1993). High-sequence
conservation among the United States bluetongue viruses cognate M2
genes which encode the nonstructural NS1 tubule protein. Virology 192,
321-327.

39
Hyatt, A. D., and Eaton, B. T. (1988). Ultrastructural distribution of the major
capsid proteins within bluetongue virus and infected cells. J. Gen. Virol.
69, 805-815.
Hyatt, A. D., Zhao, Y., and Roy, P. (1993). Release of bluetongue virus-like
particles from insect cells is mediated by BTV nonstructural protein
NS3/NS3A. Virology 193, 592-603.
IAHD. (2006). International Animal Health Division Preliminary outbreak
assessment. VITT 1200/BT.
Jeggo, M. H., Wardley, R. C., and Taylor, W. P. (1983). Host response to
bluetongue virus. In “Double-Stranded RNA Viruses” (R. W. Compans,
and D. H. L. Bishop, eds.), pp. 353-359. Elsevier, New York.
Jeong, S.J., Dasgupta, A., Jung, K. J., Um, J. H., Burke, A., Park, H. U., and
Brady, J. N. (2007). PI3K/AKT inhibition induces caspase-dependent
apoptosis in HTLV-1-transformed cells. Virology 370, 264-272.
Johnson, D. A., Akamine, P., Radzio-Andzelm, E., Madhusudan, M., and Taylor,
S.S. (2001). Dynamics of cAMP-dependent protein kinase. Chem. Rev.
101, 2243-2270.
Johnson, L. N., and Lewis, R. J. (2001). Structural basis for control by
phosphorylation. Chem. Rev. 101, 2209-2242.
Johnson, G. L., and Lapadat, R. (2002). Mitogen-activated protein kinase
pathways mediated by ERK, JNK, and p38 protein kinases. Science 298,
1911-1912.
Johnson, D. J., Ostlund, E. N., Stallknecht, D. E., Goekjian, V. H., JenkinsMoore, M., and Harris, S. C. (2006). First report of bluetongue virus
serotype 1 isolated from a white-tailed deer in the United States. J. Vet.
Diagn. Invest. 18, 398-401.
Joklik, W. K. (1983). The members of the family reoviridae. In “The Reoviridae”
(W. K. Joklik, ed.), pp. 1-7. Plenum, New York.
Kahlon, J., Sugiyama, K., and Roy, P. (1983). Molecular basis of bluetongue
virus neutralization. J. Virol. 48, 627-632.
Kam, P. C. A., and Ferch, N. I. (2000). Apoptosis: Mechanisms and clinical
implications. Anaesthesia 55, 1081-1093.
Kar, A. K., Ghosh, M., and Roy, P. (2004). Mapping the assembly pathway of
bluetongue virus scaffolding protein VP3. Virology 324, 387-399.

40
Kar, A. K., Iwatani, N., and Roy, P. (2005). Assembly and intracellular
localization of the bluetongue virus core protein VP3. J. Virol. 79, 1148711495.
Kar, A. K., and Roy, P. (2003). Defining the structure-function relationships of
bluetongue virus helicase protein VP6. J. Virol. 77, 11347-11356.
Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K.,
Tsujimura, T., Takeda, K., Fujita, T., Takeuchi, O., and Akira, S. (2005).
Cell type-specific involvement of RIG-I in antiviral response. Immunity 23,
19–28.
Kerr, J. F. R., Wyllie, A. H., and Currie, A. R. (1972). Apoptosis: A basic
biological phenomenon with wide-ranging implications in tissue kinetics.
British J. Cancer 26, 239-257.
Kitamura, T., Ogawa, W., Sakaue, H., Hino, Y., Kuroda, S., Takata, M.,
Matsumoto, M., Maeda, T., Konishi, H., Kikkawa, U., and Kasuga, M..
(1998). Requirement for activation of the serine-threonine kinase akt
(Protein Kinase B) in insulin stimulation of protein synthesis but not of
glucose transport. Mol. Cell. Biol. 18, 3708-3717.
Kornblau, S. M., Womble, M., Qiu, Y. H., Jackson, C. E., Chen, W., Konopleva,
M., Estey, E. H., and Andreeff, M. (2006). Simultaneous activation of
multiple signal transduction pathways confers poor prognosis in acute
myelogenous leukemia. Blood 108, 2358–2365.
Knight, P. R., Sreekumar, A., Siddiqui, J., Laxman, B., Copeland, S., Chinnaiyan,
A., and Remick, D. G. (2004). Development of a sensitive microarray
immunoassay and comparison with standard enzyme-linked immunoassay
for cytokine analysis. Shock 21, 26-30.
Krebs, E. G. (1981). Phosphorylation and dephosphorylation of glycogen
phosphorylase: a prototype for reversible covalent enzyme modification.
Curr. Top. Cell Regul. 18, 401-419.
Kyriakis, J. M., Woodgett, J. R. and Avruch, J. (1995). The stress-activated
protein kinases. A novel ERK subfamily responsive to cellular stress and
inflammatory cytokines. Ann. N.Y. Acad. Sci. 766, 303-319.
Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J.,
Devon, K., Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D.,
Harris, K., Heaford, A., Howland, J., Kann, L., Lehoczky, J., LeVine, R.,
McEwan, P., McKernan, K., Meldrim, J., Mesirov, J.P., Miranda, C.,
Morris, W., Naylor, J., Raymond, C., Rosetti, M., Santos, R., Sheridan, A.,

41
Sougnez, C., Stange-Thomann, N., Stojanovic, N., Subramanian, A.,
Wyman, D., Rogers, J., Sulston, J., Ainscough, R., Beck, S., Bentley, D.,
Burton, J., Clee, C., Carter, N., Coulson, A., Deadman, R., Deloukas, P.,
Dunham, A., Dunham, I., Durbin, R., French, L., Grafham, D., Gregory, S.,
Hubbard, T., Humphray, S., Hunt, A., Jones, M., Lloyd, C., McMurray, A.,
Matthews, L., Mercer, S., Milne, S., Mullikin, J. C., Mungall, A., Plumb, R.,
Ross, M., Shownkeen, R., Sims, S., Waterston, R. H., Wilson, R. K.,
Hillier, L. W., McPherson, J. D., Marra, M. A., Mardis, E. R., Fulton, L. A.,
Chinwalla, A. T., Pepin, K. H., Gish, W. R., Chissoe, S. L., Wendl, M. C.,
Delehaunty, K. D., Miner, T. L., Delehaunty, A., Kramer, J. B., Cook, L. L.,
Fulton, R. S., Johnson, D. L., Minx, P. J., Clifton, S. W., Hawkins, T.,
Branscomb, E., Predki, P., Richardson, P., Wenning, S., Slezak, T.,
Doggett, N., Cheng, J. F., Olsen,A., Lucas, S., Elkin, C., Uberbacher, E.,
Frazier, M., Gibbs, R. A., Muzny, D. M., Scherer, S. E., Bouck, J. B.,
Sodergren, E. J., Worley, K. C., Rives, C. M., Gorrell, J. H., Metzker, M.
L., Naylor, S. L., Kucherlapati, R. S., Nelson, D. L., Weinstock, G. M.,
Sakaki, Y., Fujiyama, A., Hattori, M., Yada, T., Toyoda, A., Itoh, T.,
Kawagoe, C., Watanabe, H., Totoki, Y., Taylor, T., Weissenbach, J.,
Heilig, R., Saurin, W., Artiguenave, F., Brottier, P., Bruls, T., Pelletier, E.,
Robert, C., Wincker, P., Smith, D. R., Doucette-Stamm, L., Rubenfield, M.,
Weinstock, K., Lee, H. M., Dubois, J., Rosenthal, A., Platzer, M.,
Nyakatura, G., Taudien, S., Rump, A., Yang, H., Yu, J., Wang, J., Huang,
G., Gu, J., Hood, L., Rowen, L., Madan, A., Qin, S., Davis, R. W.,
Federspiel, N. A., Abola, A. P., Proctor, M. J., Myers, R. M., Schmutz, J.,
Dickson, M., Grimwood, J., Cox, D. R., Olson, M. V., Kaul, R., Raymond,
C., Shimizu, N., Kawasaki, K., Minoshima, S., Evans, G. A., Athanasiou,
M., Schultz, R., Roe, B. A., Chen, F., Pan, H., Ramser, J., Lehrach, H.,
Reinhardt, R., McCombie, W. R., de la Bastide, M., Dedhia, N., Blöcker,
H., Hornischer, K., Nordsiek, G., Agarwala, R., Aravind, L., Bailey, J. A.,
Bateman, A., Batzoglou, S., Birney, E., Bork, P., Brown, D. G., Burge, C.
B., Cerutti, L., Chen, H. C., Church, D., Clamp, M., Copley, R. R., Doerks,
T., Eddy, S. R., Eichler, E. E., Furey, T. S., Galagan, J., Gilbert, J. G.,
Harmon, C., Hayashizaki, Y., Haussler, D., Hermjakob, H., Hokamp, K.,
Jang, W., Johnson, L. S., Jones, T. A., Kasif, S., Kaspryzk, A., Kennedy,
S., Kent, W. J., Kitts, P., Koonin, E. V., Korf, I., Kulp, D., Lancet, D., Lowe,
T. M., McLysaght, A., Mikkelsen, T., Moran, J. V., Mulder, N., Pollara, V.
J., Ponting, C. P., Schuler, G., Schultz, J., Slater, G., Smit, A. F., Stupka,
E., Szustakowski, J., Thierry-Mieg, D., Thierry-Mieg, J., Wagner, L.,
Wallis, J., Wheeler, R., Williams, A., Wolf, Y. I., Wolfe, K. H., Yang, S. P.,
Yeh, R. F., Collins, F., Guyer M. S., Peterson, J., Felsenfeld, A.,
Wetterstrand, K.A., Patrinos, A.,, Morgan, M. J., de Jong, P., Catanese, J.
J., Osoegawa, K., Shizuya, H., Choi, S., and Chen, Y. J. (2001). Initial
sequencing and analysis of the human genome. Nature 409, 860-921.
Lecatsas, G. (1968). Electron microscopic study of the formation of bluetongue
virus. Onderstepoort J. Vet. Res. 35, 139-149.

42
Leng, S. X., McElhaney, J. E., Walston, J. D., Xie, D., Fedarko, N. S., Kuchel, G.
A. (2008). ELISA and multiplex technologies for cytokine measurement in
inflammation and aging research. J. Gerontol. A. Biol. Sci. Med. Sci. 63,
879-884.
Lloyd, A. C. (2006). Distinct functions for ERKs? J. Biol. 5, 13.
Lodish, H., Berk, A., Zipursky, S. L., Matsudaira, P., Baltimore, D., and Darnell, J.
(2000). Cancer. In “Molecular Cell Biology” (H. A. Lodish, et al. eds), pp.
1054-1084. Freeman, San Francisco.
Lymperopoulos, K., Noad, R., Tosi, S., Nethisinghe, S., Brierly, I., and Roy, P.
(2006). Specific binding of bluetongue virus NS2 to different viral plusstrand RNAs. Virology 353, 17-26.
Mahrt, C. R., and Osburn, B. I. (1986). Experimental bluetongue virus infection
of sheep; effect of vaccination: Pathologic, immunofluorescent, and
ultrastructural studies. Am. J. Vet. Res. 47, 1198-1203.
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002).
The Protein Kinase Complement of the Human Genome. Science 298,
1912-1934.
Manso-Ribeiro, J., Rosa-Azevedo, J. A., Noronha, F. O., Braco-Forte, M. C.,
Grave-Pereira, C., and Vasco-Fernandes, M.. (1957). Fievre catarrhale
du mouton (Blue-tongue). Bull. Off. Int. Epizoot. 48, 350-367.
Martin, S. J. (1993). Apoptosis: Suicide, execution or murder? Trends Cell Biol.
3,141-144.
Martin, S. A., and Zweerink, H. J. (1972). Isolation and characterization of two
types of bluetongue virus particles. Virology 50, 495-506.
Martinez-Costas, J., Sutton, G., Ramadevi, N., and Roy, P. (1998).
Guanylyltransferase and RNA 5'-triphosphatase activities of the purified
expressed VP4 protein of bluetongue virus. J. Mol. Biol. 280, 859-866.
Mayo, L. D., Seo, Y. R., Jackson, M. W., Smith, M. L., Rivera-Guzman, J.,
Korgaonkar, C. K., and Donner, D. B. (2005). Phosphorylation of human
p53 at serine 46 determines promoter selection and whether apoptosis is
attenuated or amplified. J. Biol. Chem. 280, 25953-25959.
McDill, L. (2002). Bluetongue Virus, Animal Disease Diagnostic Laboratory:
www.addl.purdue.edu/newsletters/2002/spring/bluetongue.shtml.

43
McPhee, D. A., Parsonson, I. A., and Dell-Porta, A. J. (1982). Comparative
studies on the growth of Australian bluetongue virus serotypes in
continuous cell lines and embryonated chicken eggs. Vet. Microbiol. 7,
401-410.
Mecham, J. O., Dean, V. C., and Jochim, M. M. (1986). Correlation of serotype
specificity and protein structure of the five U.S. serotypes of bluetongue
virus. J. Gen. Virol. 67, 2617-2624.
Meloche S., and Pouysségur, J. (2007). The ERK1/2 mitogen-activated protein
kinase pathway as a master regulator of the G1- to S-phase transition.
Oncogene 26, 3227-3239.
Mertens, P. P., and Sangar, D. V. (1985). Analysis of the terminal sequences of
the genome segments of four orbiviruses. Prog. Clin. Biol. Res. 178, 371387.
Meylan, E., Burns, K., Hofmann, K., Blancheteau, V., Martinon, F., Kelliher, M.,
and Schopp, J. T. (2004). RIP1 is an essential meditor of Toll-like
receptor 3-induced NF-kappa B activation. Nat. Immunol. 5, 503-507.
Mitchell, J. Baik, W. N., Castellino, F. J., and Miles, L. A. (2006). Plasminogen
inhibits T TNFα-induced apoptosis in monocytes. Blood 107, 4383–4390.
Modrof, J., Lymperopoulos, K., and Roy, P. (2005). Phosphorylation of
bluetongue virus nonstructural protein 2 is essential for formation of viral
inclusion bodies. J. Virol. 79, 10023-10031.
Morgan, E. M., and Zweerink, H. J. (1975). Characterization of transcriptase
and replicase particles isolated from reovirus-infected cells. Virology 68,
455-466.
Morgan, E., Varro, R., Sepulveda, H., Ember, J. A., Apgar, J., Wilson, J., Lowe,
L., Chen, R., Shivraj, L., Agadir, A., Campos, R., Ernst, D., and Gaur, A.
(2004). Cytometric bead array: a multiplexed assay platform with
applications in various areas of biology. Clin. Immunol. 110, 252-266.
Mortola, E., Noad, R., and Roy, P. (2004). Bluetongue virus outer capsid
proteins are sufficient to trigger apoptosis in mammalian cells. J. Virol. 78,
2875-2883.
Mumby, M. C., and Walter, G. (1993). Protein serine/threonine phosphatases:
structure, regulation, and functions in cell growth. Physiological Reviews
73, 673.

44
Myers, R., Greiner, S., Harvey, M., Soeffker, D., Frenzke, M., Abraham, K.,
Shaw, A., Rozenblatt, S., Federspiel, M. J., Russell, S. J., and Peng, K.
W. (2005). Oncolytic activities of approved mumps and measles vaccines
for therapy of ovarian cancer. Cancer Gene. Ther. 12, 593-599.
Nagaleekar, V. K., Tiwari, A. K., Kataria, R. S., Bais, M. V., Ravindra, P. V., and
Kumar, S. (2007). Bluetongue virus induces apoptosis in cultured
mammalian cells by both caspase-dependent extrinsic and intrinsic
apoptotic pathways. Arch. Virol. 152, 1751-1756.
Nason, E. L., Rothagel, R., Mukherjee, S. K., Kar, A. K, Forzan, M., Prasad, B.
V., and Roy, P. (2004). Interactions between the inner and outer capsids
of bluetongue virus. J. Virol. 78, 8059-8067.
Newton, A. C. (2003). Regulation of the ABC kinases by phosphorylation,
protein kinase C as a paradigm. J. Biochem. 370, 361-371.
Nibert, M. L., Schiff, L. A., and Fields B. N. (1996). Reoviruses and their
replication. In “Fundamental Virology” (B. N. Fields, D. M. Knipe, and P.
M. Howley, eds.), pp. 691-730. Lippincott-Raven Publishers, Philadelphia.
O'Neill, L. A. (2006). Targeting signal transduction as a strategy to treat
inflammatory diseases. Nat. Rev. Drug Discov. 5, 549-563
Osaki, M., Oshimura, M., and Ito, H. (2004). PI3K-Akt pathway: Its functions
and alterations in human cancer. Apoptosis 9, 667-676.
Patan, S. (2004). Vasculogenesis and angiogenesis. Can. Treat. Res. 117, 332.
Patil, C. S., and Kirkwood, K. L. (2007). P38 MAPK signaling in oral-related
diseases. J. Dent. Res. 86, 812-825.
Pearson, G., Robinson, F., Beers, G. T., Xu, B. E., Karandikar, M., Berman, K.,
and Cobb, M. H. (2001). Mitogen-activated protein (MAP) kinase
pathways: regulation and physiological functions. Endocr. Rev. 22, 153–
183.
Porras, A., Zuluaga, S., Black, E., Valladares, A., Alvarez, A. M., Ambrosino, C.,
Benito, M., and Nebreda, A. R. (2004). p38α mitogen-activated protein
kinase sensitizes cells to apoptosis induced by different stimuli. Mol. Biol.
Cell 15, 922–933.
Ramadevi, N., Burroughs, N. J., Mertens, P. P., Jones, I. M., and Roy, P.
(1998a). Capping and methylation of mRNA by purified recombinant VP4
protein of bluetongue virus. Proc. Natl. Acad. Sci. USA 95, 13537-13542.

45
Ramadevi, N., Rodriguez, J., and Roy, P. (1998b). A leucine zipper-like domain
is essential for dimerization and encapsidation of bluetongue virus
nucleocapsid protein VP4. J. Virol. 72, 2983-2990.
Ramadevi, N., and Roy, P. (1998). Bluetongue virus core protein VP4 has
nucleoside triphosphate phosphohydrolase activity. J. Gen. Virol. 79,
2475-2480.
Raman, M., Chen, M., and Cobb, M. H. (2007). Differential regulation and
properties of MAPKs. Oncogene 26, 3100-3112
Ray L.B., and Sturgill, T. J. (1988). Characterization of insulin-stimulated
microtubule-associated protein kinase. Rapid isolation and stabilization of
a novel serine/threonine kinase from 3T3-L1 cells. J. Biol. Chem. 263,
12721-127217.
Reuter, C., Morgan, M., and Bergmann, L. (2000). Targeting the Ras signaling
pathway: A rational, mechanism-based treatment for hematologic
malignancies? Blood 96, 1655-1669.
Roy, P. (1989). Bluetongue virus genetics and genome structure. Virus Res.
13, 179-206.
Roy, P. (1992). Bluetongue virus proteins. J. Gen. Virol. 73, 3051-3064.
Roy, P. (1996). Orbivirus structure and assembly. Virology 216, 1-11.
Roy, P., Adachi, A., Urakawa, T., Booth, T. F., and Thomas, C. P. (1990).
Identification of bluetongue virus VP6 protein as a nucleic acid-binding
protein and the localization of VP6 in virus-infected vertebrate cells. J.
Virol. 64, 1-8.
Rubin, G. M., Yandell, M. D., Wortman, J. R., Gabor-Miklos, G. L., Nelson, C. R.,
Hariharan, I. K., Fortini, M. E., Li, P. W., Apweiler, R., Fleischmann, W.,
Cherry, J. M., Henikoff, S., Skupski, M. P., Misra, S., Ashburner, M.,
Birney, E., Boguski, M. S., Brody, T., Brokstein, P., Celniker, S. E.,
Chervitz, S. A., Coates, D., Cravchik, A., Gabrielian, A., Galle, R. F.,
Gelbart, W. M., George, R. A., Goldstein, L. S. B., Gong, F., Guan, P.,
Harris, N. L., Hay, B. A., Hoskins, R. A., Li, J., Li, Z., Hynes, R. O., Jones,
S. J. M., Kuehl, P. M., Lemaitre, B., Littleton, J. T., Morrison, D. K.,
Mungall, C., O'Farrell, P. H., Pickeral, O. K., Shue, C., Vosshall, L. B.,
Zhang, J., Zhao, Q., Zheng, X. H., Zhong, F., Zhong, W., Gibbs, R.,
Venter, J. C., Adams, M. D. and Lewis, S. (2000). Comparative genomics
of the eukaryotes. Science 287, 2204–2215.

46
Ruscica, M., Dozio, E., Motta, M., and Magni, P. (2007). Modulatory actions of
neuropeptide Y on prostate cancer growth: role of MAP kinase/ERK 1/2
activation. Adv. Exp. Med. Biol. 604, 96-100.
Saha, S. K., Pietras, E. M., He, J. Q., Kang, J. R., Liu, S. –Y., Oganesyan, G.,
Shahangian, A., Zarnegar, B., Shiba, T. L., Wang, Y., and Cheng, G.
(2006). Regulation of antiviral responses by a direct and specific
interaction between TRAF3 and Cardif. EMBO J. 25, 3257–3263.
Salh, B. (2007). c-Jun N-terminal kinases as potential therapeutic targets.
Expert Opin. Ther. Targets 11, 1339-1353.
Schindler, J. F., Monahan, J. B., and Smith, W. G. (2007). p38 pathway kinases
as anti-inflammatory drug targets. J. Dent. Res. 86, 800-811.
Singh, R., and Czaja, M. J. (2007). Regulation of hepatocyte apoptosis by
oxidative stress. J. Gastroenterol. Hepatol. 1, S45-48
Sledz, C. A., and Williams, B. R. G. (2005). RNA interference in biology and
disease. Blood 106, 787–794.
Spruell, J. (1905). Malarial catarrhal fever (bluetongue) of sheep in South Africa.
J. Comp. Pathol. Ther. 18, 321-337.
Ståhl, A., Svensson, M., Mörgelin, M., Svanborg, C., Tarr, P. I., Mooney, J. C.,
Watkins, S. L., Johnson, R., and Karpman, D. (2006).
Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to
platelets through TLR4 and CD62 and is detected on circulating platelets
in patients with hemolytic uremic syndrome. Blood 108, 167–176.
Stauber, N., Martinez-Costas, J., Sutton, G., Monastyrskaya, K., and Roy, P.
(1997). Bluetongue virus VP6 protein binds ATP and exhibits an RNAdependent ATPase function and a helicase activity that catalyze the
unwinding of double-stranded RNA substrates. J. Virol. 71, 7220-7226.
Sturzenbecker, L., Nibert, M., Furlong, D., and Fields, B. N. (1987). Intracellular
digestion of reovirus particles requires a low pH and is an essential step in
the viral infectious cycle. J. Virol. 61, 2351-2361.
Takeda, K., Kaisho, T., and Akira, S. (2003). Toll-like receptors. Annu. Rev.
Immunol. 21, 335-376.
Takeda, K., Noguchi, T., Naguro, I., and Ichijo, H. (2007). Apoptosis signalregulating kinase 1 in stress and immune response. Annu. Rev.
Pharmacol. Toxicol. 48, 199-225.

47
Tan, B. H, Nason, E., Staeuber, N., Jiang, W., Monastryrskaya, K, and Roy, P.
(2001). RGD tripeptide of bluetongue virus VP7 protein is responsible for
core attachment to Culicoides cells. J. Virol. 75, 3937-3947.
Taraporewala, Z. F., Chen, D., and Patton, J. T. (2001). Multimers of the
bluetongue virus nonstructural protein, NS2, possess nucleotidyl
phosphatase activity: Similarities between NS2 and rotavirus NSP2.
Virology 280, 221-231.
Theofilopoulos, A. N., Baccala, R., Beutler, B., and Kono, D. H. (2005). Type I
interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev.
Immunol. 23, 307–336.
Thomas, C. P., Booth, T. F., and Roy, P. (1990). Synthesis of bluetongue virusencoded phosphoprotein and formation of inclusion bodies by
recombinant baculovirus in insect cells: It binds the single-stranded RNA
species. J. Gen. Virol. 71, 2073-2083.
Toker, A., and Yoeli-Lerner, M. (2006). Akt signaling and cancer: Surviving but
not moving on. Cancer Res. 66, 3963-3966.
Tournier C., Hess, P., Yang, D. D., Xu, J., Turner, T. K., Nimnual, A., Bar-Sagi,
D., Jones, S. N., Flavell, R. A., and Davis, R. J. (2000). Requirement of
JNK for stress-induced activation of the cytochrome c-mediated death
pathway. Science 288, 870-874.
Tyler, K. L., Bronson, R. T., Byers, K. B., and Fields, B. (1985). Molecular basis
of viral neurotropism: Experimental reovirus infection. Neurology 35, 8892.
Uitenweerde, J. M., Theron, J., Stoltz, M. A., and Huismans, H. (1995). The
multimeric nonstructural NS2 proteins of bluetongue virus, African
horsesickness virus, and epizootic hemorrhagic disease virus differ in their
single-stranded RNA-binding ability. Virology 209, 624-632.
Urakawa, T., and Roy, P. (1988). Bluetongue virus tubules made in insect cells
by recombinant baculoviruses: Expression of the NS1 gene of bluetongue
virus serotype 10. J. Virol. 62, 3919-3927.
Urbano, P., and Urbano, F. G. (1994). The Reoviridae family. Comp. Immunol.
Microbiol. Infect. Dis. 17, 151-161.
Valerie, K., Yacoub, A., Hagan, M. P., Curiel, D. T., Fisher, P. B., Grant, S., and
Dent, P. (2007). Radiation-induced cell signaling: Inside-out and outsidein. Mol. Cancer. Ther. 6, 789-801.

48
Van Dijk, A. A., and Huismans, H. (1980). The in vitro activation and further
characterization of the bluetongue virus-associated transcriptase.
Virology 104, 347-356.
Van Dijk, A. A., and Huismans, H. (1988). In vitro transcription and translation of
bluetongue virus mRNA. J. Gen. Virol. 69, 573-581.
Verwoerd, D. W. (1970). Failure to demonstrate in vitro as opposed to in vivo
transcription of the bluetongue virus genome. Onderstepoort J. Vet. Res.
37, 225-227.
Verwoerd, D. W., Els, H. J., DeVilliers, E. M., and Huismans, H. (1972).
Structure of the bluetongue virus capsid. J. Virol. 10, 783-794.
Verwoerd, D. W., Huismans, H., and Erasmus, B. J. (1979). In “Comprehensive
Virology” (H. Fraenken-Contrat and R. R. Wagner, eds.), pp. 285-345.
Plenum, New York.
Verwoerd, D. W., Louw, H., and Oellermann, R. A. (1970). Characterization of
bluetongue virus ribonucleic acid. J. Virol. 5, 1-7.
Wang, Y. (2007). Mitogen-activated protein kinases in heart development and
diseases. Circulation 116, 1413-1423.
Wang, L. F., Hyatt, A. D., Whiteley, P. L., Andrew, M., Li, J. K. –K., and Eaton,
B. T. (1996). Topography and immunogenicity of bluetongue virus VP7
epitopes. Arch. Virol. 141, 111-123.
Watanabe, Y., Millward, S., and Graham, A. F. (1968). Regulation of
transcription of the reovirus genome. J. Mol. Biol. 36, 107-123.
Whicher, J. T., and Evans, S. W. (1990). Cytokines in disease. Clin. Chem.
367, 1269-1281
Widmann, C., Gibson, S., Jarpe, M. B., and Johnson, G. L. (1999). Mitogenactivated protein kinase: Conservation of a three-kinase module from
yeast to human. Physiol Rev. 79, 143-180.
Williams, B. R. (1999). PKR; a sentinel kinase for cellular stress. Oncogene.
18, 6112-6120.
Williams, B. R. (2001). Signal integration via PKR. Sci. STKE 2001, RE2.
Wu, X., Chen, S. Y., Iwata, H., Compans, R. W., and Roy, P. (1992). Multiple
glycoproteins synthesized by the smallest RNA segment (S10) of
bluetongue virus. J. Virol. 66, 7104-7112.

49
Wirblich, C., Bhattacharya, B., and Roy, P. (2006). Nonstructural protein 3 of
bluetongue virus assists virus release by recruiting ESCRT-I protein
Tsg101. J. Virol. 80, 460-473.
Wyllie, A. H. (1997). Apoptosis: An overview. British Medical Bulletin 53: 451465.
Xiao, A.T., Dong, C. Y., Li, J. K. -K., Chen, D. E., Liu, J., and Zhang, W. Y.
(2004). Studies on the infectivity of bluetongue virus strain HbC3 to
several human and animal tumor cells. Virologica. Sinica. 19, 349-352.
Xie, S,, Wang, Q., Wu, H., Cogswell, J., Lu, L., Jhanwar-Uniyal, M., and Dai, W.
(2001). Reactive oxygen species-induced phosphorylation of p53 on
serine 20 is mediated in part by polo-like kinase-3. J. Biol. Chem. 276,
36194-36199.
Yang, Y. Y., and Li, J. K. –K. (1993). Glycosylation of the major outer capsid
protein of bluetongue viruses. Virology 194, 350-354.
Ying, C. C., Blanchette, P., and Branton, P. E. (2007). The adenovirus E4orf6
E3 ubiquitin ligase complex assembles in a novel fashion. Virology 364,
36-44.
Yoeli-Lerner, M., and Toker, A. (2006). Akt/PKB signaling in cancer: A function
in cell motility and invasion. Cell Cycle 5, 603-605.
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi,
M., Taira, K., Akira, S., and Fujita, T. (2004). The RNA helicase RIG-I
has an essential function in double-stranded RNA-induced innate antiviral
responses. Nat. Immunol. 5, 730–737.
Yu, Y., Fukusho, A., Ritter, D. G., and Roy, P. (1988). Complete nucleotide
sequence of the group-reactive antigen VP7 gene of bluetongue virus.
Nucleic Acids Res. 16, 1620.
Zarbl, H., Skup, D., and Millward, S. (1980). Reovirus progeny subviral particles
synthesize uncapped mRNA. J. Virol. 34, 497-505.
Zekri, A. R., Bahnassy, A. A., Seif-Eldin, W. M., Alam El-Din, H. M., Madbouly,
M. S., Zidan, A. Z., El-Hoshy, K., El-Ramly, A., and Abdel-Hamid, N. A.
(2006). Role of Human Papilloma Virus (HPV) in common and genital
warts and its relation to P53 expression. J. Egypt Natl. Canc. Inst. 18:
117-124.

50
Zhou, G., Bao, Z. Q., and Dixon, J. E. (1995). Components of a new human
protein kinase signal transduction pathway. J. Biol. Chem. 270, 1266512669.
Zweerink, H. J., McDowell, M. J., and Joklik, W. K. (1971). Essential and
nonessential noncapsid reovirus proteins. Virology 45, 716-723.

51
CHAPTER 2
BLUETONGUE VIRUS (BTV)-INDUCED CELL DEATH CORRELATES
DIRECTLY WITH BTV-INDUCED CYTOKINE EXPRESSION
ABSTRACT
Bluetongue virus (BTV) naturally infects ruminants, even though it is most
commonly cultured in vitro in baby hamster kidney (BHK-21) and monkey kidney
(Vero) cells. BTV does not normally replicate in human cells though BTV
administration has been shown to cause cell death and apoptosis in human HEP3G and A549 carcinoma transformed cell. In addition, studies suggest that BTV
infection of human cell lines is selective for transformed cells. As a novel
oncolytic virus, understanding the mechanism of cell death may lead to future
therapies for cancer. To better understand the mechanism of BTV-induced cell
death, we determined the rate of BTV-induced as well as polyinosinicpolycytidylic acid (poly I:C)-induced cell death in four cell lines (A498, HEP-G2,
A549, and Vero). We also determined the profile and magnitude of BTV-induced
and poly-I:C-induced cytokine expression in each cell line. Each cell line was
found to express interleukin-6 (IL-6), IL-8, monocyte chemotactic protein 1 (MCP1), regulated upon activation T-cell expressed and secreted protein (RANTES),
tissue inhibitor of metaloproteinases 1 (TIMP-1), and vasoendothelial growth
factor (VEGF). IL-6, IL-8, MCP-1, and RANTES were found to be inducible both
by BTV and poly I:C. The magnitude of cytokine expression was cell line
dependent. BTV-induced cytokine expression correlated directly with BTVinduced cell death.
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INTRODUCTION
The ability of bluetongue virus (BTV) to cause disease is heavily species
dependent. In cell culture, BTV’s ability to replicate and cause cell death is also
quite variable. BTV causes cell death in some human carcinoma transformed
lines while primary cultures are not susceptible to BTV-induced cell death (Xiao
et al., 2004; Chiang et al., 2006). The ability of BTV to cause death in carcinoma
transformed lines can be due to multiple mechanisms including innate immunity.
Our objective was to determine the rates of cell death in 4 cell lines (A498, HEPG2, A549, and Vero). We also determined which cytokines are expressed upon
infection and the contribution of dsRNA to this cytokine expression.
Bluetongue virus (BTV), classified in the genus Orbivirus within the family
Reoviridae, can cause disease in a variety of animals though only in ruminant
species. Though BTV naturally infects ruminants, it is most commonly cultured in
vitro in baby hamster kidney (BHK-21) or monkey kidney (Vero) cells. BTV does
not naturally replicate in humans, but can infect human cells in vitro. Chiang et
al. (2006) demonstrated viral S3 gene replication in BTV-serotype-10-treated
human microvascular lung endothelial cells (ECs), and other studies have
demonstrated BTV infectivity in transformed human cells (Xiao et al., 2004; Hu et
al., 2008). Fig. 2-1 and 2-2 show evidence of BTV-induced cell death in
carcinoma transformed HEP-3G and A549 cells.
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FIG. 2-1. Mockinfected (left) and
BTV-infected (right)
HEP-3G cells.
Visualized by light
microscopy 36 hours
P.I. by Hu et al.,
2008.

FIG. 2-2. Mockinfected (left) and
BTV-infected (right)
A549 cells.
Visualized by light
microscopy 36 hours
P.I. by Hu et al.,
2008.

Chiang et al. (2006) also observed elevated expression of TNFα, IL-1β,
and IL-6 mRNA, in human microvascular lung ECs consistent with cytokine
mRNA expression observed in bovine primary lung microvascular ECs (DeMaula
et al., 2002). However, comparable cytokine expression could be induced with
poly(inosinic):poly(cytidylic) acid (poly I:C), indicating BTV genomic dsRNA may
be the cause of inducible cytokine expression (Chiang et al., 2006).
Our objective was to characterize cell death as well as cytokine and
chemokine expression, in BTV-serotype-17-infected human cells transformed by
carcinoma (A498, HEP-G2, and A549 cells) and determine if poly I:C could
induce similar changes. We hypothesized that BTV would induce cell death in all
tested cells in a time-dependent manner and that infection would lead to the
production of pro-inflammatory cytokines.
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MATERIALS AND METHODS
Cell Culture
Five cell lines were used in this study, including BHK-21 baby hamster
kidney cells, A498 human kidney cells, HEP-G2 human liver cells, A549 human
lung epithelial cells, and Vero African green monkey kidney cells (American Type
Culture Collection, Manassas, VA). Designated CCL-10, HTB-4, HB-8065, CCL185, and CRL-1587, respectively by the American Type Culture Collection. Each
cell line was propagated in 75 cm2 flasks seeded at 1X106 cells and cultured in
MEM/EBSS plus 10% FBS (Hyclone, Logan, UT) under a 5% CO2 atmosphere.
BTV Stock Propagation
Original stocks were triple plaque purified and stored frozen in aliquots
(Kowalik et al., 1990; Li and Yang, 1990). Seed virus was prepared by infecting
BHK-21 cells with frozen viral stock. Cells were infected at 80% confluency and
harvested by scraping three days post infection (P.I.). After scraping, cells were
pelleted, washed, resuspended in fresh media, then gently sonicated three times
using a VirSonic 50 sonicator (VirTis Inc., Gardiner, NY) prior to 0.22 μm filter
sterilization. Viral titer was determined by plaque assay, using Vero cell
monolayers (Fillmore et al., 2002; Hayama and Li, 1994). Mock infections were
similarly prepared using uninfected BHK-21 cells.
Plate Preparation and BTV Infection
96-well plates were seeded one day prior to experimentation in
MEM/EBSS plus 10% FBS (Hyclone Laboratories, Logan, UT), such that the
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culture was approximately 50% confluent when starting the experiment. Prior to
experimentation, plates were rinsed with MEM/EBSS. BTV infection occurred at
an MOI of 1 using BTV serotype 17. Mock infections were performed using a
comparable volume of uninfected BHK-21 cells, prepared as described above.
Plates were incubated at 37 °C under 5% CO2 in MEM/EBSS plus 5% FBS.
Poly I:C Treatment of Cell Lines
Stock poly I:C (Sigma, St. Louis, MO) was prepared at 2 mg/mL in
MEM/EBSS and further prepared as serial half-log dilutions at 0, 0.1, 0.32, 1.0,
3.2, 10, 32, and 100 μg/mL. Three 96-well plates per cell line were prepared as
described above and treated with poly I:C (n=4). Samples of the cell culture
supernatant were taken daily for 3 days (stored at -80 °C) for cytokine analysis,
and one plate from each cell line was stained on days 1, 2, and 3 with neutral
red.
Neutral Red Staining
A 0.034% solution of neutral red (Fisher Scientific, Fairlawn, NJ) in saline
was prepared and filter sterilized. Immediately before use, the solution was
diluted to 0.011% in MEM/EBSS. All media were removed from the plate, 200
μL of the 0.011% neutral red solution was added, and plates were incubated at
37 °C under 5% CO2 for two hours. Plates were then rinsed once with PBS, and
neutral red was extracted by adding 100 μg/mL extraction buffer, made by
combining 500 mL Sorensen citrate (0.1 M sodium citrate [Sigma, St. Louis, MO]
and 0.1 M hydrochloric acid [Fisher Scientific, Fairlawn, NJ]) and 500 mL ethanol
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(Pharmco-AAPER, Brookfield, CT). Absorbance at 540 nm was read using a
SpectraMax Plus384 microplate reader (Molecular Devices, Sunnydale, CA).
Quantitation of Secreted Analyte Expression
Supernatant samples, collected previously and stored at -80 °C, were
thawed at room temperature. Cytokines were detected by multiplex
immunoassay (Quansys Biosciences, Logan, UT). Samples were tested for:
Interleukin 1 alpha (IL-1α), IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL13, interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), TNFβ,
transforming growth factor beta 1 (TGF-β1), monocyte chemotactic protein 1
(MCP-1), regulated upon activation T-cell expressed and secreted protein
(RANTES), angiotensin 2 (ANG2), hepatocyte growth factor (HGF), tissue
inhibitor of metalloproteinases (TIMP), thrombopoetin (TPO), vasoendothelial
growth factor (VEGF), platelet derived growth factor (PDGF), eotaxin (EO),
macrophage inflammatory protein 1 alpha (MIP-1α), and C-reactive protein
(CRP). Follow-up experimentation was performed only on IL-1α, IL-1β, IL-6, IL-8,
IFNγ, TNFα, MCP-1, and RANTES. The chemiluminescent signal was detected
using an Alpha Innotech 8900 Gel Documentation System (San Leandro, CA).
Plates were exposed for one minute, and signal intensity was quantified using
software provided by Alpha Innotech.
Statistical Analysis
P-values were calculated in Excel (Microsoft Corporation, Redmond, WA)
using a two-tailed Student’s t-test.
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RESULTS
Human Tumor Cells Detach and Die
Progressively Throughout BTV Infection
Numerous viruses are oncolytic (Vidal et al., 2006), including BTV (Hu et
al., 2008). In this study, we first explored cell death in three human cell lines
transformed by carcinoma: A498, HEP-G2, and A549 to confirm the findings of
Hu et al. (2008) and compare the effects of BTV in different types of tissue. Cell
death continuously increased over the course of infection for all tested cells lines.
The A498 cells were most susceptible to BTV-induced cell death, with only 12%
viability on day 3, compared with mock-infected cells, followed by Vero cells with
43% viability on day 3. A549 cells were comparable to Vero cells with 45%
viability on day 3 followed last by HEP-G2 cells with 70% viability on day 3.
Surprisingly, BTV caused greater cell death in A498 cells than in the common
laboratory host, Vero. Percent viability on day 3 in each cell line is shown in Fig.
2-3. Viability in each cell line was also determined when treated with poly I:C
instead of BTV. Cells were treated at either 1 μg/mL or 50 μg/mL. One μg/mL
poly I:C did not cause a statistically significant change in viability in any tested
cell line. Fifty μg/mL poly I:C caused statistically significant cell death only in
A498 cells, with death comparable to BTV-induced cell death (see Fig. 2-3).

Inflammatory Mediators Are Elevated
During BTV Infection
Samples from the viability study were tested for 25 different cytokines and
chemokines. Six were found to be expressed by these three cell lines.
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FIGURE 2-3: Percent viability of A498, HEP-G2, A549, and Vero cells.
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FIG. 2-3. Percent viability of A498, HEP-G2, A549, and Vero cells as
determined by neutral red staining 3 days P.I. Cells were either mockinfected, BTV-infected at an MOI of 1, 1 μg/mL poly I:C treated, or 50
μg/mL poly I:C treated (n=4). * indicates conditions with statistically
significant decreases in cell viability compared with the placebo.
Of the six, four (IL-6, IL-8, MCP-1 and RANTES) were found to be significantly
elevated upon BTV infection, while the other two (VEGF and TIMP) were
constitutively expressed by the cell but did not change significantly with infection
(data not shown).
A new array with IL-6, IL-8, MCP-1, RANTES, IL-1α, TNFα, IL-10, IL12p70, MIP-1α, and EO was prepared to further explore cytokine expression.
Using this array, IL-6, IL-8, MCP-1, and RANTES were found expressed from all
4 cell lines with cytokine expression correlating directly with cell death.
Concentrations of the four BTV-induced cytokines are shown in table 2-1. Also
shown in table 2-1 are cytokine levels from cells treated with poly I:C at 1 μg/mL
and 50 μg/mL. A498, A549, and Vero cells expressed cytokines in response to
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TABLE 2-1
Cytokine Expression (pg/mL) from A498, A549 and Vero Cells
Seeded in 96-well Plates 3 Days Post Treatment (n=4)
A498
pg/mL STDEV
Mockinfected

A549
pg/mL
STDEV

Vero
pg/mL
STDEV

IL-6
IL-8
MCP-1
RANTES

280
1100
4650
150

90
250
620
50

200
630
1110
190

40
60
80
20

1010
0
2520
0

140
0
300
0

IL-6
IL-8
MCP-1
RANTES

3310
1810
8450
390

310
250
1230
120

540
3100
2950
5670

100
300
300
290

12700
2770
19900
200

1720
570
1780
60

Poly I:C
1.0 μg/mL

IL-6
IL-8
MCP-1
RANTES

3850
8900
14900
3820

1180
890
530
1060

390
1060
1720
1130

170
90
300
100

2691
30
8730
610

820
10
1770
100

Poly I:C
50 μg/mL

IL-6
IL-8
MCP-1
RANTES

13600
13300
18900
7580

740
470
770
1480

420
4590
7080
6050

70
380
810
900

14800
310
20800
2290

2070
100
730
890

BTVinfected

poly I:C treatment while HEP-G2 cells did not express.
Prior studies by Chiang et al. (2006) showed that IL-1β and TNFα were
secreted from BTV infected human lung primary ECs, but neither one was
expressed during this study. It is possible that IL-1β and TNFα are responses
specific to human primary lung microvascular ECs, MALT-associated lymphocyte
carryover in the primary cell isolation process, or that the pathway is inactivated
as a result of transformation by carcinoma.
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Poly I:C Causes Cell Death in A498 Cells,
but Induces Cytokine Expression in A498,
A549, and Vero Cells
One of the possible mechanisms by which BTV could cause cytokine
expression is through innate immunity. Chiang et al. (2006) used BTV-10 as a
model for virus-induced vascular permeability in human ECs and found that the
effects BTV had on the ECs could be replicated using synthetic dsRNA. To test
for innate immunity’s role in the host cell response to BTV, each cell line was
then treated with poly I:C in a dose dependent manner, ranging from 0.1 μg/mL
to 100 μg/mL. Percent viability as a function of poly I:C concentration is shown in
Fig. 2-4. This study demonstrated no statistically significant change in cell
viability in HEP-G2, A549, or Vero cells treated with poly I:C, but a strong change
was dose dependent between 1 and 100 μg/mL but displayed a second peak in
cell death at 0.32 μg/mL.
Poly I:C treated samples were sampled at 24, 48, and 72 hours post
treatment and assayed for cytokine expression. A498, A549, and Vero cells all
expressed cytokines during poly I:C treatment while HEP-G2 cells did not. Both
A498 and Vero cells had peak cytokine responses at 0.32 μg/mL and 100 μg/mL
poly I:C, while A549 cells only showed poly-I:C-induced cytokine expression at
concentrations above 3.2 μg/mL. Cytokine expression did increase slightly in
A549 cells treated with 0.32 μg/mL, suggesting there may have been a second
peak, though the change was not statistically significant. Interestingly, cytokine
expression stopped or slowed dramatically 48 hours post treatment, also in a cell
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line dependent manner. Fig. 2-5 through 2-16 show cytokine expression from
A498, A549, and Vero cells as a function of poly I:C concentration and time.
DISCUSSION
Bluetongue disease was first characterized over 100 years ago in BTV’s
natural host ruminants. It has only recently been shown to have selectively
oncolytic effects in certain human cell lines (Xiao et al., 2004; Hu et al., 2008).
Selective oncolysis by viruses has been observed previously in both DNA and
RNA viruses, each employing different mechanisms (Strong et al., 1998;
Vorburger et al., 2004; Vidal et al., 2006). Little is known about the mechanism
by which BTV causes oncolysis. BTV is closely related to reovirus, another
FIG. 2-4 Percent viability as a function of poly I:C concentration.
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poly I:C concentration (mcg/mL)
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FIG. 2-4. Percent viability as a function of poly I:C concentration.
A498, HEP-G2, A549, and Vero cells were treated with
concentrations of poly I:C ranging from 0.1 to 100 μg/mL (n=4) and
stained with neutral red three days P.I. A498 cell viability was
significantly affected by treatment with poly I:C.
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FIGURE 2-5 IL-6 expression in A498 cells as function poly I:C concentration
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FIG. 2-5. IL-6 expression in A498 cells as a function of poly I:C
concentration, at 24, 48, and 72 hours P.I. Cells were treated with
concentrations of poly I:C ranging from 0.1 to 100 μg/mL (n=4)
and assayed for cytokine expression using supplies from Quansys
Biosciences.
FIGURE 2-6 IL-8 expression in A498 cells as function poly I:C concentration
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FIG. 2-6. IL-8 expression from A498 cells as a function of poly I:C
concentration at 24, 48, and 72 hours P.I. Cells were treated with
concentrations of poly I:C ranging from 0.1 to 100 μg/mL (n=4)
and assayed for cytokine expression using supplies from Quansys
Biosciences.
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FIGURE 2-7 MCP-1 expression in A498 cells as function poly I:C concentration
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FIG. 2-7. MCP-1 expression from A498 cells as a function of
poly I:C concentration at 24, 48, and 72 hours P.I. Cells were
treated with concentrations of poly I:C ranging from 0.1 to 100
μg/mL (n=4) and assayed for cytokine expression using supplies
FIGURE 2-8 RANTES expression in A498 cells as function poly I:C concentration
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FIG. 2-8. RANTES expression from A498 cells as a function of
poly I:C concentation at 24, 48, and 72 hours P.I. Cells were
treated with concentrations of poly I:C ranging from 0.1 to 100
μg/mL (n=4) and assayed for cytokine expression using supplies
from Quansys Biosciences.
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FIGURE 2-9 IL-6 expression in A549 cells as function poly I:C concentration
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FIG. 2-9. IL-6 expression from A549 cells as a function of poly
I:C concentration at 24, 48, and 72 hours P.I. Cells were
treated with concentrations of poly I:C ranging from 0.1 to 100
μg/mL (n=4) and assayed for cytokine expression using
supplies from Quansys Biosciences.
FIGURE 2-10 IL-8 expression in A549 cells as function poly I:C concentration
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FIG. 2-10. IL-8 expression from A549 cells as a function of poly
I:C concentration at 24, 48, and 72 hours P.I. Cells were treated
with concentrations of poly I:C ranging from 0.1 to 100 μg/mL
(n=4) and assayed for cytokine expression using supplies from
Quansys Biosciences.
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FIGURE 2-11 MCP-1 expression in A549 cells as function poly I:C concentration
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FIG. 2-11. MCP-1 expression from A549 cells as a function
of poly I:C concentration at 24, 48, and 72 hours P.I. Cells
were treated with concentrations of poly I:C ranging from 0.1
to 100 μg/mL (n=4) and assayed for cytokine expression
using supplies from Quansys Biosciences.
FIGURE 2-12 RANTES expression in A549 cells as function poly I:C concentration
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FIG. 2-12. RANTES expression from A549 cells as a function
of poly I:C concentration at 24, 48, and 72 hours P.I. Cells
were treated with concentrations of poly I:C ranging from 0.1 to
100 μg/mL (n=4) and assayed for cytokine expression using
supplies from Quansys Biosciences.
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FIGURE 2-13 IL-6 expression in Vero cells as function poly I:C concentration
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FIG. 2-13. IL-6 expression from Vero cells as a function of poly
I:C concentration at 24, 48, and 72 hours P.I. Cells were treated
with concentrations of poly I:C ranging from 0.1 to 100 μg/mL
(n=4) and assayed for cytokine expression using supplies from
Quansys Biosciences.
FIGURE 2-14 IL-8 expression in Vero cells as function poly I:C concentration
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FIG. 2-14. IL-8 expression from Vero cells as a function of poly
I:C concentration at 24, 48, and 72 hours P.I. Cells were treated
with concentrations of poly I:C ranging from 0.1 to 100 μg/mL
(n=4) and assayed for cytokine expression using supplies from
Quansys Biosciences.
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FIGURE 2-15 MCP-1 expression in Vero cells as function poly I:C concentration
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FIG. 2-15. MCP-1 expression from Vero cells as a function of
poly I:C concentration at 24, 48, and 72 hours P.I. Cells were
treated with concentrations of poly I:C ranging from 0.1 to 100
μg/mL (n=4) and assayed for cytokine expression using supplies
from Quansys Biosciences.
FIGURE 2-16 RANTES expression in Vero cells as function poly I:C concentration
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FIG. 2-16. RANTES expression from Vero cells as a function of
poly I:C concentration at 24, 48, and 72 hours P.I. Cells were
treated with concentrations of poly I:C ranging from 0.1 to 100
μg/mL (n=4) and assayed for cytokine expression using supplies
from Quansys Biosciences.
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oncolytic virus, and may share a similar mechanism, though BTV is predicted to
have particular advantages over reovirus because humans are seronegative to
BTV (Wildner, 2003).
To further explore the therapeutic potential of BTV in cancer, we
compared cell death and cytokine expression in A498, HEP-G2, and A549 cells
during BTV infection and poly I:C treatment. Our hypothesis was that BTV
infection causes cell line dependent death while simultaneously inducing cytokine
expression. We showed elevated expression of pro-inflammatory cytokines from
BTV-17 infected human carcinoma transformed cells (see Table 2-1) and that
infected cells die as a direct result of infection (see Fig. 2-1). Cytokine
expression and cell death directly correlated between cell lines and with time.
The rate of cytokine expression and cell death were primarily cell line dependent,
but continuously increased as long as there were viable cells, indicating that
activation was continuous until death. All tested cell lines expressed the same
cytokines, suggesting the mechanism of induction is similar in each cell line. We
hypothesized that cell death and cytokine expression are related through
conserved intracellular signaling events. Various intracellular pathways were
tested for involvement and are discussed in Chapter 4.
We also hypothesized that innate immunity was the initiator of this
intracellular signaling. Prior studies from our lab infecting A498, HEP-G2, and
A549 cells with DNA and RNA viruses showed that all three cell lines responded
to viral infection with the expression of IL-6, however, only cells infected with
RNA viruses induced RANTES expression (data not shown). In this experiment,
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RANTES was observed in all tested lines suggesting each cell line recognized
the virus as an RNA virus and responded accordingly. Because every cell line
responded with RANTES expression, we conclude that the event is conserved
across each cell line and is functional in each cell line. The cytokine expression
pattern is consistent with type-I interferon signaling through the transcription
factors IRF3 and IRF7 leading to JAK-STAT signaling which generally results in
the production of CXC chemokine ligand 10 (CXCL10), MCP-1, and RANTES.
TLR3 is also known to activate the type-I interferon pathway as well as the
nuclear translocation factor kappa B (NFκB) pathway, though the cytokine
pattern is not fully consistent with this. We observe IL-6 and IL-8 expression, but
not IL-1 or TNFα as is generally observed in NFκB associated signaling. The
lack of IL-1 or TNFα may be carcinoma or cell type related.
Though there are multiple innate immunity mechanisms, focus was on
immunity to dsRNA, since BTV’s genome is dsRNA. To test the contribution of
dsRNA to the observed cell death and cytokine expression, cells were treated
with poly I:C. First, cells were treated with either 1 μg/mL or 50 μg/mL poly I:C.
Treatment resulted in cell death only in A498 cells, and only at 50 μg/mL (Fig. 21), suggesting that BTV-induced cell death was not entirely the result of an innate
immune response to BTV dsRNA; also evidenced by no concentration of poly I:C
generating statistically significant changes in viability in HEP-G2, A549, or Vero
cells.
A498 cells have a greater sensitivity to dsRNA than the other cell lines,
which may explain why these cells are more susceptible to BTV-induced cell
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death but does not entirely explain BTV’s mechanism of inducing cell death. The
experiment was repeated using a broader range of poly I:C concentrations (Fig.
2-2). Like the previous study, only the A498 cells died in response to poly I:C
treatment, but the study revealed two peaks in poly-I:C-induced cell death. One
peak at 0.32 μg/mL and a second peak at 100 μg/mL This type of curve
suggested two different dsRNA response mechanisms. One functional only at
low concentrations of poly I:C, and the other responding only at very high
concentrations of poly I:C. When tested for cytokines, the same trend was
observed in the A498 cells (Fig. 2-3 through 2-6). The similar patterns suggest
that the same two mechanisms which induced cell death in A498 cells also
induced cytokine expression. HEP-G2, A549, and Vero cells were also tested for
cytokines. HEP-G2 cells did not express any cytokines in response to poly I:C,
A549 cells expressed cytokines in a dose dependent manner mainly at
concentrations greater 3.2 μg/mL, and Vero cells displayed a cytokine pattern
similar to A498 cells. Vero cells having a pattern similar to A498 cells is not
entirely surprising given that both cell lines were originally isolated from kidneys,
suggesting the second mechanism may be more active in kidney derived cells.
There remains, however, distinctions between A498 and Vero cells, including a
lack of poly-I:C-induced cell death in Vero cells. Even though both anti-dsRNA
mechanisms in Vero cells are recognizing the poly I:C, the response does not
lead to apoptosis in Vero cells.
We conclude from these experiments, that BTV induces cytokine
expression in immortalized human A498, A549, and HEP-G2 cells and
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subsequently kills the infected cell with cell line dependent severity. The BTVinduced cytokine response is pro-inflammatory, including IL-6, IL-8, MCP-1, and
RANTES. Double-stranded RNA can induce expression of the same cytokines
but only causes cell death in A498 cells, and only at unnaturally high
concentrations. We conclude that BTV-induced cell death is not the result of
innate immune responses to BTV dsRNA, though observed cytokines can be
partially attributed to innate immune responses to dsRNA.
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CHAPTER 3
BLUETONGUE VIRUS INDUCED CELL DEATH AND CYTOKINE
EXPRESSION IS CAUSED BY THE CELL’S
RESPONSE TO INFECTION

ABSTRACT

Bluetongue virus (BTV) is a dsRNA virus which must utilize its own
replication machinery for transcription but must rely on host machinery for
translation. Packaging of viral transcription proteins makes BTV less reliant on
host mechanisms than other viruses, which may contribute to its diverse species
tropism in vitro. Though BTV does not naturally cause disease in humans, it can
cause cell death and cytokine expression in human carcinoma transformed cells.
To better understand the mechanism of induced cell death, viral RNA and protein
expression were quantified by qRT-PCR and Western blotting, respectively. Our
hypothesis was that cell death and cytokine expression are a direct result of viral
replication and thus RNA and protein expression would directly correlate with cell
death and cytokine expression. BTV RNA and protein were found in all tested
human carcinoma transformed cell lines, but RNA expression showed no
correlation with cell death or cytokine expression while protein expression
inversely correlated with cell death and cytokine expression. The data indicates
that cell death and cytokine expression are not a direct result of the virus, but the
result of the cell’s response to infection.
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INTRODUCTION

Bluetongue virus (BTV) is a dsRNA virus with a genome composed of 10
segments (Verwoerd, 1970). Each segment codes for a different protein except
segment 10 which codes for two proteins (NS3 and NS3a) via a non-overlapping
open reading frame (Mertens and Sangar, 1985). During replication, proteins
necessary in mRNA processing are usually produced first, followed by structural
proteins and progeny genomic RNA (Roy, 1989). Prior to this study, BTV RNA
expression of all ten genes in human cells had not been tested.
Protein expression was also compared between human cell lines. Viral
proteins are classified into two general types: structural and non-structural. The
latter type includes all proteins not normally found within the viral protein itself,
but are synthesized during replication for the purpose of facilitating replication.
The objective of this study was to characterize viral RNA and protein
expression in infected human cell lines and compare these results with the cell
death and cytokine expression observed in Chapter 2. The hypothesis was that
RNA expression and protein expression directly correlate between the tested
human cell lines, and that cell death increases proportionately with accumulation
of viral RNA and protein.

MATERIALS AND METHODS

Cell Culture
Five cell lines were used in this study, including BHK-21 baby hamster
kidney cells, A498 human kidney cells, HEP-G2 human liver cells, A549 human
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lung epithelial cells, and Vero African green monkey kidney cells (American Type
Culture Collection, Manassas, VA). Designated CCL-10, HTB-4, HB-8065, CCL185, and CRL-1587, respectively by the American Type Culture Collection. Each
cell line was propagated in 75 cm2 flasks seeded at 1X106 cells and cultured in
MEM/EBSS plus 10% FBS (Hyclone, Logan, UT) under a 5% CO2 atmosphere.
BTV Stock Propagation
Original stocks were triple plaque purified and stored frozen in aliquots
(Kowalik et al., 1990; Li and Yang, 1990). Seed virus was prepared by infecting
BHK-21 cells with frozen viral stock. Cells were infected at 80% confluency and
harvested by scraping three days post infection (P.I.). After scraping, cells were
pelleted, washed, resuspended in fresh media, then gently sonicated three times
using a VirSonic 50 sonicator (VirTis Inc., Gardiner, NY) prior to 0.22 μm filter
sterilization. Viral titer was determined by plaque assay, using Vero cell
monolayers (Hayama and Li, 1994; Fillmore et al., 2002). Mock infections were
similarly prepared using uninfected BHK-21 cells.

BTV mRNA Expression
BHK-21, A498, HEP-G2, and A549 cells were seeded into separate 6-well
plates at 1 X 105 cells per well. Three wells from each cell line were infected with
BTV serotype 17 at an MOI of 1, while the other three wells were mock infected.
At 24, 48, and 72 hours, cells from one BTV infected well and one mock infected
well were collected by scraping. Collected samples were centrifuged, washed
once with PBS, and stored at -80C until all samples had been collected. Total
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RNA was isolated from each sample using the Qiagen total RNA extraction kit
(Valencia, CA) and reverse transcribed using the Bio-Rad reverse transcription
kit and random hexamer primers (Hercules, CA). After reverse transcription, the
presence and amount of each BTV gene was determined by quantitative real
time PCR (qRT-PCR) as described by Buccambusco et al. (2005) using the
primers listed in Table 3-1.

TABLE 3-1
Primer Sequences and Gene Location Used in the
Quantitation of Each BTV cDNA by qRT-PCR

Primer

Location

Sequence

L1 F

2107-2126

5’-ACAAAGGATTCGACACGCTT-3’

L1 R

2402-2383

5’-TTCATGTCCACACTTCGCCA-3’

L2 F

1224-1347

5’-GACGACTTATGACAGCGGATACAT-3’

L2 R

1547-1526

5’-GCAAAACTAACTCGGACCGTAA-3’

L3 F

2209-2233

5’-TGTTAGAGGCCCCACCAGAAATAG-3’

L3 R

2424-2403

5’-CATAGCTGAAAGGTAAGCCCTG-3’

M1 F

1624-1643

5’-AAACGGCTGACGAACTGAAA-3’

M1 R

1848-1829

5’-CATTTCTCACATGCCATGGA-3’

M2 F

565-589

5’-AGGCTTCAGAGAGAAGTCAGGACG-3’

M2 R

774-751

5’-CGGTTGCTACAGCAGTGGCCATA-3’

M3 F

36-54

5’-TGGAGCGCTTTTTGAGAA-3’

M3 R

277-257

5’-GACTGTTTCCCGATCATACA-3’

S1 F

13-31

5’-AGCCATATGTTGAGTATA-3’
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S1 R

284-267

5’-TAGAGATGGACACTATCGC-3’

S2 F

1024-1043

5’-TGAGCGTGTTGCTTTTGTCT-3’

S2 R

1104-1086

5’-AATCATGCGGTCACAAGCG-3’

S3 F

16-36

5’-ATGTCAGCTGCGATGCTTCT-3’

S3 R

264-244

5’-TATGCGTCTATCCACATCTG-3’

S4 F

732-752

5’-CCAAGGTCCGTATCGTGTAGA-3’

S4 R

821-802

5’-TAAGTGTGTAGCGCCGCGTA-3’

BTV Protein Western Blot
Cells were prepared as described by Li and Yang (1990). Briefly, two
flasks of cells from each cell line were seeded separately at 1 X 106 cells/flask
and allowed to adhere overnight. One flask from each cell line was infected with
BTV serotype 17 at an MOI of 1, while the second flask was mock infected. Cells
were harvested 72 hours P.I. by scraping. Samples were washed once in PBS
and the cell pellet stored at -80 oC until use. Prior to electrophoresis, cell pellets
were resuspended in PBS and lysed by sonication. The protein concentration of
each sample was determined by BCA assay and each sample adjusted to 1
mg/mL protein using PBS. Samples were then diluted to a final concentration of
500 μg/mL in Lameli buffer with 5% 2-ME and boiled for 10 minutes. Boiled
samples were electrophoresed on 10% polyacrylamide, and electrophoretically
transferred to PVDF membrane (12V 1A 90 min). Membranes were blocked with
5% BSA for 30 minutes then incubated with rabbit anti-BTV17 antibody diluted
1:1000 in 5% BSA overnight at 4 oC with gentle shaking. Antibody binding was
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detected by incubating the membrane with HRP-labeled goat anti-rabbit
secondary antibody (Sigma, St. Louis, MO) diluted 1:5000 for 2 hours at room
temperature with gentle shaking. HRP activity was visualized with TMB
membrane substrate (Sigma, St. Louis, MO).

Statistical Analysis
P-values were calculated in Excel (Microsoft Corporation, Redmond, WA)
using two-tailed Student’s t-test. Coefficient of variation (%CV) was calculated
by dividing the standard deviation of the group by the group average.

RESULTS

All BTV Genes are Transcribed During Infection
Data from Chapter 2 showed that cell death in human cells is cell line
dependent. To under stand how this cell death related to viral replication, RNA
for each gene was quantified by qRT-PCR. RNA for every BTV gene was found
expressed in the tested human cell lines, consistent with active viral replication.
The RT-PCR data shows that the detected viral RNA was not from the genome
of the original infecting virus nor a cross reaction with cellular RNA. Fig. Tables
3-2 through 3-5 show the cycle threshold, c(T), values for each gene in BHK-21,
A498, HEP-G2, and A549 cells 72 hours P.I. Figures 3-1 to 3-11 show the qRTPCR amplification curves for each primer set.
Cell lines showed strong consistency in amount of each gene produced,
with cycle threshold [c(T)] values between genes in the same cell line
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FIG. 3-1. qRT-PCR graphs for the L1 transcript 72 hours P.I. BTV17 L1 transcript amplification by qRT-PCR in
(A) BHK-21, (B) A498, (C) HEP-G2, and (D) A549 cells 72 hours post BTV (green line) or placebo (red line)
infection. The cycle threshold is measured at the point at which the exponential rise in product crosses the
threshold value set at 0.05.
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FIG. 3-2. qRT-PCR graphs for the L2 transcript 72 hours P.I. BTV17 L2 transcript amplification by qRT-PCR in
(A) BHK-21, (B) A498, (C) HEP-G2, and (D) A549 cells 72 hours post BTV (green line) or placebo (red line)
infection. The cycle threshold is measured at the point at which the exponential rise in product crosses the
threshold value set at 0.05.
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FIG. 3-3. qRT-PCR graphs for the L3 transcript 72 hours P.I. BTV17 L3
transcript
A498
Cells amplification by qRT-PCR in
(A) BHK-21, (B) A498, (C) HEP-G2, and (D) A549 cells 72 hours post BTV (green line) or placebo (red line)
infection. The cycle threshold is measured at the point at which the exponential rise in product crosses the
threshold value set at 0.05.
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FIG. 3-4. qRT-PCR graphs for the M1 transcript 72 hours P.I. BTV17 M1
transcript
A498
Cells amplification by qRT-PCR in
(A) BHK-21, (B) A498, (C) HEP-G2, and (D) A549 cells 72 hours post BTV (green line) or placebo (red line)
infection. The cycle threshold is measured at the point at which the exponential rise in product crosses the
threshold value set at 0.05.
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FIG. 3-5. qRT-PCR graphs for the M2 transcript 72 hours P.I. BTV17 M2
transcript
A498
Cells amplification by qRT-PCR in
(A) BHK-21, (B) A498, (C) HEP-G2, and (D) A549 cells 72 hours post BTV (green line) or placebo (red line)
infection. The cycle threshold is measured at the point at which the exponential rise in product crosses the
threshold value set at 0.05.
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FIG. 3-6. qRT-PCR graphs for the M3 transcript 72 hours P.I. BTV17 M3
transcript
A498
Cells amplification by qRT-PCR in
(A) BHK-21, (B) A498, (C) HEP-G2, and (D) A549 cells 72 hours post BTV (green line) or placebo (red line)
infection. The cycle threshold is measured at the point at which the exponential rise in product crosses the
threshold value set at 0.05.
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FIG. 3-7. qRT-PCR graphs for the S1 transcript 72 hours P.I. BTV17 S1
transcript
A498
Cells amplification by qRT-PCR in
(A) BHK-21, (B) A498, (C) HEP-G2, and (D) A549 cells 72 hours post BTV (green line) or placebo (red line)
infection. The cycle threshold is measured at the point at which the exponential rise in product crosses the
threshold value set at 0.05.
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FIG. 3-8. qRT-PCR graphs for the S2 transcript 72 hours P.I. BTV17 S2
transcript
A498
Cells amplification by qRT-PCR in
(A) BHK-21, (B) A498, (C) HEP-G2, and (D) A549 cells 72 hours post BTV (green line) or placebo (red line)
infection. The cycle threshold is measured at the point at which the exponential rise in product crosses the
threshold value set at 0.05.
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FIG. 3-9. qRT-PCR graphs for the S3 transcript 72 hours P.I. BTV17 S3
transcript
A498
Cells amplification by qRT-PCR in
(A) BHK-21, (B) A498, (C) HEP-G2, and (D) A549 cells 72 hours post BTV (green line) or placebo (red line)
infection. The cycle threshold is measured at the point at which the exponential rise in product crosses the
threshold value set at 0.05.
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FIG. 3-10. qRT-PCR graphs for the S4 transcript 72 hours P.I. BTV17 A498
S4 transcript
amplification by qRT-PCR in
Cells
(A) BHK-21, (B) A498, (C) HEP-G2, and (D) A549 cells 72 hours post BTV (green line) or placebo (red line)
infection. The cycle threshold is measured at the point at which the exponential rise in product crosses the
threshold value set at 0.05.
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FIG. 3-11. qRT-PCR graphs for the GAPDH transcript 72 hours P.I. Human
GAPDH transcript amplification by
A498 Cells
qRT-PCR in (A) BHK-21, (B) A498, (C) HEP-G2, and (D) A549 cells 72 hours post BTV (green line) or placebo
(red line) infection. The cycle threshold is measured at the point at which the exponential rise in product crosses
the threshold value set at 0.05.
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maintaining an average %CV of 7.7%. In BHK-21, the average c(T) was 35.8 +/4.3 in mock-infected and 14.9 +/- 1.4 in BTV-infected cells. For A498, the
average was 34.9 +/- 3.2 for mock-infected and 15.9 +/- 1.4 for BTV-infected
cells. Average HEP-G2 mock-infected cell c(T) was 32.6 +/-2.3 but 23.1 +/- 1.3
in BTV-infected cells, while A549 mock-infected cells averaged 34.9 +/- 2.3 but
29.9 +/- 2.2 in BTV-infected cells.

TABLE 3-2
BHK-21 Cycle Threshold Values at 72 Hours P.I.
Control

Infection

Gene

c(T)

Tm

c(T)

Tm

L1

31.1

84

14.7

83

L2

37.8

76

15.9

80

L3

30.6

83

15.3

83

M1

None

NA

14.1

83

M2

35.6

78

14.3

85

M3

None

NA

15.1

82

S1

None

NA

17.6

85

S2

32.7

83

12.9

82

S3

None

NA

14.8

84

S4

30.1

82

13.5

83

GAPDH

19.5

85

23.3

85
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TABLE 3-3
A498 Cycle Threshold Values at 72 Hours P.I.
Control

Infection

Gene

c(T)

Tm

c(T)

Tm

L1

37.0

83

15.7

83

L2

38.6

75

17.5

80

L3

32.9

83

16.2

83

M1

31.7

81

15.1

83

M2

33.1

85

15.2

85

M3

None

NA

14.6

83

S1

33.7

74

18.8

84

S2

30.4

84

14.8

82

S3

33.7

82

16.2

84

S4

37.8

82

14.7

84

GAPDH

21.6

85

21.4

85

TABLE 3-4
HEP-G2 Cycle Threshold Values at 72 Hours P.I.
Control
Gene

Infection

c(T)

Tm

c(T)

Tm

L1

33.3

83

22.6

83

L2

37.8

77

24.7

80

L3

30.6

82

23.0

83

M1

30.3

75

22.5

82

M2

32.6

83

23.3

85

M3

None

NA

22.7

82

S1

33.4

74

25.4

85

S2

32.0

82

21.0

82

S3

31.3

84

22.7

84

S4

31.6

82

22.5

83

GAPDH

21.3

86

21.1

86

92
TABLE 3-5
A549 Cycle Threshold Values at 72 Hours P.I.
Control

Infection

Gene

c(T)

Tm

c(T)

Tm

L1

35.4

84

29.4

83

L2

36.4

76

32.0

80

L3

33.4

80

29.5

83

M1

32.5

75

29.1

83

M2

33.3

79

32.1

84

M3

None

NA

32.5

82

S1

34.1

74

33.0

85

S2

32.8

81

26.8

81

S3

34.1

83

27.6

83

S4

36.4

79

28.0

83

GAPDH

19.7

86

19.8

86

To ensure consistency in the data, RNA concentrations in the purified
RNA samples were determined spectrophotometrically at A260 and A280
absorbance and then adjusted to 50 μg/mL total RNA prior to reverse
transcription. Furthermore, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was measured simultaneously to confirm normalization of the samples.
The average %CV of GAPDH c(T) values between mock-infected and BTVinfected cells was 0.7%. Average GAPDH values between cell lines was 21.0 +/1.3 corresponding to a %CV of 6.1%, suggesting good consistency between
samples.
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BTV Proteins Are Expressed During Infection
In order to identify viral protein expression, Western blots were performed
on mock-infected and BTV-infected cultures. Western blot results using purified
rabbit anti-BTV17 antisera are shown in Fig. 3-12. Bands were identified in all 3
cell lines with molecular weights consistent with BTV proteins NS2 and VP7.
Band intensity for the two putative BTV proteins was strongest in HEP-G2 cells,
followed by A549 cells. BTV protein expression was weakest in A498 cells, with
only one viral protein band clearly detectable on the Western blot (see Fig. 3-12).

FIG. 3-12. Western blot
of mock-infected and
BTV-infected cells.
A498, HEP-G2, and
A549 cells were either
infected with BTV
serotype 17. Cells
were harvested 72
hours P.I. The
samples were
processed by sonication
and protein content
adjusted to 500 mcg/mL
prior to PAGE analysis.
Gel was blotted to a
PVDF membrane and
stained with rabbit antiBTV17 antisera, and
visualized with TMB
substrate.
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DISCUSSION

BTV has therapeutic potential in cancer because of its ability to kill human
cancer cells and reduce human tumor size (Xiao et al., 2004). In this experiment
BTV is shown to replicate in each cell, though the efficiency of replication is
heavily cell line dependent.
RNA production was highest in the kidney derived A498 cells, followed by
HEP-G2 and last by A549 cells. RNA concentrations in A498 cells were
comparable to RNA concentrations observed in the laboratory host BHK-21
(Table 3-2). It may be that the high viral RNA expression is related to the tissue
type as BHK-21 and A498 are both kidney derived cells. However, protein
expression in A498 cells was severely limited in comparison to the other cell lines
as determined by Western blotting with anti-BTV17 antisera. Even though A498
cells produced the most RNA of any cell, they produced the least protein. HEPG2, on the other hand, showed strong RNA expression, though not nearly as
high as A498 cells, but showed the most BTV protein (Fig. 3-12). A549 cells
expressed the least amount of BTV RNA, with concentrations barely above
controls, though every BTV gene was detected in A549 cells.
Within each cell line, all of the genes quantified in a narrow range of cycle
threshold values (1.29-17.6 for BHK-21 cells, 14.6-18.8 for A498 cells, 21.0-25.4
for HEP-G2 cells, and 26.8-33.0 for A549 cells). This narrow range suggests
there was no preferential over/under expression or over/under degradation of a
particular gene.
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Based on c(T) numbers, of the human cell lines, A498 cells produced the
most viral RNA, with levels within the standard deviation of the BHK-21 cells.
HEP-G2 produced the next highest level of viral RNA, though considerably less
than A498. Human A549 cells showed the lowest amount of RNA, with levels
clearly above background, but substantially lower than HEP-G2 and A498 (see
Table 3-1 through 3-4). Testing was performed 72 hours P.I., so these values
represent cumulative RNA expression over 3 days.
One possibility for the differences in RNA levels is differences in the rate
of RNA degradation in each cell line, though BTV viral RNA would be expected to
degrade at a faster rate than cellular mRNA due to its lack of polyadenylation.
However, the testing was a measure of total viral RNA, and genomic dsRNA is
not degraded by the host and is therefore expected to accumulate as a function
of time and replication rate. Given the lack of a clear relationship between RNA
and protein among the human cells, the differences in expression are probably
not related to rates of RNA degradation but related to the replication rate being
influenced by the intracellular environment. Specifically, the activity of antiviral
defense mechanisms, such as type I interferon.
The role of the intracellular environment suggests that viral tropism may
be as much related to innate immune system activity and usability of the host
transcription/translation machinery as it is related to receptor expression. BTV
may equally infect various tissues, but only concentrate in the tissues in which it
replicates most efficiently.
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Hence, BTV may equally infect primary and cancerous cells, but only
cancerous cells are conducive to efficient viral replication. A strong possibility,
since cancer cell expression is highly modified from its primary counterpart with
various genes turned on and others, such as innate defense mechanisms, turned
off.
The influence of the intracellular environment is supported by the inverse
correlation between protein expression and cell death/cytokine expression. A498
cells expressed the most RNA but least protein. These cells also displayed the
most cell death and cytokine expression. HEP-G2 which expressed the most
protein was the least susceptible to BTV-induced cell death, and expressed the
least amount of cytokines. A549 cells, which showed the least amount of RNA,
showed modest protein expression, cell death, and cytokine expression.
This inverse relationship between cell death/cytokine expression and viral
protein expression indicates that the cell death and cytokine expression are both
functions of the cell’s response to infection rather than a direct result of the virus.
If the virus was completely in control, all four variables would be expected to rise
proportionately. As the virus replicates, RNA and protein expression would
increase, and as replication completes, cell death would increase, and cytokine
expression would increase steadily. In this scenario, differences in fitness
between cell lines would lead to proportionate changes in all four variables.
However, expression between the four variables is not proportionate indicating
influences by the host cell.
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Possible influences include innate immunity, as well as altered signaling.
For example, the type-I interferon response leads to cytokine expression,
activation of the caspase pathways, and phosphorylation of EIF-2 thereby
shutting down protein synthesis (Watanabe, 2004). In the presence of a
functioning type-I interferon pathway, viral protein production would remain low in
the presence of high viral RNA and would be inversely related to cell death and
cytokine expression, as was seen in A498 cells. The same pattern, however was
not seen in every cell line, suggesting there may be other mechanisms present
as discussed in Chapter 4.
In conclusion, the objective of this experiment was to correlate BTV RNA
and protein expression to the cytokine and cell death data of the previous
experiment. Our hypothesis was that cell death and cytokine expression
correlates directly with viral RNA and protein expression consistent with cytokine
expression and cell death the direct result of viral replication. We observed high
levels of both RNA and protein in each cell line, showing that the virus is fully
capable of infecting and replicating in each line; however, comparisons between
the three human cell lines showed no obvious correlation between RNA and cell
death or cytokine expression, and an inverse correlation between viral protein
expression and cell death. The data does not support our initial hypothesis, but
rather suggests that the magnitude of cell death and cytokine expression is cell
line dependent and a function of the cell’s ability to respond to infection.
No matter the reason for BTV’s selective infectivity, it is clear that the virus
is fully capable of utilizing human host machinery to begin replication; and though
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the rate is not as efficient as in a native host, it is sufficient enough to induce cell
death and cytokine expression in carcinoma transformed cells.
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CHAPTER 4
CELLULAR RESPONSES TO BLUETONGUE VIRUS INFECTION DO NOT
INCLUDE ACTIVATION OF NFκB, P38 MAPK, OR JAK-STAT SIGNALING

ABSTRACT

BTV causes cell death and cytokine expression in human carcinoma
transformed cells. The magnitude of cell death and cytokine expression are a
function of the cell’s response to infection, not a direct result of viral replication.
Our objective was to determine the contributions of major apoptotic and
inflammatory signaling molecules to the observed cell death and cytokine
expression. Our hypothesis was that the cell promotes apoptosis by
dephosphorylating PBK and induces cytokine expression through activation of
NFκB and p38 MAPK signaling. PKB, NFκB, MAPK family, and tyrosine kinase
signaling contributions were all determined by selective inhibition of signaling
activity. Phosphorylation levels of PKB and MAPK family members were
subsequently measured by ELISA.
Inhibition of PKB, NFκB, and MAPK activity all had no effect on cell death
or cytokine expression though PKB and p38 MAPK were both constitutively
phosphorylated in A498 and A549 cells. Phosphorylation of PKB and p38 MAPK
was subsequently lost upon infection with BTV. Tyrosine kinase signaling was
found to be involved in both cell death and cytokine expression, involving EGFR,
but not JAK-STAT signaling. A 35 kDa tyrosine phosphorylated protein with
multiple phosphorylation states was isolated by two-dimensional gel
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electrophoresis, though the identity of the protein remains unknown. We
conclude that conventional pro-inflammatory signaling through NFκB, p38 MAPK,
and JAK-STAT are not involved in BTV-induced cell death and cytokine
expression, but that PKB, EGFR, and an unknown tyrosine kinase pathway are
involved.

INTRODUCTION

In previous chapters, bluetongue virus (BTV) was shown to infect human
carcinoma transformed cells, resulting in cytokine expression and cell death.
Cell death and cytokine expression were not the direct result of viral infection, but
the result of the cell’s response to infection. Even though the virus is fully
replicating its genome in each cell line, cell death and cytokine expression were
markedly disproportionate. This data suggested that host defense mechanisms
are involved, though the data does not match up exactly with literature for any
specific process (Mahalingam et al., 1999; Nociari et al., 2007). The fact that
each cell line produced the same cytokine pattern and that cell death compared
between cell lines directly correlated with the magnitude of cytokine expression
suggested the same mechanisms are acting in each cell line and that cell death
and cytokine expression are related through intracellular signaling.
PKB was chosen for this study because prior studies by our lab suggested
changes in PKB signaling occur during viral infection. The MAPK family was
chosen because of its role in apoptosis, inflammation, and innate immunity. In
addition, Chiang et al. (2006) demonstrated activation of p38 MAPK signaling
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during BTV infection of human primary endothelial cells. We also tested NFkB
and tyrosine kinase signaling because of their involvement in inflammation and
innate immunity. These various signaling molecules represent a broad spectrum
of potential signaling molecules involved in the cell’s response to infection. The
objective of this investigation was to determine the involvement of these signaling
molecules in the human carcinoma transformed cell’s response to BTV infection.
Our hypothesis was that the cell responds to infection by dephosphorylating PKB
and by activating both NFκB and p38 MAPK signaling.

MATERIALS AND METHODS

Cell Culture
Five cell lines were used in this study, including BHK-21 baby hamster
kidney cells, A498 human kidney cells, HEP-G2 human liver cells, A549 human
lung epithelial cells, and Vero African green monkey kidney cells (American Type
Culture Collection, Manassas, VA). Designated CCL-10, HTB-4, HB-8065, CCL185, and CRL-1587, respectively by the American Type Culture Collection. Each
cell line was propagated in 75 cm2 flasks seeded at 1X106 cells and cultured in
MEM/EBSS plus 10% FBS (Hyclone, Logan, UT) under a 5% CO2 atmosphere.
BTV Stock Propagation
Original stocks were triple plaque purified and stored frozen in aliquots
(Kowalik et al., 1990; Li and Yang, 1990). Seed virus was prepared by infecting
BHK-21 cells with frozen viral stock. Cells were infected at 80% confluency and
harvested by scraping three days post infection (P.I.). After scraping, cells were
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pelleted, washed, resuspended in fresh media, then gently sonicated three times
using a VirSonic 50 sonicator (VirTis Inc., Gardiner, NY) prior to 0.22 μm filter
sterilization. Viral titer was determined by plaque assay, using Vero cell
monolayers (Hayama and Li, 1994; Fillmore et al., 2002;). Mock infections were
similarly prepared using uninfected BHK-21 cells.

Plate Preparation and BTV Infection
96-well plates were seeded one day prior to experimentation in
MEM/EBSS plus 10% FBS (Hyclone Laboratories, Logan, UT), such that the
culture was approximately 50% confluent when starting the experiment. Prior to
experimentation, plates were rinsed with MEM/EBSS. BTV infection occurred at
an MOI of 1 using BTV serotype 17. Mock infections were performed using a
comparable volume of uninfected BHK-21 cells, prepared as described above.
Plates were incubated at 37 °C under 5% CO2 in MEM/EBSS plus 5% FBS.
Neutral Red Staining
A 0.034% solution of neutral red (Fisher Scientific, Fairlawn, NJ) in saline
was prepared and filter sterilized. Immediately before use, the solution was
diluted to 0.011% in MEM/EBSS. All media was removed from the plate, 200
mcL of the 0.011% neutral red solution was added, and plates were incubated at
37 °C under 5% CO2 for two hours. Plates were then rinsed once with PBS, and
neutral red was extracted by adding 100 μg/mL neutral red extraction buffer (1:1
ratio of Sorensen citrate buffer [0.1 M sodium citrate (Sigma, St. Louis, MO) and
0.1 M hydrochloric acid (Fisher Scientific, Fairlawn, NJ)] and absolute ethanol
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(Pharmco-AAPER, Brookfield, CT). Absorbance at 540 nm was read using a
SpectraMax Plus384 microplate reader (Molecular Devices, Sunnydale, CA).

Determination of Phosphorylated PKB Expression
Rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies,
Danvers, MA) was deposited onto the bottom of a 96-well plate in a defined
location using a Genomic Solutions (Ann Arbor, MI) non-contact printing
machine. Samples collected previously were diluted into cell lysis buffer (Cell
Signaling Technologies, Danvers, MA) with 1 mM PMSF (Sigma, St. Louis, MO).
Cells were then sonicated on ice 3 times for 10 seconds each using VirSonic 50
sonicator (Virtis Inc., Gardiner, NY), and clarified by centrifugation. Supernatant
was incubated on the 96-well plates at room temperature on a lab rotator set at
120 RPM for 1 hour. Following TBST wash, plates were incubated with
biotinylated mouse anti-phospho-AKT1 antibody (Cell signaling technologies,
Danvers, MA) diluted in 5% BSA. Binding was detected by horse radish
peroxidase (HRP) conjugated streptavidin (Biolegend Inc., San Diego, CA)
diluted in 5% BSA and subsequently visualized with Pierce chemiluminescent
substrate (Rockford, IL) on an Alpha Innotec 8900 gel documentation system
(San Leandro, CA). Luminescent signal intensity was quantified using software
provided with the Alpha Innotec camera.

Determination of Phosphorylated p44/42
MAPK and p38α MAPK Expression
Cell pellets, collected previously, were processed and subsequently
assayed for expression with the PathScan Inflammation 4-plex array (Cell
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Signaling Technologies, Danvers, MA) according to the manufacturer’s
recommended protocol.

Determination of Phosphorylated SAPK/JNK
Expression
Cell pellets, collected previously, were processed and subsequently
assayed for expression with the PathScan Phospho-SAPK/JNK (Thr183/Tyr185)
Sandwich ELISA Kit (Cell Signaling Technologies, Danvers, MA) according to the
manufacturer’s recommended protocol.

Activity Inhibition of p38 MAPK, ERK-1/2,
SAPK/JNK, and NFκB
P38 MAPK kinase activity inhibitor SB-203580, the MEK-1/2 kinase
activity inhibitor U-0126, SAPK/JNK kinase activity inhibitor SP600125, and
NFκB activity inhibitor QNZ were acquired from Biomol International, Inc.
(Plymouth Meeting, PA). Each was reconstituted to 2 mg/mL in DMSO (Sigma,
St. Louis, MO) and tested at a final concentration of 1 μg/mL in MEM/EBSS plus
5% FBS. Each inhibitor stock was stored at -20 °C in DMSO when not in use,
and working solutions were prepared immediately before use. Cells were seeded
into 96-well plates as described previously. Inhibitor was loaded into each well
and then either mock-infected, BTV-infected, treated with 1 μg/mL, or treated
with 50 μg/mL of polyinosinic:polycytidylic acid (poly I:C) (n=4). Supernatant was
harvested three days P.I., and the plates stained with neutral red.
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Activity Inhibition of Tyrosine Kinase Families
General tyrosine kinase activity inhibitor Genistein, the Src kinase activity
inhibitor PP2, JAK2, JAK3, and STAT-3 inhibitor AG490, platelet derived growth
factor receptor (PDGFR) kinase activity inhibitor AG1278, and epidermal growth
factor receptor (EGFR) kinase activity inhibitor AG1478 were acquired
(Calbiochem, San Diego, CA). Each was reconstituted in DMSO and tested at a
final concentration of 1 μg/mL in MEM/EBSS plus 5% FBS. Each inhibitor stock
was stored at -20 °C in DMSO when not in use, and working solutions were
prepared immediately before use. Cells were seeded into 96-well plates as
described previously. Inhibitor was loaded into each well and either mockinfected, BTV-infected, treated with 1 μg/mL, or treated with 50 μg/mL of poly I:C
(n=4). Supernatant was harvested three days P.I., and the plates stained with
neutral red.

Quantitation of Secreted Analyte Expression
Supernatant samples, collected previously and stored at -80 °C, were
thawed at room temperature. Cytokines were detected by multiplex
immunoassay (Quansys Biosciences, Logan, UT). Samples were tested for: IL1α, IL-1β, IL-6, IL-8, IFNγ, TNFα, MCP-1, and RANTES. The chemiluminescent
signal was detected using an Alpha Innotech 8900 Gel Documentation System
(San Leandro, CA). Plates were exposed for one minute, and signal intensity was
quantified using software provided by Alpha Innotech.
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Tyrosine Phosphorylation by Western Blot
Cell samples were diluted in Lameli buffer and protein concentration
determined using the BCA method. After titration, samples were adjusted to a
final concentration of 500 μg/mL in Lameli buffer, 2-ME added to each sample,
and boiled for 10 minutes. Samples were then electrophoresed on 10%
polyacrylamide, and electrophoretically transferred to polyvinylidene fluoride
(PVDF) membrane (12V 1A 90 min). Membranes were blocked with 5% BSA for
30 minutes. The PVDF membrane was incubated overnight at 4 oC with gentle
shaking in 5% BSA containing Cell Signaling Technologies (Danvers, MA)
biotinylated anti-phospho-tyrosine mouse monoclonal antibody. Antibody binding
was detected by incubating the membrane with HRP-labeled streptavidin for 2
hours at room temperature with gentle shaking. Binding was visualized with TMB
membrane substrate (Sigma, St. Louis, MO).

Two-Dimensional Gel Electrophoresis
Samples were prepared by diluting cells in water and boiling for 10
minutes followed by dilution into isoelectric focusing (IEF) rehydration buffer (8 M
Urea, 2% CHAPS, and 50 mM DTT), and incubated at room temperature for 5
minutes. Samples were then clarified by centrifugation to remove the bulk of the
genomic DNA and insoluble particulates. The supernatant was applied to BioRad Laboratories (Hercules, CA) ReadyStripTM IPG strips, and allowed to actively
rehydrate for 12 hours. IEF was performed on the Bio-Rad Protean IEF cell
apparatus. After focusing, IPG strips were reduced with DTT (6 M Urea, 0.375 M
Tris pH 8.8, 2% SDS, 20% glycerol, 2% w/v DTT) and free cysteines acetylated
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with iodoacetamide (6 M Urea, 0.375 M Tris pH 8.8, 2% SDS, 20% glycerol,
2.5% w/v iodoacetamide). Samples were then electrophoresed on 10%
polyacrylamide. Mini gels were run at 100 volts 20 mA for 1 to 2 hours, while
large gels were run at 150 to 300 volts 100 mA for 5-7 hours. After completion of
the run, gels to be stained were incubated overnight with Coomassie blue stain
(Sigma, St. Louis, MO). Gels to be transferred to PVDF were treated according
to the protocols described for phospho-tyrosine Western blotting.

Mass Spectroscopy
Proteins resolved by two dimensional gel electrophoresis were excised
from Coomassie blue stained gels. In gel trypsin digestion and mass analysis of
digested peptides was performed by the Utah State University Center for
Integrated Biosystems mass spectroscopy lab (Logan, UT).

Statistical Analysis
P-values were calculated in Excel (Microsoft Corporation, Redmond, WA)
using two-tailed Student’s t-test.

RESULTS

Inhibition of PKB Activity Does Not Affect
Cell Death or Cytokine Expression
PKB plays a key role in cell survivability and BTV infection leads to
reduced survival rates in infected cells. To examine the contribution of PKB
phosphorylation to cell death and cytokine expression, PKB activity in A498,
HEP-G2, A549, and Vero cells was inhibited using Triciribine (n=4). Triciribine
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treatment resulted in no significant change in cell death compared to untreated
cells (Fig. 4-1 through 4-4). Triciribine treatment also had no significant effect on
cytokine expression. Fig. 4-5 through 4-8 compare cytokine expression from
mock-infected, BTV-infected, and poly I:C treated cells. Our hypothesis was that
even though Triciribine alone did not affect cell death or cytokine expression,
Triciribine would contribute to cell death and cytokine expression in BTV-infected
cells. While BTV-infected and poly I:C treated cells showed statistically
significant increases in cell death and cytokine expression compared to mock
infections, Triciribine treatment had no influence on the dependent variables (Fig.
4-1 through 4-8).
Inhibition of NFκB Does Not Affect Cell
Death or Cytokine Expression
Using the same experimental design as used in PKB inhibition, cells were
treated with QNZ inhibitor to block NFκB activity. NFκB plays an important role
in both apoptosis and inflammation, by promoting cell survival while
simultaneously inducing transcription of multiple pro-inflammatory cytokines and
chemokines (Ghosh and Hayden, 2008). When cells were treated with QNZ,
however, no significant change in cell death or cytokine expression occurred as
observed in Fig. 4-1 through 4-8.

Inhibition of MAPK Signaling Does Not
Affect Cell Death or Cytokine Expression
Using the same experimental design as used in PKB inhibition, MAPK
signaling was inhibited. There are three groups in the MAPK family of signaling
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molecules: p38 MAPK, ERK-1/2, and SAPK/JNK. Each group has separate
functions but all have an important role either in cell viability or inflammation.
Interestingly, none of the inhibitors resulted in a significant change in cell death
as shown in Fig. 4-9 through 4-12. Though BTV and poly-I:C-induced cell death
compared with mock- infected cells, the inhibitors given singly had no influence
on cell death. Likewise, MAPK family inhibition had no effect on cytokine
expression. Fig. 4-13 through 4-16 show cytokine expression from A498 cells.
Comparisons between inhibitors is similar in HEP-G2, A549, and Vero cells (data
not shown).
FIGURE 4-1. Percent viability of A498 cells treated with Triciribine or QNZ 3 days P.I.
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FIG. 4-1. Percent viability of A498 cells treated with Triciribine or
QNZ 3 days P.I. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Viability was determined by neutral red staining 3
days P.I.
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FIGURE 4-2. Percent viability of HEP-G2 cells treated with Triciribine or QNZ 3 days P.I.
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FIG. 4-2. Percent viability of HEP-G2 cells treated with Triciribine or
QNZ 3 days P.I. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Viability was determined by neutral red staining 3
days P.I.
FIGURE 4-3. Percent viability of A549 cells treated with Triciribine or QNZ 3 days P.I.
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FIG. 4-3. Percent viability of A549 cells treated with Triciribine or
QNZ 3 days P.I. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Viability was determined by neutral red staining 3
days P.I.
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FIGURE 4-4. Percent viability of Vero cells treated with Triciribine or QNZ 3 days P.I.
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FIG. 4-4. Percent viability of Vero cells treated with Triciribine or QNZ
3 days P.I. Treated cells were subsequently either mock-infected,
BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly I:C treated
(n=4). Viability was determined by neutral red staining 3 days P.I.
FIGURE 4-5. IL-6 expression from A498 cells treated with Triciribine or QNZ.
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FIG. 4-5. IL-6 expression from A498 cells treated with either placebo,
PKB inhibitor Triciribine, or NFκB inhibitor QNZ. Treated cells were
subsequently either mock-infected, BTV-infected, 1 μg/mL poly I:C
treated, or 50 μg/mL poly I:C treated (n=4). Cytokine expression was
determined 3 days P.I. using supplies provided by Quansys Biosciences.
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FIGURE 4-6. IL-8 expression from A498 cells treated with Triciribine or QNZ.
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FIG. 4-6. IL-8 expression from A498 cells treated with either placebo,
PKB inhibitor Triciribine, or NFκB inhibitor QNZ. Treated cells were
subsequently either mock-infected, BTV-infected, 1 μg/mL poly I:C
treated, or 50 μg/mL poly I:C treated (n=4). Cytokine expression was
determined 3 days P.I. using supplies provided by Quansys Biosciences.
FIGURE 4-7. MCP-1 expression from A498 cells treated with Triciribine or QNZ.
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FIG. 4-7. MCP-1 expression from A498 cells treated with either placebo,
PKB inhibitor Triciribine, or NFκB inhibitor QNZ. Treated cells were
subsequently either mock-infected, BTV-infected, 1 μg/mL poly I:C
treated, or 50 μg/mL poly I:C treated (n=4). Cytokine expression was
determined 3 days P.I. using supplies provided by Quansys Biosciences.
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FIGURE 4-8. RANTES expression from A498 cells treated with Triciribine or QNZ.
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FIG. 4-8. RANTES expression from A498 cells treated with either
placebo, PKB inhibitor Triciribine, or NFκB inhibitor QNZ. Treated cells
were subsequently either mock-infected, BTV-infected, 1 μg/mL poly I:C
treated, or 50 μg/mL poly I:C treated (n=4). Cytokine expression was
determined 3 days P.I. using supplies provided by Quansys Biosciences.
FIGURE 4-9. MAPK inhibitor treated A498 cell viability 3 days P.I.
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FIG. 4-9. MAPK inhibitor treated A498 cell viability 3 days P.I.
Cells were treated with either placebo, SB-203580, U-0126, or
SP600125. Treated cells were either mock-infected, BTVinfected, 1 μg/mL poly I:C treated, or 50 μg/mL poly I:C treated
(n=4). Viability was determined by neutral red staining 3 days P.I.
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FIGURE 4-10. MAPK inhibitor treated HEP-G2 cell viability 3 days P.I.
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FIG. 4-10. MAPK inhibitor treated HEP-G2 cell viability 3 days P.I.
Cells were treated with either placebo, SB-203580, U-0126, or
SP600125. Treated cells were either mock-infected, BTV-infected, 1
μg/mL poly I:C treated, or 50 μg/mL poly I:C treated (n=4). Viability
was determined by neutral red staining 3 days P.I.
FIGURE 4-11. MAPK inhibitor treated A549 cell viability 3 days P.I.
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FIG. 4-11. MAPK inhibitor treated A549 cell viability 3 days P.I.
Cells were treated with either placebo, SB-203580, U-0126, or
SP600125. Treated cells were either mock-infected, BTV-infected,
1 μg/mL poly I:C treated, or 50 μg/mL poly I:C treated (n=4).
Viability was determined by neutral red staining 3 days P.I.
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FIGURE 4-12. MAPK inhibitor treated Vero cell viability 3 days P.I.
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FIG. 4-12. MAPK inhibitor treated Vero cell viability 3 days P.I.
Cells were treated with either placebo, SB-203580, U-0126, or
SP600125. Treated cells were either mock-infected, BTV-infected,
1 μg/mL poly I:C treated, or 50 μg/mL poly I:C treated (n=4).
Viability was determined by neutral red staining 3 days P.I.
FIGURE 4-13. IL-6 expression from MAPK inhibitor treated A498 cells 3 days P.I.
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FIG. 4-13. IL-6 expression from A498 cells treated with either
placebo, p38 MAPK inhibitor SB-203580, ERK-1/2 inhibitor U-0126,
or SAPK/JNK inhibitor SP600125. Treated cells were subsequently
either mock-infected, BTV-infected, 1 μg/mL poly I:C treated, or 50
μg/mL poly I:C treated (n=4). Cytokine expression was determined
3 days P.I. using supplies provided by Quansys Biosciences.
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FIGURE 4-14. IL-8 expression from MAPK inhibitor treated A498 cells 3 days P.I.
Placebo

SB-203580

U-0126

SP600125

16000

14000

12000

IL-8 (pg/mL)

10000

8000

6000

4000

2000

0
Mock-infected

BTV-infected

1 mcg/mL poly I:C

50 mcg/mL poly I:C

FIG. 4-14. IL-8 expression from A498 cells treated with either
placebo, p38 MAPK inhibitor SB-203580, ERK-1/2 inhibitor U-0126, or
SAPK/JNK inhibitor SP600125. Treated cells were subsequently
either mock-infected, BTV-infected, 1 μg/mL poly I:C treated, or 50
μg/mL poly I:C treated (n=4). Cytokine expression was determined 3
days P.I. using supplies provided by Quansys Biosciences.
FIGURE 4-15. MCP-1 expression from MAPK inhibitor treated A498 cells 3 days P.I.
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FIG. 4-15. MCP-1 expression from A498 cells treated with either
placebo, p38 MAPK inhibitor SB-203580, ERK-1/2 inhibitor U-0126,
or SAPK/JNK inhibitor SP600125. Treated cells were subsequently
either mock-infected, BTV-infected, 1 μg/mL poly I:C treated, or 50
μg/mL poly I:C treated (n=4). Cytokine expression was determined
3 days P.I. using supplies provided by Quansys Biosciences.
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FIGURE 4-16. RANTES expression from MAPK inhibitor treated A498 cells 3 days P.I.
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FIG. 4-16. RANTES expression from A498 cells treated with either
placebo, p38 MAPK inhibitor SB-203580, ERK-1/2 inhibitor U-0126,
or SAPK/JNK inhibitor SP600125. Treated cells were subsequently
either mock-infected, BTV-infected, 1 μg/mL poly I:C treated, or 50
μg/mL poly I:C treated (n=4). Cytokine expression was determined
3 days P.I. using supplies provided by Quansys Biosciences.

BTV Infection Results in Loss of PKB
and p38 MAPK Phosphorylation in vitro
Previous experiments showed that neither PKB, NFκB, p38 MAPK, ERK1/2, nor SAPK/JNK inhibition had any affect on cell death or cytokine expression.
However, preliminary Western blots (data not shown) and current literature on
MAPK (Chiang et al., 2006) suggested both PKB and the MAPK family had
involvement in BTV-induced cytokine expression. Therefore, PKB and MAPK
phosphorylation levels were directly measured in A498, HEP-G2, and A549 cells
to ensure inhibitor functionality three days P.I. and determine if lack of activity
was a result of changes in downstream signaling.
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None of the tested cell lines constitutively expressed phosphorylated ERK1/2, while HEP-G2 cells did not express phosphorylated PKB or phosphorylated
p38 MAPK. All of the cell lines expressed phosphorylated SAPK/JNK, while
A498 and A549 cells expressed both phosphorylated PBK and phosphorylated
p38 MAPK as shown in Fig. 4-17 and 4-18, respectively.
Interestingly, phosphorylation of both PKB and p38 MAPK declined
significantly to near background levels when cells were infected with BTV as
shown in Fig. 4-17 and 4-18. Poly I:C treatment did not have an effect on A549
cells, though there was a significant decline in PKB phosphorylation in poly I:C
treated A498 cells, though not to levels observed during BTV-infection. Resting
primary cells do not constitutively express phosphorylated PKB or any of the
MAPKs, but are phosphorylated upon infection with BTV or upon treatment with
poly I:C in vitro (Chiang et al., 2006). The herein observed levels of
phosphorylated PKB and p38 MAPK are likely a consequence of the
transformation by carcinoma, and the subsequent decline in p38 MAPK
phosphorylation along with the lack of corresponding IL-1 and TNFα expression
represents a clear distinction between infection of primary cells and carcinoma
cells.

Inhibition of Tyrosine Kinase Activity Does
Not Affect BTV-Induced Cell Death
Using the same experimental design as used in PKB inhibition, cells were
treated with five different inhibitors of tyrosine kinase activity. AG1296 and
AG1478 directly inhibit receptor tyrosine kinases, PP2 and AG490 inhibit
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receptor associated tyrosine kinases, and Genistein is a pan tyrosine kinase
activity inhibitor. Each has a major role in tyrosine based signal transduction.
Fig. 4-19 through 4-22 show the effects of each tyrosine kinase inhibitor on A498,
HEP-G2, A549, and Vero cell viability, respectively.
Viability in the four cell lines was unaffected by treatment with inhibitors
alone. Likewise, BTV-induced cell death was unaffected in A498, HEP-G2, and
Vero cells. A549 cell viability, however, declined as a result of Genistein
treatment (Fig. 4-21).
When cells were treated with poly I:C instead of BTV, the tyrosine kinase
activity inhibitors protected the A498 cells from poly-I:C-induced cell death. This
was only observed in A498 cells because they are the only cells which lose
viability in the presence of poly I:C. In A498 cells, four of five tyrosine kinase
inhibitors provided protection from poly-I:C-induced cell death (Fig. 4-19).
FIGURE 4-17. PKB phosphorylation levels in A498 and A549 cells 3 days P.I.
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FIG. 4-17. Phosphorylation levels of PKB Ser473 in A498 and
A549 cells. Cells were either mock-infected, BTV-infected, or poly
I:C treated (n=6). S/N ratios were determined 3 days P.I. using
supplies provided by Quansys Biosciences.
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FIGURE 4-18. p38 MAPK phosphorylation levels in A498 and A549 cells 3 days P.I.
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FIG. 4-18. Phosphorylation levels of p38 MAPK at Thr180/Tyr182 in
A498 and A549 cells. Cells were either mock-infected, BTV-infected,
or poly I:C treated (n=6). S/N ratios were determined 3 days P.I.
using supplies provided by Quansys Biosciences.
Findings were followed up on by testing poly I:C in the presence of each
tyrosine kinase inhibitor treated in a dose dependent manner. As observed
before, A498 cells were affected by tyrosine kinase activity inhibition, as shown in
Fig. 4-23 through 4-27. BTV-induced cell death was not protected by treatment
with any of the inhibitors while all the inhibitors provided some protection from
poly-I:C-induced cell death. Though all of the tyrosine kinase inhibitors were
cytotoxic, every poly-I:C-treated curve experienced a rise in cell viability with
treatment concentration before falling as a result of cytotoxicity. The most
effective was Genistein, the general tyrosine kinase inhibitor where treatment at
>3.2 μg/mL resulted in full protection from poly-I:C-induced cell death.
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FIGURE 4-19. Tyrosine kinase inhibitor treated A498 cell viability 3 days P.I.
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FIG. 4-19. Tyrosine kinase inhibitor treated A498 cell viability 3
days P.I. Vero cells treated were with either placebo, pan tyrosine
kinase inhibitor Genistein, Src inhibitor PP2, JAK-STAT inhibitor
AG490, PDGFR inhibitor AG1296, or EGFR inhibitor AG1478.
Treated cells were either mock-infected, BTV-infected, 1 μg/mL
poly I:C treated, or 50 μg/mL poly I:C treated (n=4). Viability was
determined by neutral red staining 3 days P.I.
FIGURE 4-20. Tyrosine kinase inhibitor treated HEP-G2 cell viability 3 days P.I.
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FIG. 4-20. Tyrosine kinase inhibitor treated HEP-G2 cell
viability 3 days P.I. Vero cells treated were with either
placebo, pan tyrosine kinase inhibitor Genistein, Src
inhibitor PP2, JAK-STAT inhibitor AG490, PDGFR inhibitor
AG1296, or EGFR inhibitor AG1478. Treated cells were
either mock-infected, BTV-infected, 1 μg/mL poly I:C
treated, or 50 μg/mL poly I:C treated (n=4). Viability was
determined by neutral red staining 3 days P.I.
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FIGURE 4-21. Tyrosine kinase inhibitor treated A549 cell viability 3 days P.I.
Placebo

Genestein

PP2

AG490

AG1296

AG1478

120

100

% Viability

80

60

40

20

0
Mock-infected

BTV-infected

1 mcg/mL poly I:C

50 mcg/mL poly I:C

FIG. 4-21. Tyrosine kinase inhibitor treated A549 cell viability 3
days P.I. Vero cells treated were with either placebo, pan
tyrosine kinase inhibitor Genistein, Src inhibitor PP2, JAK-STAT
inhibitor AG490, PDGFR inhibitor AG1296, or EGFR inhibitor
AG1478. Treated cells were either mock-infected, BTV-infected,
1 μg/mL poly I:C treated, or 50 μg/mL poly I:C treated (n=4).
Viability was determined by neutral red staining 3 days P.I.
FIGURE 4-22. Tyrosine kinase inhibitor treated Vero cell viability 3 days P.I.
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FIG. 4-22. Tyrosine kinase inhibitor treated Vero cell viability 3
days P.I. Vero cells treated were with either placebo, pan tyrosine
kinase inhibitor Genistein, Src inhibitor PP2, JAK-STAT inhibitor
AG490, PDGFR inhibitor AG1296, or EGFR inhibitor AG1478.
Treated cells were either mock-infected, BTV-infected, 1 μg/mL
poly I:C treated, or 50 μg/mL poly I:C treated (n=4). Viability was
determined by neutral red staining 3 days P.I.
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FIGURE 4-23. Genistein treated A498 cells 3 days P.I.
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FIG. 4-23. Genistein treated A498 cells 3 days P.I. A498 cells
were treated with pan tyrosine kinase inhibitor Genistein in a dose
dependent manner. Treated cells were either mock-infected,
BTV-infected, or 50 μg/mL poly I:C (n=4) treated. Viability was
determined by neutral red staining 3 days P.I.
FIGURE 4-24. PP2 treated A498 cells 3 days P.I.
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FIG. 4-24. PP2 treated A498 cells 3 days P.I. A498 cells were
treated with Src inhibitor PP2 in a dose dependent manner.
Treated cells were either mock-infected, BTV-infected, or 50
μg/mL poly I:C (n=4) treated. Viability was determined by neutral
red staining 3 days P.I.
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FIGURE 4-25. AG490 treated A498 cells 3 days P.I.
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FIG. 4-25. AG490 treated A498 cells 3 days P.I. A498 cells were
treated with JAK-STAT inhibitor AG490 in a dose dependent
manner. Treated cells were either mock-infected, BTV-infected,
or 50 μg/mL poly I:C (n=4) treated. Viability was determined by
neutral red staining 3 days P.I.
FIGURE 4-26. AG1296 treated A498 cells 3 days P.I.

mock-infected

BTV-infected

poly I:C treated

1.6

1.4

Neutral Red Optical Density

1.2

1

0.8

0.6

0.4

0.2

0
Blank

0.1

0.32

1

3.2

10

AG1296 concentration (mcg/mL)

FIG. 4-26. AG1296 treated A498 cells 3 days P.I. A498 cells
were treated with PDGFR inhibitor AG1296 in a dose dependent
manner. Treated cells were either mock-infected, BTV-infected,
or 50 μg/mL poly I:C (n=4) treated. Viability was determined by
neutral red staining 3 days P.I.
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FIGURE 4-27. AG1478 treated A498 cells 3 days P.I.
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FIG. 4-27. AG1478 treated A498 cells 3 days P.I. A498 cells
were treated with EGFR inhibitor AG1478 in a dose dependent
manner. Treated cells were either mock-infected, BTV-infected,
or 50 μg/mL poly I:C (n=4) treated. Viability was determined by
neutral red staining 3 days P.I.

Genistein and AG1478 Treatment Reduces
Cytokine Expression from Poly I:C-Treated,
but Not BTV-Infected Cells
In addition to measuring cell viability during treatments with tyrosine
kinase inhibitors, cytokines were measured 3 days P.I. None of the tyrosine
kinase inhibitors were found to significantly reduce resting cell cytokine
expression, but Genistein treatment did significantly reduce cytokine expression
from BTV-infected A549 cells, though Genistein also exacerbated BTV-induced
cell death suggesting that the decline in cytokine expression was a result of
fewer viable cells. BTV-infected Vero cells were also affected by tyrosine kinase
inhibition, most notably from Genistein, but also from Src and EGFR inhibitors.
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Cytokine expression from BTV-infected A498 and HEP-G2 cells was unaffected
by treatment with Genistein or any other tyrosine kinase inhibitor.
Unlike BTV-infected cells, Genistein and AG1478 consistently reduced
cytokine expression from poly-I:C-treated A498, A549, and Vero cells as shown
in Fig. 4-28 through 4-39. This reduction suggests the involvement of EGFR
signaling in the cell’s response to dsRNA and may also lead to cell death in some
cell lines.

Tyrosine Phosphorylation is Activated
During Infection with BTV
Previous testing demonstrated that tyrosine kinase signaling can have an
influence on cell death and cytokine expression in human carcinoma transformed
FIGURE 4-28. IL-6 expression from tyrosine kinase inhibitor treated A498 cells 3 days P.I.
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FIG. 4-28. IL-6 expression from A498 cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Cytokine expression was determined 3 days P.I.
using supplies provided by Quansys Biosciences.
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FIGURE 4-29. IL-8 expression from tyrosine kinase inhibitor treated A498 cells 3 days P.I.
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FIG. 4-29. IL-8 expression from A498 cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Cytokine expression was determined 3 days P.I.
using supplies provided by Quansys Biosciences.
cells. Inhibition of signaling resulted in both protection from poly-I:C-induced cell
death in A498 cells, and reduced cytokine expression in each cell line. To
identify changes in tyrosine signaling during infection, Western blots were
performed on both mock-infected and BTV-infected human carcinoma
transformed cells. Fig. 4-40 and 4-41 are Western blots using anti-BTV17
antiserum and mouse anti phosphorylated-tyrosine monoclonal antibodies,
respectively. There are distinct bands in Fig. 4-41 present only in BTV-infected
cells indicating the presence of a tyrosine phosphorylated protein present only in
BTV-infected cells (indicated by an arrow in Fig. 4-41). Band intensity was the
strongest in HEP-G2 cells followed by A549 cells and not resolvable in A498
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FIGURE 4-30. MCP-1 expression from tyrosine kinase inhibitor treated A498 cells 3 days P.I.
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FIG. 4-30. MCP-1 expression from A498 cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Cytokine expression was determined 3 days P.I.
using supplies provided by Quansys Biosciences.

cells. The bands in Fig. 4-41 were comparable in molecular weight to bands
identified in Fig. 4-40 as probable BTV protein (compare to Fig. 4-40), with the 35
kDa band the most prominent.
Following these findings, each tyrosine kinase inhibitor tested previously
was tested for its ability to prevent phosphorylation of the band identified in the
above mentioned Western blot. HEP-G2 cells were selected for the study
because band intensity was strongest in these cells. Cells were cultured in the
presence of each MAPK inhibitor or each tyrosine kinase activity inhibitor and
BTV. Three days P.I., cells were harvested and assayed by Western blot for
phosphorylated tyrosine (Fig. 4-42). Phosphorylation of the 35 kDa protein

129
FIGURE 4-31. RANTES expression from tyrosine kinase inhibitor treated A498 cells 3 days
P.I.
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FIG. 4-31. RANTES expression from A498 cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Cytokine expression was determined 3 days P.I.
using supplies provided by Quansys Biosciences.
remained in samples treated with MAPK inhibitors but was reduced by treatment
with all tyrosine kinase inhibitors. Genistein, the general tyrosine kinase activity
inhibitor was the most effective at inhibiting phosphorylation of 35 kDa protein but
all tyrosine kinase activity inhibitors resulted in noticeable reductions in band
intensity.

Unknown Tyrosine Phospho-Protein is a 35
kDa Protein Displaying Multiple Isoelectric
Points Between 6.5 and 7.5
In addition to identifying the tyrosine kinase signaling pathways that can influence
phosphorylation of the 35 kDa protein, two dimensional gel electrophoresis was
performed to isolate the unknown protein. BTV-infected and mock-infected A549
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FIGURE 4-32. IL-6 expression from tyrosine kinase inhibitor treated A549 cells 3 days P.I.
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FIG. 4-32. IL-6 expression from A549 cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Cytokine expression was determined 3 days P.I.
using supplies provided by Quansys Biosciences.
cells were harvested three days P.I. from T75 flasks. Proteins from each sample
were separated by two-dimensional gel electrophoresis and stained with
Coomassie blue. Fig. 4-43 is the mock-infected sample without the 35 kDa spots
(area where spots should be is indicated by an arrow), and Fig. 4-44 is the BTVinfected sample with 35 kDa spots indicated by the arrow. Replicate gels were
blotted onto PVDF membrane and phosphorylated tyrosine containing proteins
identified. Spots on the gel of the BTV-infected A549 cells were found near a
molecular weight of 35 kDa, which correlated to the subject bands on Fig. 4-41.
The 35 kDa protein displayed multiple isoelectric points between 6.5 and 7.5.
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FIGURE 4-33. IL-8 expression from tyrosine kinase inhibitor treated A549 cells 3 days P.I.
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FIG. 4-33. IL-8 expression from A549 cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Cytokine expression was determined 3 days P.I.
using supplies provided by Quansys Biosciences.
The spot with an isoelectric point of approximately 7.3 was the most
intense and was excised for MALDI-TOF mass spectroscopic analysis. Peptide
fragment molecular weights identified by MALDI-TOF mass spectroscopy can be
seen in Fig. 4-45. Comparisons against known peptide fragment databases did
not yield any credible predictions as to the identity of the unknown protein.
Though the identity of the 35 kDa protein remains unknown, the protein
clearly displays multiple charge states, possibly the result of multiple
phosphorylation sites.

Testing also indicates that this 35 kDa protein is

phosphorylated by a kinase capable of inhibition by multiple inhibitors or possibly
can be phosphorylated by multiple tyrosine kinases.
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FIGURE 4-34. MCP-1 expression from tyrosine kinase inhibitor treated A549 cells 3 days P.I.
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FIG. 4-34. MCP-1 expression from A549 cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Cytokine expression was determined 3 days P.I.
using supplies provided by Quansys Biosciences.

DISCUSSION

BTV was recently shown in human cells to replicate selectively in
cancerous cells (Xiao et al., 2004). Understanding the mechanisms through
which BTV causes cell death may provide new avenues of research and potential
targets in the treatment of cancer. Chapter 2 demonstrated the involvement of
cellular apoptotic and inflammatory pathways. The objective of this study was to
determine the involvement of key inflammatory and apoptotic signaling molecules
in BTV-induced cell death in carcinoma transformed cells.
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FIGURE 4-35. RANTES expression from tyrosine kinase inhibitor treated A549 cells 3 days
P.I.
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FIG. 4-35. RANTES expression from A549 cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Cytokine expression was determined 3 days P.I.
using supplies provided by Quansys Biosciences.

The signaling molecule PKB was first explored because of its involvement
in regulating cell survival. It is a known proto-oncogene, over-phosphorylated in
various cancers, along with its upstream and downstream signaling molecules
(Yuan and Cantley, 2008). We hypothesized the carcinoma transformed cell
responds to BTV infection by shutting down PKB related signaling leading to cell
death. Testing revealed phosphorylated PKB in mock-infected A498 and A549
cells, but not in HEP-G2 cells. Subsequent infection with BTV resulted in
complete loss of phosphorylation while poly I:C treatment did not affect the level
of phosphorylation. The observations for A498 and A549 cells is consistent with
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FIGURE 4-36. IL-6 expression from tyrosine kinase inhibitor treated Vero cells 3 days P.I.
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FIG. 4-36. IL-6 expression from Vero cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly I:C
treated (n=4). Cytokine expression was determined 3 days P.I. using
supplies provided by Quansys Biosciences.
the hypothesis, though testing with PKB inhibitor, Triciribine, demonstrated that a
loss of PKB phosphorylation alone is not sufficient to cause cell death. Triciribine
treatment in mock-infected cells had no effect on cell death in any of the tested
cell lines, indicating that additional signals are required to cause cell death.
BTV clearly supplies these additional signals during infection, possibly as
a result of viral replication. BTV’s genome is dsRNA which can activate an
innate immune response to the dsRNA, which can lead to cell death in primary
and carcinoma transformed cells (Zhang and Samuel, 2007). Our hypothesis
was that the reductions in phosphorylated PKB during BTV infection made it
possible for dsRNA-induced pro-apoptotic signals to proceed. To test this,
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FIGURE 4-37. IL-8 expression from tyrosine kinase inhibitor treated Vero cells 3 days P.I.
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FIG. 4-37. IL-8 expression from Vero cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Cytokine expression was determined 3 days P.I.
using supplies provided by Quansys Biosciences.

Triciribine treated cells were also treated with poly I:C. However, inhibition of
PKB phosphorylation by Triciribine had no effect on poly-I:C-induced cell death
(Fig. 4-1 to 4-4) disproving our hypothesis and indicating that BTV was also
activating non-PKB, non-dsRNA related apoptotic pathways.
In addition to activating apoptosis, BTV also activates pro-inflammatory
signaling pathways as evidenced by the expression of cytokine and chemokines
during infection. Double stranded RNA activates the same or similar proinflammatory signaling pathways leading to expression of the same cytokines
and chemokines (Chapter 2), suggesting it was possible that apoptosis and
cytokine expression were activated through the same signaling procedure. One
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FIGURE 4-38. MCP-1 expression from tyrosine kinase inhibitor treated Vero cells 3 days P.I.
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FIG. 4-38. MCP-1 expression from Vero cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Cytokine expression was determined 3 days P.I.
using supplies provided by Quansys Biosciences.

signaling molecule involved in both inflammation and apoptosis is nuclear
translocation factor kappa B (NFκB). NFκB plays a central role in inflammatory
signaling in nearly all cells. Activation, however, leads to expression of
interleukin 1 (IL-1) and tumor necrosis factor alpha (TNFα), in addition to the
cytokines observed in Chapter 2. NFκB also promotes cell survival when
activated. The lack of IL-1 and TNFα as well as the presence of apoptosis
suggested NFκB was probably not involved during BTV infection.
NFκB involvement was tested using the inhibitor QNZ. BTV-infected and
poly-I:C-treated cells were both treated with QNZ, and subsequently measured
for cell death and cytokine expression (Fig. 4-1 through 4-8). NFκB was found to
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FIGURE 4-39. RANTES expression from tyrosine kinase inhibitor treated Vero cells 3 days P.I.
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FIG. 4-39. RANTES expression from Vero cells treated with either
placebo, pan tyrosine kinase inhibitor Genistein, Src inhibitor PP2,
JAK-STAT inhibitor AG490, PDGFR inhibitor AG1296, or EGFR
inhibitor AG1478. Treated cells were subsequently either mockinfected, BTV-infected, 1 μg/mL poly I:C treated, or 50 μg/mL poly
I:C treated (n=4). Cytokine expression was determined 3 days P.I.
using supplies provided by Quansys Biosciences.

have no influence on the observed cell death or cytokine expression, indicating
that BTV-induced cell death and cytokine expression involves either signaling
through non-NFκB mediated pathways or other pathways are compensating for
the inhibited NFκB pathway. The observed cytokines are known to be activated
by multiple pathways leading us to conclude that NFκB signaling is not involved
in the cell’s response to BTV infection.
One potential alternative pathway was MAPK signaling. MAPK signaling
can lead to cytokine expression very similar to NFκB signaling.

In addition,

studies in human primary cells showed that BTV activates p38 MAPK during
infection leading to the expression of cytokines (Chiang et al., 2006). Normal

138

FIG. 4-40. Western blot using anti-BTV17 antisera. Mock-infected and BTVinfected A498, HEP-G2, or A549 cells were harvested 3 days P.I., protein
concentration adjusted to 500 μg/mL, ran on a 10% polyacrylamide gel, blotted
to PVDF membrane and stained with rabbit anti-BTV17 antisera. Column (1)
Bio-Rad prestained protein marker with weights indicated in kilodaltons, (2)
mock-infected A498 cells, (3) BTV-infected A498 cells, (4) mock-infected HEPG2 cells, (5) BTV-infected HEP-G2 cells, (6) mock-infected A549 cells, (7) BTVinfected A549 cells. Arrows indicate bands present only in BTV-infected
samples.
p38

MAPK-induced

cytokine

expression,

however,

includes

Il-1

and

TNFα expression which are not observed in any of the tested human carcinoma
transformed cells, suggesting that if the pathway is also activated in transformed
cells, it is not functioning properly. ERK-1/2 and SAPK-JNK pathways were both
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FIG. 4-41. Western blotusing anti-phospho tyrosine antibodies. Mockinfected and BTV-infected A498, HEP-G2, or A549 cells were harvested 3
days P.I., protein concentration adjusted to 500 μg/mL, ran on a 10%
polyacrylamide gel, blotted to PVDF membrane and stained with rabbit antiBTV17 antisera. Column (1) Bio-Rad prestained protein marker with weights
indicated in kilodaltons, (2) mock-infected A498 cells, (3) BTV-infected A498
cells, (4) mock-infected HEP-G2 cells, (5) BTV-infected HEP-G2 cells, (6)
mock-infected A549 cells, (7) BTV-infected A549 cells. Arrows indicate
bands present only in BTV-infected samples.
tested along with p38 MAPK for involvement during BTV infection and during
poly I:C treatment. cell death or cytokine expression. Further testing revealed
that p38 MAPK was constitutively phosphorylated in A498 and A549 cells, but is
subsequently de-phosphorylated upon infection with BTV. A surprising
observation that is markedly different from primary cells. P38 MAPK is not

140

FIG. 4-42. Western blot of BTV-infected, inhibitor treated, HEP-G2 cells
harvested 3 days P.I. Column (1) Bio-Rad prestained protein marker with
weights indicated in kilodaltons, (2) Placebo, (3) SB-203580, (4) U-1026, (5)
SP600125, (6) Genistein, (7) PP2, (8) AG490, (9) AG1296, (10) AG1478.
Protein concentration was adjusted to 500 μg/mL, ran on a 10% polyacrylamide
gel, blotted to PVDF membrane and stained with mouse anti-phos-tyrosine
antibodies. Arrow indicates 35 kDa tyrosine phosphorylated protein bands.
Inhibition of p38 MAPK, ERK-1/2, and SAPK/JNK all had no significant effect on
phosphorylated in mock- infected primary cells but is phosphorylated upon
infection with BTV. This observation reveals p38 MAPK is a key differentiator
between some primary and carcinoma transformed cells. The observation also
suggests either that p38 MAPK signaling requires other signals to lead to
cytokine expression or that the p38 MAPK signaling pathway is broken
downstream of p38 MAPK in carcinoma transformed cells.
ERK-1/2 and SAPK/JNK were also tested for level of phosphorylation.
ERK-1/2 was not phosphorylated in mock-infected or BTV-infected cells, while
SAPK/JNK was constitutively phosphorylated in mock-infected cells but remained
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FIG. 4-43. Coomassie blue stained gel of mock-infected
A549 cells 3 days P.I. Sample protein concentration was
adjusted to 500 μg/mL, ran on a 10% polyacrylamide gel and
subsequently stained with Coomassie blue. Arrow indicates
the location where the 35 kilodalton protein displaying
isoforms between 6.5 and 7.5 pI should be found.
unaffected by infection with BTV. Given the lack of a significant change in
phosphorylation combined with no significant change in cell death or cytokine
expression during inhibitor treatment, we concluded that ERK-1/2 and SAPK/JNK
signaling are not involved in the cell’s response to BTV-infection. P38 MAPK
signaling on the other hand is significantly affected by infection with BTV,
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FIG. 4-44. Coomassie blue stained gel of BTV-infected
A549 cells 3 days P.I. Sample protein concentration was
adjusted to 500 μg/mL, ran on a 10% polyacrylamide gel and
subsequently stained with Coomassie blue. Arrow indicates
the location where the 35 kilodalton protein displaying
multiple isoforms between 6.5 and 7.5 pI .
suggesting that altered p38 MAPK signaling plays a central role in cell
transformation and BTV-oncotrophism. DeMaula et al. (2001) demonstrated that
in bovine endothelial cells expressed greater levels of IL-1, IL-6, and TNFα
relative to ovine endothelial cells which correlated with higher viral titers but less
severe disease and pathology. The elevated expression indicates greater
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FIG. 4-45. MALDI-TOF mass spectroscopy analysis of a 35 kDa protein
isolated from BTV-infected A549 cells 3 days P.I. The ~7.3 pI isoform of the
35 kDa protein identified in Fig. 4-44 was excised from the polyacrylamide gel
and was subject to in gel trypsin digestion. The unknown protein is a tyrosine
phosphorylated protein displaying multiple isoelectric points.
activation of the NFκB and p38 MAPK pathways, as is also found in human
primary endothelial cells. Greater activation of these pathways leads to reduced
apoptosis, which in vivo reduces hemorrhage, and the corresponding coagulation
and necrosis. However, in the tested carcinoma transformed cell lines, these
pathways are not activated, as evidenced by the lack of IL-1 and TNFα
expression, and are therefore not protected from apoptosis.
Though p38 MAPK signaling was affected by BTV-infection and may play
an important role in preventing apoptosis and promoting IL-1 and TNFα
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expression from primary cells, it is not the pathway through with cytokine
expression occurs in carcinoma transformed cells. To further explore the
signaling pathways utilized by carcinoma cells to induce apoptosis and cytokine
expression, tyrosine kinase signaling was tested. Tyrosine kinase signaling is
best known for its role in conveying extracellular signals through receptor
tyrosine kinases (RTKs), though tyrosine kinase signaling is utilized by many
systems including innate immunity. For example, type I interferons signal
through the JAK-STAT pathway, which involves tyrosine kinase signaling
(Schindler and Plumlee, 2008). To determine tyrosine kinase signaling
involvement during infection, the profile of tyrosine phosphorylated proteins in
BTV-infected cells were compared with mock-infected cells (Fig. 4-41). This
Western blot suggested there was at least one protein selectively tyrosine
phosphorylated during BTV-infection. These findings led us to acqure a panel of
tyrosine kinase inhibitors. Each inhibitor was reduced to levels which were not
cytotoxic and studies performed with mock-infected, BTV-infected, and poly-I:Ctreated cells. None of the inhibitors were shown to have a significant impact on
cell death or cytokine expression in mock-infected cells. BTV-infected cells also
were not significantly affected by tyrosine kinase inhibition, except for A549 and
Vero cells wherein Genistein, the general tyrosine kinase inhibitor, caused an
increase in cell death. If a tyrosine kinase signaling pathway were conveying
pro-inflammatory or pro-apoptotic signals, then inhibition would have protected
the cells from death rather than increased cell death. Instead, it may be that the
tyrosine kinases are conveying cell survival signals, and inhibition of the signaling
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promoted apoptosis. For example, EGFR and Src, two tyrosine kinases, are
upstream activators of phosphoinositol-3-kinase (PI-3K) mediated PKB
phosphorylation. However, cell death was present only in the A549 and Vero
cells indicating the increase in cell death is related only to some cell lines. Also,
EGFR and Src kinase inhibitors did not have the same effect indicating the
example pathway is not the pathway being affected by Genistein.
Unlike BTV-infected or mock-infected cells, poly-I:C-treated cells were
affected by tyrosine kinase inhibition. A498 cells were protected from poly-I:Cinduced cell death, suggesting that A498 cells respond to poly I:C through
tyrosine kinase signaling. Interestingly, all of the tyrosine kinase inhibitors
partially protected A498 cells from poly-I:C-induced cell death, suggesting that
the inhibitors all cross inhibit the same pathway.
Poly-I:C-treated HEP-G2, A549, and Vero cell viability were unaffected by
tyrosine kinase inhibition, but cytokine expression was affected. A498, A549,
and Vero cells all showed reductions in cytokine expression during tyrosine
kinase inhibition. The reductions were most prevalent in Genistein and AG1478
treated cells. AG1478 inhibits EGFR signaling which may be related to the
reduction in PKB signaling shown previously during BTV infection. PKB
involvement and the changes in cytokine expression observed during AG1478
treatment suggest some EGFR involvement during BTV-infection, possibly part
of the innate immune response. In addition, cell death and cytokine expression
from poly-I:C-treated cells may utilize the same signaling pathway(s), but
protection from cell death is only observed in A498 cells because these cells are
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the only ones in which poly I:C induced cell death. However, the more significant
tyrosine kinase inhibitor is Genistein, which suggests that there remains
additional tyrosine kinases, apart from the four major families tested, which are
involved in both cell death and cytokine expression.
After determining the effect each inhibitor had on cell death and cytokine
expression, each inhibitor was used to determine the identity of the tyrosine
phosphorylated protein observed in Fig. 4-41. HEP-G2 cells were treated with
each tyrosine kinase inhibitor and each MAPK inhibitor and then tested for
changes in phosphorylation of the 35 kDa protein by Western blot. MAPK
inhibitors were tested along with tyrosine kinase activity inhibitors because MAPK
activation involves tyrosine phosphorylation in the activation site and needed to
be excluded. Fig. 4-42 demonstrated, that in HEP-G2 cells, phosphorylation of
the unknown protein was inhibited by every tested tyrosine kinase inhibitor, but
not the MAPK inhibitors. Indicating that the unknown protein is not one of the
MAPK proteins. The pathway of phosphorylation could not be determined as
hoped, but instead suggests the observed protein is phosphorylated by a tyrosine
kinase that can be inhibited by many compounds. The same conclusion was
made from the A498 poly I:C data, raising the possibility that the same pathway
that is protecting A498 cells from poly-I:C-induced death is the same protein
identified here in HEP-G2 cells. This protein, however, was weakly
phosphorylated in A498 cells and BTV-induced cell death is not protected by
inhibition of this protein.
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In an effort to identify the unknown protein and its function, BTV-infected
and mock-infected A549 cells were resolved by two-dimensional gel
electrophoresis. One set was stained with Coomassie blue (Fig. 4-43 and 4-44),
and the other set was transferred to PVDF and tyrosine phosphorylated proteins
determined by Western blot. The unknown tyrosine phosphorylated protein was
found to be about 35 kDa in size and had multiple isoelectric points suggesting
multiple phosphorylation states. The protein, however, could not be identified by
mass spectroscopy leaving no answer to its function.
Findings in Chapter 2 suggested that cell death and cytokine expression
were directly related. We hypothesized that this relationship was through
conserved intracellular signaling. Our objective was to determine the role of key
apoptotic and pro-inflammatory signaling molecules in the cell’s response to BTV
infection. We conclude that both PKB and p38 MAPK play a role in
transformation of the A498 and A549, but not HEP-G2 cell lines and that BTV
induced cell death by inactivating these pathways. The inactivation of p38 MAPK
during infection is one distinguishing characteristic of BTV infection of carcinoma
transformed cells compared with BTV-infected human primary cells, and explains
the lack of IL-1 and TNFα expression and the increased rate of apoptosis of
carcinoma transformed cells relative to primary cells.
Other MAPK family members were not affected by BTV infections, but
tyrosine kinase signaling is involved. BTV infection leads to increased tyrosine
phosphorylation. This tyrosine signaling promotes cell death in A498 cells,
promotes cell survival in BTV-infected A549 and Vero cells, and promotes

148
cytokine expression in A498, A549, and Vero cells. Tyrosine signaling
involvement in cell death is highly variable between cell lines but utilizes a
signaling pathway that is capable of cross inhibition by multiple classes of kinase
inhibitors. Cytokine signaling occurs through both an unknown pathway and
partially through EGFR signaling. The unknown pathway involved in cytokine
expression may be the same pathway involved in cell death. Western blotting
suggests this pathway involves a 35 kDa protein with multiple phosphorylation
states, though the pathway remains unknown. However, this pathway does not
involve PDGFR signaling or JAK-STAT signaling, and therefore does not involve
type I interferon signaling. The other two conventional inflammatory pathways,
p38 MAPK and NFκB are also not involved, leaving the mechanism by which
carcinoma transformed cells respond to BTV infection distinct from primary cells
and independent of conventional inflammatory pathways. BTV selectively kills
carcinoma transformed cells because their cellular response to BTV infection
does not include activation of NFκB, p38 MAPK, or JAK-STAT signaling.
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CHAPTER 5
SUMMARY AND CONCLUSION
SUMMARY
Bluetongue virus (BTV) is a dangerous pathogen to ruminants recently reemerging in epidemic form in Europe, but it is BTV’s effects in human carcinoma
transformed cells that is the subject of this study. In ruminants, like sheep, BTV
causes bluetongue disease, a hemorrhagic disease that is often fatal. However,
BTV does not cause disease in humans and the population remains largely
seronegative, suggesting that not only are humans not compatible hosts, but that
we don’t usually get infected. However, BTV will infect human cells in vitro.
When primary cultures are infected, viral RNA can be detected but there is no
cell death, though BTV will cause cell death in carcinoma transformed cells.
The study objectives were to determine infectivity of BTV serotype 17 in
three human cell lines, quantify cell death and cytokine expression, and
determine the involvement of key intracellular signaling molecules in the
observed cell death and cytokine expression. First, BTV was found to induce cell
death in all three human cell lines. Cell death was most significant in A498 cells
followed by A549 cells and last by HEP-G2 cells (Fig. 2-3). Cytokine expression
from the same cells was subsequently found elevated in all cell lines upon
infection with BTV (Table 2-1). Cytokine expression is the cell’s primary means
of communication with the immune system and consequently the expression
profile provides great insight into the cell’s response to infection. Multiplex
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cytokine testing methods were employed to examine multiple cytokines (25 in
total). Four cytokines were found elevated upon infection, including IL-6, IL-8,
MCP-1, and RANTES. All are pro-inflammatory cytokines which are expressed
constitutively by cancer cells and naturally expressed by damaged or stressed
cells. Cytokine production directly correlated with cell death between the cell
lines which suggested that cell death and cytokine expression were both
activated through the same signaling cascade, and that all three human cell lines
utilized this same pathway. Our hypothesis was that this signaling pathway was
activated by innate immunity’s response to BTV generated dsRNA.
To understand the involvement of innate immunity in viral induced
inflammation and cell death, studies were repeated with polyinosinic:polycytosinic acid (poly I:C) treated cells. Poly I:C is a synthetic dsRNA molecule
known to induce anti-dsRNA responses in vitro and in vivo. Studies following a
similar procedure in primary lung endothelial cells found that synthetic dsRNA
could induce cytokine expression and p38 MAPK phosphorylation commensurate
with BTV infection. However, poly I:C treatment in human carcinoma
transformed cells had no detectable effect on cell death in HEP-G2, A549, and
Vero cells, and only resulted in cell death in A498 cells at abnormally high
concentrations of poly I:C (Fig. 2-4). Poly I:C could induce cytokine expression in
A498, A549, and Vero cells, though cytokine expression did not include IL-1 and
TNFα as was seen in primary cells.
Viral RNA and protein expression were subsequently measured in each
cell line. Our objective was to determine the relative extent of replication
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between cell lines. Our hypothesis was that cell death and cytokine expression
were directly related to viral replication. However, RNA expression from BTV
was highest in A498 cells generating concentrations statistically indistinguishable
from BHK-21 cells, while BTV generated the lowest concentrations of RNA in
A549 cells. Surprisingly, viral protein expression did not directly correlate with
RNA expression and was inversely proportionate, between cell lines, with cell
death and cytokine expression. The data did not support the initial hypothesis,
but suggested that cell death and cytokine expression are a function of the cell’s
ability to detect and respond to infection rather than the virus rate of replication.
Protein and RNA studies in conjunction with cell death and cytokine
testing suggested that the host cell is quickly recognizing the infection in a cell
line dependent manner and is activating pro-apoptotic pathways. To better
understand the intracellular events taking place, we acquired inhibitors to a
number of signaling molecules central to inflammation and apoptosis. These
included protein kinase B (PKB), p38 mitogen-activated protein kinase (p38
MAPK), extracellular signal regulated kinase (ERK-1/2), stress activated protein
kinase (SAPK/JNK), nuclear translocating factor kappa B (NFκB), and the major
tyrosine kinase families. The respective proteins were inhibited in mock-infected,
BTV-infected, and poly I:C treated cells. However, only the tyrosine kinase
inhibitors had any appreciable effect on cell death, which was observed only in
poly I:C treated A498, and BTV-infected A549 cells. The tyrosine kinase
inhibitors were also the only inhibitors to reduce cytokine expression. The effects
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were most overt with the pan-tyrosine kinase inhibitor and the endothelial growth
factor receptor (EGFR) inhibitor.
Inhibition studies suggested that none of the tested signaling proteins
were singly involved in cell death or cytokine expression. It was expected that if
there was involvement, there would have been differences in either cell death or
cytokine expression upon treatment.
In addition to the inhibition studies, phosphorylation of PKB, p38 MAPK,
ERK-1/2, and SAPK/JNK were directly measured. These direct measurements
confirmed that the inhibitors were functioning, as the level of phosphorylation
diminished in the presence of the respective inhibitor, thereby validating the
results of the inhibition studies. Direct measurements also revealed that A498
and A549 cells constitutively expressed active (phosphorylated) PKB; but when
infected with BTV, phosphorylation was inhibited. It was hypothesized that BTV
reduced phosphorylation of PKB by activating alternate pro-apoptotic
mechanisms; and that this dephosphorylation permitted normal apoptotic
mechanisms to take place. However, there was no detectable change in cell
death when uninfected cells were treated with PKB inhibitor suggesting that
dephosphorylation of AKT alone is not sufficient to induce apoptosis.
P38 MAPK was also found to be constitutively phosphorylated in mockinfected cells. This level of phosphorylation is consistent with transformation by
carcinoma, as p38 MAPK phosphorylation leads to protection from apoptosis. In
these cells, infection with BTV caused p38 MAPK dephosphorylation. Prior
studies found that p38 MAPK was not phosphorylated in primary cells, but then
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phosphorylated during BTV infection. This phosphorylation lead to IL-1 and
TNFα expression, which is not seen in carcinoma transformed cells. These
discrepancies in p38 MAPK phosphorylation suggest that lack of functional p38
MAPK signaling in carcinoma transformed cells may be a primary reason for
BTV’s oncotrophism. Other MAPK family members: ERK-1/2 and JNK were also
tested for changes in phosphorylation upon infection, but were not significantly
affected.
Lack of NFκB or p38 MAPK involvement in cytokine expression suggested
possible involvement of tyrosine kinase signaling. Innate immunity to dsRNA is
known to signal through tyrosine kinase signaling pathways, such as the Janus
kinase (JAK-STAT) signaling pathway. Western blots using anti-phosphorylated
tyrosine antibodies suggested that there was differential tyrosine phosphorylation
between mock-infected and BTV-infected cells. One specific 35 kDa protein in
BTV-infected cells was particularly phosphorylated. The tyrosine kinase
inhibitors were all tested for their ability to phosphorylate this protein in HEP-G2
cells. Cells were treated with each tyrosine kinase and MAPK inhibitor and the
proteins stained by Western blot with anti-phospho-tyrosine antibodies three
days P.I. Surprisingly, each tyrosine kinase inhibitor caused a reduction in
phosphorylation on the unknown protein, suggesting that the unknown protein is
phosphorylated by a kinase to which many different inhibitors function. The
identity of the protein could not be determined by mass spectroscopy but the
inhibition of phosphorylation combined with the lack of changes in cell death or
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cytokine expression in HEP-G2 cells during inhibitor treatment indicates that the
35 kDa protein is not integrally involved in the cell’s response to infection.
CONCLUSION
BTV is a dangerous ruminant pathogen which does not naturally cause
disease in humans, but is capable of infecting and killing human carcinoma cells
in vitro while simultaneously inducing an immune response from the infected cell.
The cellular immune response includes the production of pro-inflammatory
cytokines and chemokines followed by apoptosis. The key differences in
infection between carcinoma cells and primary endothelial cells includes
extensive cell death in carcinoma cells; lack of IL-1 and TNFα expression;
constitutive PKB and p38 MAPK phosphorylation, which is subsequently lost
upon infection; and a lack of poly I:C inducible cytokine expression or p38 MAPK
phosphorylation.
Cytokine production and cell death are the product of the cell recognizing
and responding to infection. Hence, greater cell death correlates with reduced
viral protein production. Both apoptosis and cytokine expression are related
through intracellular signaling. The cell responds to infection by activating
tyrosine kinase signaling leading to cytokine expression through a non-NFκB
pathway and subsequently dephosphorylating PKB and p38 MAPK, leading to
apoptosis. Tyrosine kinases, PKB, and p38 MAPK are all related through EGFR
signaling shown here to affect cytokine production and may be the primary cause
of cell death, cytokine expression, and p38 MAPK dysfunction.

156
We conclude that BTV can infect many types of cells, including primary
and carcinoma transformed cells, but that BTV-induced cell death is a function of
the cell’s response to infection and is therefore cell dependent. Carcinoma
transformed cells are susceptible to cell death because they do not respond to
infection through NFκB or p38 MAPK signaling which traditionally leads to
protection from apoptosis. As a result, when a carcinoma cell is infected with
BTV, the virus is recognized by innate immunity and responds by expressing
cytokines and subsequently inducing apoptosis.
FUTURE RESEARCH
This study focused entirely on cells transformed by carcinoma. Future
studies would involve direct comparisons between primary epithelial cells and
carcinoma transformed cells. Additionally, p38-MAPK was shown to be
dephosphorylated during BTV infection, contrary to observations in primary cells.
We would want to inhibit p38 MAPK phosphorylation in primary cells, and inhibit
p38 MAPK dephosphorylation in carcinoma cells to determine the contribution
p38 MAPK signaling has on cell survival. Similar testing should also be done
with NFκB.
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